Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration  [see Warnings and Precautions ( 5.2)] , reserve tramadol hydrochloride oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

Tramadol hydrochloride oral solution should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with tramadol hydrochloride oral solution [see Warnings and Precautions ( 5.3)] .

Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).

Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient [see Warnings and Precautions ( 5.2, 5.3, 5.4)] .

Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.

Initiating Treatment with Tramadol Hydrochloride Oral Solution

Initiate treatment at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of tramadol hydrochloride oral solution.

For patients not requiring rapid onset of analgesic effect, the tolerability of tramadol hydrochloride oral solution can be improved by initiating therapy with the following titration regimen: Start tramadol hydrochloride oral solution at 25 mg/day and titrate in 25 mg increments as separate doses every 3 days to reach 100 mg/day (25 mg four times a day). Thereafter the total daily dose may be increased by 50 mg as tolerated every 3 days to reach 200 mg/day (50 mg four times a day). After titration, tramadol hydrochloride oral solution 50 mg to 100 mg can be administered as needed for pain relief every 4 to 6 hours not to exceed 400 mg/day.

For the subset of patients for whom rapid onset of analgesic effect is required and for whom the benefits outweigh the risk of discontinuation due to adverse events associated with higher initial doses, tramadol hydrochloride oral solution 50 mg to 100 mg can be administered as needed for pain relief every four to six hours, not to exceed 400 mg/day.

Conversion from tramadol hydrochloride oral solution to Extended-Release Tramadol

The relative bioavailability of tramadol hydrochloride oral solution compared to extended-release tramadol is unknown, so conversion to extended-release formulations may lead to increased risk of excessive sedation and respiratory depression.

Dosage Modification in Patients with Hepatic Impairment

The recommended dose for adult patients with severe hepatic impairment is 50 mg every 12 hours.

Dosage Modification in Patients with Renal Impairment

In all patients with creatinine clearance less than 30 mL/min, it is recommended that the dosing interval of tramadol hydrochloride oral solution be increased to 12 hours, with a maximum daily dose of 200 mg. Since only 7% of an administered dose is removed by hemodialysis, dialysis patients can receive their regular dose on the day of dialysis.

Dosage Modification in Geriatric Patients

Do not exceed a total dose of 300 mg/day in patients over 75 years old.

Individually titrate tramadol hydrochloride oral solution to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving tramadol hydrochloride oral solution to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions ( 5.2, 5.19)] . Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the tramadol hydrochloride oral solution dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase), consider reducing the dosage [see Warnings and Precautions ( 5)] . Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Do not abruptly discontinue tramadol hydrochloride oral solution in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.

When a decision has been made to decrease the dose or discontinue therapy in an opioid- dependent patient taking tramadol hydrochloride oral solution, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride oral solution) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.

There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on tramadol hydrochloride oral solution who are physically opioid-dependent, initiate the taper by a small enough increment, (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.

It may be necessary to provide the patient with a lower dosage strength to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.

When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see Warnings and Precautions ( 5.19), Drug Abuse and Dependence ( 9.3)] .

Tramadol hydrochloride oral solution is supplied as a clear liquid in 16 oz white, opaque plastic bottles, containing tramadol hydrochloride, 5 mg/mL (equivalent to tramadol 4.4 mg per 1 mL).

{ "type": "p", "children": [], "text": "Tramadol hydrochloride oral solution is supplied as a clear liquid in 16 oz white, opaque plastic bottles, containing tramadol hydrochloride, 5 mg/mL (equivalent to tramadol 4.4 mg per 1 mL)." }

Tramadol hydrochloride oral solution is contraindicated for:

{ "type": "p", "children": [], "text": "Tramadol hydrochloride oral solution is contraindicated for:" }

{ "type": "ul", "children": [ "all children younger than 12 years of age\n \n [see Warnings and Precautions (\n \n 5.7)]\n \n .\n \n ", "postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy\n \n [see Warnings and Precautions (\n \n 5.7)]\n \n .\n \n " ], "text": "" }

Tramadol hydrochloride oral solution is also contraindicated in patients with:

{ "type": "p", "children": [], "text": "Tramadol hydrochloride oral solution is also contraindicated in patients with:" }

{ "type": "ul", "children": [ "Significant respiratory depression\n \n [see Warnings and Precautions (\n \n 5.3)]\n \n .\n \n ", "Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment\n \n [see Warnings and Precautions (\n \n 5.13)]\n \n .\n \n ", "Known or suspected gastrointestinal obstruction, including paralytic ileus\n \n [see Warnings and Precautions (\n \n 5.17)]\n \n .\n \n ", "Hypersensitivity to tramadol, any other component of this product or opioids\n \n [see Warnings and Precautions (\n \n 5.18)]\n \n .\n \n ", "Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days\n \n [see Drug Interactions (\n \n 7)]\n \n .\n \n " ], "text": "" }

Dosing errors can result in accidental overdose and death. Avoid dosing errors that may result from confusion between mg and mL when prescribing, dispensing, and administering tramadol hydrochloride oral solution. Ensure that the dose is communicated clearly and dispensed accurately.

Instruct patients and caregivers on how to measure and take or administer the correct dose of tramadol hydrochloride oral solution and to use extreme caution when measuring the dose. Strongly advise patients and caregivers to always use a graduated device that can measure and deliver the prescribed dose accurately, and to never use household teaspoons or tablespoons to measure a dose because these are not adequate measuring devices.

Tramadol hydrochloride oral solution contains tramadol, a Schedule IV controlled substance. As an opioid, tramadol hydrochloride oral solution exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence ( 9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed tramadol hydrochloride oral solution. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing tramadol hydrochloride oral solution, and reassess all patients receiving tramadol hydrochloride oral solution for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as tramadol hydrochloride oral solution, but use in such patients necessitates intensive counseling about the risks and proper use of tramadol hydrochloride oral solution along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.2)] .

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing tramadol hydrochloride oral solution. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see Overdosage ( 10)] . Carbon dioxide (CO 2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of tramadol hydrochloride oral solution, the risk is greatest during the initiation of therapy or following a dosage increase.

To reduce the risk of respiratory depression, proper dosing and titration of tramadol hydrochloride oral solution are essential [see Dosage and Administration ( 2)] . Overestimating the tramadol hydrochloride oral solution dosage when converting patients from another opioid product can result in a fatal overdose with the first dose. Accidental ingestion of even one dose of tramadol hydrochloride oral solution, especially by children, can result in respiratory depression and death due to an overdose of tramadol.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose.

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration ( 2.5)] .

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with tramadol hydrochloride oral solution. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered.

Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone  [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.2, 5.3, 5.4), Overdosage ( 10)] .

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of tramadol hydrochloride oral solution with benzodiazepines and/or other CNS depressants , including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions ( 7)] .

If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation).

If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.3), Overdosage ( 10)] .

Advise both patients and caregivers about the risks of respiratory depression and sedation when tramadol hydrochloride oral solution is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions ( 7)] .

Use of tramadol hydrochloride oral solution for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations ( 8.1)] .

To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following:

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com. FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint.

Life-threatening respiratory depression and death have occurred in children who received tramadol. Tramadol and codeine are subject to variability in metabolism based upon CYP2D6 genotype (described below), which can lead to increased exposure to an active metabolite. Based upon postmarketing reports with tramadol or with codeine, children younger than 12 years of age may be more susceptible to the respiratory depressant effects of tramadol. Furthermore, children with obstructive sleep apnea who are treated with opioids for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to their respiratory depressant effect. Because of the risk of life-threatening respiratory depression and death:

Nursing Mothers

Tramadol is subject to the same polymorphic metabolism as codeine, with ultra-rapid metabolizers of CYP2D6 substrates being potentially exposed to life-threatening levels of the active metabolite O-desmethyltramadol (M1). At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. A baby nursing from an ultra-rapid metabolizer mother taking tramadol hydrochloride oral solution could potentially be exposed to high levels of M1, and experience life-threatening respiratory depression. For this reason, breastfeeding is not recommended during treatment with tramadol hydrochloride oral solution [see Use in Specific Populations ( 8.2)] .

CYP2D6 Genetic Variability: Ultra-rapid Metabolizer

Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (e.g., gene duplications denoted as *1/*1×N or *1/*2×N). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 1 to 10% for Whites (European, North American), 3 to 4% for Blacks (African Americans), 1 to 2% for East Asians (Chinese, Japanese, Korean), and may be greater than 10% in certain racial/ethnic groups (i.e., Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican). These individuals convert tramadol into its active metabolite, O-desmethyltramadol (M1), more rapidly and completely than other people. This rapid conversion results in higher than expected serum M1 levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) [see Overdosage ( 10)] . Therefore, individuals who are ultra-rapid metabolizers should not use tramadol hydrochloride oral solution.

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors on levels of tramadol and M1 from tramadol hydrochloride oral solution are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol hydrochloride oral solution requires careful consideration of the effects on the parent drug, tramadol which is a weak serotonin and norepinephrine reuptake inhibitor and μ-opioid agonist, and the active metabolite, M1, which is more potent than tramadol in μ-opioid receptor binding [see Drug Interactions ( 7)] .

Risks of Concomitant Use or Discontinuation of Cytochrome P450 2D6 Inhibitors

The concomitant use of tramadol hydrochloride oral solution with all cytochrome P450 2D6 inhibitors (e.g., amiodarone, quinidine) may result in an increase in tramadol plasma levels and a decrease in the levels of the active metabolite, M1. A decrease in M1 exposure in patients who have developed physical dependence to tramadol, may result in signs and symptoms of opioid withdrawal and reduced efficacy. The effect of increased tramadol levels may be an increased risk for serious adverse events including seizures and serotonin syndrome.

Discontinuation of a concomitantly used cytochrome P450 2D6 inhibitor may result in a decrease in tramadol plasma levels and an increase in active metabolite M1 levels, which could increase or prolong adverse reactions related to opioid toxicity and may cause potentially fatal respiratory depression.

Evaluate patients receiving tramadol hydrochloride oral solution and any CYP2D6 inhibitor at frequent intervals for the risk of serious adverse events including seizures and serotonin syndrome, signs and symptoms that may reflect opioid toxicity, and opioid withdrawal when tramadol hydrochloride oral solution is used in conjunction with inhibitors of CYP2D6 [see Drug Interactions ( 7)] .

Cytochrome P450 3A4 Interaction

The concomitant use of tramadol hydrochloride oral solution with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations, which could increase or prolong adverse reactions, increase the risk for serious adverse events including seizures and serotonin syndrome, and may cause potentially fatal respiratory depression.

The concomitant use of tramadol hydrochloride oral solution with all cytochrome P450 3A4 inducers or discontinuation of a cytochrome P450 3A4 inhibitor may result in lower tramadol levels. This may be associated with a decrease in efficacy, and in some patients, may result in signs and symptoms of opioid withdrawal.

Evaluate patients receiving tramadol hydrochloride oral solution and any CYP3A4 inhibitor or inducer at frequent intervals for the risk for serious adverse events including seizures and serotonin syndrome, signs and symptoms that may reflect opioid toxicity and opioid withdrawal when tramadol hydrochloride oral solution is used in conjunction with inhibitors and inducers of CYP3A4 [see Drug Interactions ( 7)] .

Opioid-Induced Hyperalgesia and Allodynia Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see Dependence ( 9.3)] . Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.

Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see Dosage and Administration ( 2.5), Warnings and Precautions ( 5.19)]

Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol products, including tramadol hydrochloride oral solution, particularly during concomitant use with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions ( 7)] . This may occur within the recommended dosage range.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and can be fatal. The onset of symptoms generally occurs within several hours to a few days of concomitant use but may occur later than that. Discontinue tramadol hydrochloride oral solution if serotonin syndrome is suspected.

Seizures have been reported in patients receiving tramadol hydrochloride oral solution within the recommended dosage range. Spontaneous postmarketing reports indicate that seizure risk is increased with doses of tramadol hydrochloride oral solution above the recommended range.

Concomitant use of tramadol hydrochloride oral solution increases the seizure risk in patients taking [see Drug Interactions ( 7)] :

Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections). In tramadol hydrochloride oral solution overdose, naloxone administration may increase the risk of seizure [see Overdosage ( 10)] .

The use of tramadol hydrochloride oral solution in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients with Chronic Pulmonary Disease

Tramadol hydrochloride oral solution-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of tramadol hydrochloride oral solution [see Warnings and Precautions ( 5.3)] .

Elderly, Cachectic, or Debilitated Patients

Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see Warnings and Precautions ( 5.3)] .

Regularly evaluate patients closely, particularly when initiating and titrating tramadol hydrochloride oral solution and when tramadol hydrochloride oral solution is given concomitantly with other drugs that depress respiration [see Warnings and Precautions ( 5.3, 5.4), Drug Interactions ( 7)] . Alternatively, consider the use of non-opioid analgesics in these patients.

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Tramadol hydrochloride oral solution may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [see Drug Interactions ( 7)] . Regularly evaluate patients for signs of hypotension after initiating or titrating the dosage of tramadol hydrochloride oral solution. In patients with circulatory shock, tramadol hydrochloride oral solution may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of tramadol hydrochloride oral solution in patients with circulatory shock.

In patients who may be susceptible to the intracranial effects of CO 2retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol hydrochloride oral solution may reduce respiratory drive, and the resultant CO 2retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with tramadol hydrochloride oral solution.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of tramadol hydrochloride oral solution in patients with impaired consciousness or coma.

Tramadol hydrochloride oral solution is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus [see Contraindications ( 4)] .

The tramadol in tramadol hydrochloride oral solution may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis for worsening symptoms.

Serious and rarely fatal anaphylactic reactions have been reported in patients receiving therapy with tramadol hydrochloride oral solution. When these events do occur, it is often following the first dose. Other reported allergic reactions include pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis and Stevens-Johnson syndrome. Patients with a history of hypersensitivity reactions to tramadol and other opioids may be at increased risk and therefore should not receive tramadol hydrochloride oral solution [see Contraindications ( 4)] . If anaphylaxis or other hypersensitivity occurs, stop administration of tramadol hydrochloride oral solution immediately, discontinue tramadol hydrochloride oral solution permanently, and do not rechallenge with any formulation of tramadol. Advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. [see Contraindications ( 4)] .

Do not abruptly discontinue tramadol hydrochloride oral solution in a patient physically dependent on opioids. When discontinuing tramadol hydrochloride oral solution in a physically dependent patient, gradually taper the dosage. Rapid tapering of tramadol in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see Dosage and Administration ( 2.5), Drug Abuse and Dependence ( 9.3)] .

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including tramadol hydrochloride oral solution. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms [see Drug Interactions ( 7)] .

tramadol hydrochloride oral solution may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of tramadol hydrochloride oral solution and know how they will react to the medication.

Hyponatremia (serum sodium < 135 mmol/L) has been reported with the use of tramadol, and many cases are severe (sodium level < 120 mmol/L). Most cases of hyponatremia occurred in females over the age of 65 and within the first week of therapy. In some reports, hyponatremia resulted from the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Monitor for signs and symptoms of hyponatremia (e.g., confusion, disorientation), during treatment with tramadol hydrochloride oral solution, especially during initiation of therapy. If signs and symptoms of hyponatremia are present, initiate appropriate treatment (e.g., fluid restriction) and discontinue tramadol hydrochloride oral solution [see Dosage and Administration( 2.5)] .

Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization. In most cases, patients had predisposing risk factors (e.g. diabetes). If hypoglycemia is suspected, monitor blood glucose levels and consider drug discontinuation as appropriate [see Dosage and Administration( 2.5)] .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tramadol hydrochloride was administered to 550 patients during the double-blind or open-label extension periods in U.S. studies of chronic nonmalignant pain. Of these patients, 375 were 65 years old or older. Table 1 reports the cumulative incidence rate of adverse reactions by 7, 30 and 90 days for the most frequent reactions (5% or more by 7 days). The most frequently reported events were in the central nervous system and gastrointestinal system. Although the reactions listed in the table are felt to be probably related to tramadol hydrochloride administration, the reported rates also include some events that may have been due to underlying disease or concomitant medication. The overall incidence rates of adverse experiences in these trials were similar for tramadol hydrochloride and the active control groups, TYLENOL with Codeine #3 (acetaminophen 300 mg with codeine phosphate 30 mg), and aspirin 325 mg with codeine phosphate 30 mg, however, the rates of withdrawals due to adverse events appeared to be higher in the tramadol hydrochloride groups.

<div class="scrollingtable"><table width="50%"> <caption> <span>Table 1: Cumulative Incidence of Adverse Reactions for Tramadol HCl Tablets in Chronic Trials of Nonmalignant Pain (N=427)</span> </caption> <col align="left" valign="top" width="30%"/> <col align="center" valign="top" width="23%"/> <col align="center" valign="top" width="23%"/> <col align="center" valign="top" width="24%"/> <thead> <tr class="First First Last Last"> <th align="left"></th><th align="center">Up to 7 Days</th><th align="center">Up to 30 Days</th><th align="center">Up to 90 Days</th> </tr> </thead> <tfoot> <tr> <td align="left" colspan="4"> <dl class="Footnote"> <dt> <a href="#footnote-reference-1" name="footnote-1">*</a> </dt> <dd>CNS Stimulation is a composite of nervousness, anxiety, agitation, tremor, spasticity, euphoria, emotional lability and hallucinations</dd> </dl> </td> </tr> </tfoot> <tbody> <tr class="First"> <td align="left">Dizziness/Vertigo</td><td align="center">26%</td><td align="center">31%</td><td align="center">33%</td> </tr> <tr> <td align="left">Nausea</td><td align="center">24%</td><td align="center">34%</td><td align="center">40%</td> </tr> <tr> <td align="left">Constipation</td><td align="center">24%</td><td align="center">38%</td><td align="center">46%</td> </tr> <tr> <td align="left">Headache</td><td align="center">18%</td><td align="center">26%</td><td align="center">32%</td> </tr> <tr> <td align="left">Somnolence</td><td align="center">16%</td><td align="center">23%</td><td align="center">25%</td> </tr> <tr> <td align="left">Vomiting</td><td align="center">9%</td><td align="center">13%</td><td align="center">17%</td> </tr> <tr> <td align="left">Pruritus</td><td align="center">8%</td><td align="center">10%</td><td align="center">11%</td> </tr> <tr> <td align="left">CNS Stimulation <a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a></td><td align="center">7%</td><td align="center">11%</td><td align="center">14%</td> </tr> <tr> <td align="left">Asthenia</td><td align="center">6%</td><td align="center">11%</td><td align="center">12%</td> </tr> <tr> <td align="left">Sweating</td><td align="center">6%</td><td align="center">7%</td><td align="center">9%</td> </tr> <tr> <td align="left">Dyspepsia</td><td align="center">5%</td><td align="center">9%</td><td align="center">13%</td> </tr> <tr> <td align="left">Dry Mouth</td><td align="center">5%</td><td align="center">9%</td><td align="center">10%</td> </tr> <tr class="Last"> <td align="left">Diarrhea</td><td align="center">5%</td><td align="center">6%</td><td align="center">10%</td> </tr> </tbody> </table></div>

Incidence 1% to Less than 5% Possibly Causally Related

The following lists adverse reactions that occurred with an incidence of 1% to less than 5% in clinical trials, and for which the possibility of a causal relationship with tramadol hydrochloride exists.

Body as a Whole: Malaise.

Cardiovascular: Vasodilation.

Central Nervous System: Anxiety, Confusion, Coordination disturbance, Euphoria, Miosis, Nervousness, Sleep disorder.

Gastrointestinal: Abdominal pain, Anorexia, Flatulence.

Musculoskeletal: Hypertonia.

Skin: Rash.

Special Senses: Visual disturbance.

Urogenital: Menopausal symptoms, Urinary frequency, Urinary retention.

Incidence Less than 1%, Possibly Causally Related

The following lists adverse reactions that occurred with an incidence of less than 1% in clinical trials of tramadol and/or reported in postmarketing experience with tramadol-containing products.

Body as a Whole: Accidental injury, Allergic reaction, Anaphylaxis, Death, Suicidal tendency, Weight loss, Serotonin syndrome (mental status change, hyperreflexia, fever, shivering, tremor, agitation, diaphoresis, seizures and coma).

Cardiovascular: Orthostatic hypotension, Syncope, Tachycardia.

Central Nervous System: Abnormal gait, Amnesia, Cognitive dysfunction, Depression, Difficulty in concentration, Hallucinations, Paresthesia, Seizure, Tremor.

Respiratory: Dyspnea.

Skin: Stevens-Johnson syndrome/Toxic epidermal necrolysis, Urticaria, Vesicles.

Special Senses: Dysgeusia.

Urogenital: Dysuria, Menstrual disorder.

Other Adverse Experiences, Causal Relationship Unknown

A variety of other adverse events were reported infrequently in patients taking tramadol hydrochloride during clinical trials and/or reported in postmarketing experience. A causal relationship between tramadol hydrochloride and these events has not been determined. However, the most significant events are listed below as alerting information to the physician.

Cardiovascular: Abnormal ECG, Hypertension, Hypotension, Myocardial ischemia, Palpitations, Pulmonary edema, Pulmonary embolism.

Central Nervous System: Migraine.

Gastrointestinal: Gastrointestinal bleeding, Hepatitis, Stomatitis, Liver failure.

Laboratory Abnormalities: Creatinine increase, Elevated liver enzymes, Hemoglobin decrease, Proteinuria.

Sensory: Cataracts, Deafness, Tinnitus.

The following adverse reactions have been identified during post-approval use of tramadol hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.

Androgen deficiency: Cases of androgen deficiency have occurred with use of opioids for an extended period of time.  [see Clinical Pharmacology ( 12.2)] .

QT prolongation/torsade de pointes: Cases of QT prolongation and/or torsade de pointeshave been reported with tramadol use. Many of these cases were reported in patients taking another drug labeled for QT prolongation, in patients with a risk factor for QT prolongation (e.g., hypokalemia), or in the overdose setting.

Eye disorders– mydriasis

Metabolism and nutrition disorders

Hyponatremia: Cases of severe hyponatremia and/or SIADH have been reported in patients taking tramadol, most often in females over the age of 65, and within the first week of therapy [see Warnings and Precautions ( 5.21)] .

Hypoglycemia: Cases of hypoglycemia have been reported in patients taking tramadol. Most reports were in patients with predisposing risk factors, including diabetes or renal insufficiency, or in elderly patients [see Warnings and Precautions ( 5.22)] .

Nervous system disorders– movement disorder, speech disorder

Psychiatric disorders– delirium

Hyperalgesia and Allodynia: Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see Warnings and Precautions ( 5.9)] .

<div class="scrollingtable"><table width="75%"> <caption> <span>Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Oral Solution</span> </caption> <col align="right" width="25%"/> <col align="left" width="75%"/> <tbody class="Headless"> <tr class="Botrule First First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Inhibitors of CYP2D6</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">The concomitant use of tramadol hydrochloride oral solution and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride oral solution is achieved. Since M1 is a more potent µ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome. <br/> After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase. This could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, such as potentially fatal respiratory depression <span class="Italics">[see Clinical Pharmacology ( <a href="#S12.3">12.3</a>)] </span>. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures and serotonin syndrome. If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride oral solution dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">Quinidine, fluoxetine, paroxetine and bupropion</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Inhibitors of CYP3A4</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">The concomitant use of tramadol hydrochloride oral solution and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Evaluate patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride oral solution is achieved. <br/> After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <span class="Italics">[see Clinical Pharmacology ( <a href="#S12.3">12.3</a>)] </span>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to tramadol. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">If concomitant use is necessary, consider dosage reduction of tramadol hydrochloride oral solution until stable drug effects are achieved. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of seizures, serotonin syndrome, and signs of respiratory depression and sedation at frequent intervals. <br/> If a CYP3A4 inhibitor is discontinued, consider increasing the tramadol hydrochloride oral solution dosage until stable drug effects are achieved and evaluate patients at frequent intervals for signs and symptoms of opioid withdrawal. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">CYP3A4 Inducers</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">The concomitant use of tramadol hydrochloride oral solution and CYP3A4 inducers can decrease the plasma concentration of tramadol <span class="Italics">[see Clinical Pharmacology ( <a href="#S12.3">12.3</a>)] </span>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol <span class="Italics">[see Warnings and Precautions ( <a href="#S5.8">5.8</a>)] </span>. <br/> After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <span class="Italics">[see Clinical Pharmacology ( <a href="#S12.3">12.3</a>)] </span>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures, serotonin syndrome, and/or potentially fatal respiratory depression. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">If concomitant use is necessary, consider increasing the tramadol hydrochloride oral solution dosage until stable drug effects are achieved. Evaluate patients for signs of opioid withdrawal. <br/> If a CYP3A4 inducer is discontinued, consider tramadol hydrochloride oral solution dosage reduction and evaluate patients at frequent intervals for seizures and serotonin syndrome, and signs of respiratory depression and sedation. <br/> Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of tramadol hydrochloride oral solution and carbamazepine is not recommended. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">Rifampin, carbamazepine, phenytoin</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death <span class="Italics">[see Warnings and Precautions ( <a href="#S5.4">5.4</a>)] </span>. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <span class="Italics">[see Dosage and Administration ( <a href="#S2.2">2.2</a>), Warnings and Precautions ( <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4</a>)] </span>. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, and alcohol.</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Serotonergic Drugs</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <span class="Italics">[see Warnings and Precautions ( <a href="#S5.10">5.10</a>)] </span>. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride oral solution immediately if serotonin syndrome is suspected.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Monoamine Oxidase Inhibitors (MAOIs)</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">MAOI interactions with opioids may manifest as serotonin syndrome <span class="Italics">[see Warnings and Precautions ( <a href="#S5.10">5.10</a>)] </span>or opioid toxicity (e.g., respiratory depression, coma) <span class="Italics">[see Warnings and Precautions ( <a href="#S5.3">5.3</a>)] </span>. </td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Do not use tramadol hydrochloride oral solution in patients taking MAOIs or within 14 days of stopping such treatment.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">phenelzine, tranylcypromine, linezolid</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">May reduce the analgesic effect of tramadol hydrochloride oral solution and/or precipitate withdrawal symptoms.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Avoid concomitant use.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Examples</span></td><td align="left" class="Botrule Lrule Rrule">butorphanol, nalbuphine, pentazocine, buprenorphine</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Muscle Relaxants</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Because respiratory depression may be greater than otherwise expected, decrease the dosage of tramadol hydrochloride oral solution and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <span class="Italics">[see Dosage and Administration <a href="#S2.2">(2.2</a>), Warnings and Precautions ( <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4</a>)] </span>. </td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Diuretics</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Anticholinergic Drugs</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Evaluate patients for signs of urinary retention or reduced gastric motility when tramadol hydrochloride oral solution is used concomitantly with anticholinergic drugs.</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Digoxin</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">Postmarketing surveillance of tramadol has revealed rare reports of digoxin toxicity.</td> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Evaluate patients at frequent intervals for signs of digoxin toxicity and adjust dosage of digoxin as needed.</td> </tr> <tr class="Botrule First Last"> <th align="left" class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Warfarin</span></th> </tr> <tr> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Clinical Impact:</span></td><td align="left" class="Botrule Lrule Rrule">Postmarketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.</td> </tr> <tr class="Last"> <td align="right" class="Botrule Lrule Rrule" valign="top"><span class="Italics">Intervention:</span></td><td align="left" class="Botrule Lrule Rrule">Frequently reevaluate the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.</td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"75%\">\n<caption>\n<span>Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Oral Solution</span>\n</caption>\n<col align=\"right\" width=\"25%\"/>\n<col align=\"left\" width=\"75%\"/>\n<tbody class=\"Headless\">\n<tr class=\"Botrule First First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Inhibitors of CYP2D6</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">The concomitant use of tramadol hydrochloride oral solution and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride oral solution is achieved. Since M1 is a more potent µ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome. \n <br/> After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase. This could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, such as potentially fatal respiratory depression\n \n <span class=\"Italics\">[see Clinical Pharmacology (\n \n <a href=\"#S12.3\">12.3</a>)]\n \n </span>.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures and serotonin syndrome. If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride oral solution dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Quinidine, fluoxetine, paroxetine and bupropion</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Inhibitors of CYP3A4</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">The concomitant use of tramadol hydrochloride oral solution and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Evaluate patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride oral solution is achieved. \n <br/> After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease\n \n <span class=\"Italics\">[see Clinical Pharmacology (\n \n <a href=\"#S12.3\">12.3</a>)]\n \n </span>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to tramadol.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">If concomitant use is necessary, consider dosage reduction of tramadol hydrochloride oral solution until stable drug effects are achieved. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of seizures, serotonin syndrome, and signs of respiratory depression and sedation at frequent intervals. \n <br/> If a CYP3A4 inhibitor is discontinued, consider increasing the tramadol hydrochloride oral solution dosage until stable drug effects are achieved and evaluate patients at frequent intervals for signs and symptoms of opioid withdrawal.\n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">CYP3A4 Inducers</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">The concomitant use of tramadol hydrochloride oral solution and CYP3A4 inducers can decrease the plasma concentration of tramadol\n \n <span class=\"Italics\">[see Clinical Pharmacology (\n \n <a href=\"#S12.3\">12.3</a>)]\n \n </span>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol\n \n <span class=\"Italics\">[see Warnings and Precautions (\n \n <a href=\"#S5.8\">5.8</a>)]\n \n </span>. \n <br/> After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase\n \n <span class=\"Italics\">[see Clinical Pharmacology (\n \n <a href=\"#S12.3\">12.3</a>)]\n \n </span>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures, serotonin syndrome, and/or potentially fatal respiratory depression.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">If concomitant use is necessary, consider increasing the tramadol hydrochloride oral solution dosage until stable drug effects are achieved. Evaluate patients for signs of opioid withdrawal. \n <br/> If a CYP3A4 inducer is discontinued, consider tramadol hydrochloride oral solution dosage reduction and evaluate patients at frequent intervals for seizures and serotonin syndrome, and signs of respiratory depression and sedation. \n <br/> Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of tramadol hydrochloride oral solution and carbamazepine is not recommended.\n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Rifampin, carbamazepine, phenytoin</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Benzodiazepines and Other Central Nervous System (CNS) Depressants</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death\n \n <span class=\"Italics\">[see Warnings and Precautions (\n \n <a href=\"#S5.4\">5.4</a>)]\n \n </span>.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose\n \n <span class=\"Italics\">[see Dosage and Administration (\n \n <a href=\"#S2.2\">2.2</a>), Warnings and Precautions (\n \n <a href=\"#S5.2\">5.2</a>,\n \n <a href=\"#S5.3\">5.3</a>,\n \n <a href=\"#S5.4\">5.4</a>)]\n \n </span>.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, and alcohol.</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Serotonergic Drugs</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome\n \n <span class=\"Italics\">[see Warnings and Precautions (\n \n <a href=\"#S5.10\">5.10</a>)]\n \n </span>.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride oral solution immediately if serotonin syndrome is suspected.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Monoamine Oxidase Inhibitors (MAOIs)</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">MAOI interactions with opioids may manifest as serotonin syndrome\n \n <span class=\"Italics\">[see Warnings and Precautions (\n \n <a href=\"#S5.10\">5.10</a>)]\n \n </span>or opioid toxicity (e.g., respiratory depression, coma)\n \n <span class=\"Italics\">[see Warnings and Precautions (\n \n <a href=\"#S5.3\">5.3</a>)]\n \n </span>.\n \n </td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Do not use tramadol hydrochloride oral solution in patients taking MAOIs or within 14 days of stopping such treatment.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">phenelzine, tranylcypromine, linezolid</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">May reduce the analgesic effect of tramadol hydrochloride oral solution and/or precipitate withdrawal symptoms.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Avoid concomitant use.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Examples</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">butorphanol, nalbuphine, pentazocine, buprenorphine</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Muscle Relaxants</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Because respiratory depression may be greater than otherwise expected, decrease the dosage of tramadol hydrochloride oral solution and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose\n \n <span class=\"Italics\">[see Dosage and Administration\n \n <a href=\"#S2.2\">(2.2</a>), Warnings and Precautions (\n \n <a href=\"#S5.3\">5.3</a>,\n \n <a href=\"#S5.4\">5.4</a>)]\n \n </span>.\n \n </td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Diuretics</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Anticholinergic Drugs</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Evaluate patients for signs of urinary retention or reduced gastric motility when tramadol hydrochloride oral solution is used concomitantly with anticholinergic drugs.</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Digoxin</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Postmarketing surveillance of tramadol has revealed rare reports of digoxin toxicity.</td>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Evaluate patients at frequent intervals for signs of digoxin toxicity and adjust dosage of digoxin as needed.</td>\n</tr>\n<tr class=\"Botrule First Last\">\n<th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\"><span class=\"Bold\">Warfarin</span></th>\n</tr>\n<tr>\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Clinical Impact:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Postmarketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.</td>\n</tr>\n<tr class=\"Last\">\n<td align=\"right\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Italics\">Intervention:</span></td><td align=\"left\" class=\"Botrule Lrule Rrule\">Frequently reevaluate the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.</td>\n</tr>\n</tbody>\n</table></div>" }

Risk Summary

Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome  [see Warnings and Precautions ( 5.5)] . Available data with tramadol hydrochloride oral solution in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage or adverse maternal outcomes. There are adverse outcomes reported with fetal exposure to opioid analgesics ( see Clinical Considerations).

In animal reproduction studies, tramadol administration during organogenesis decreased fetal weights and reduced ossification in mice, rats, and rabbits at 1.4, 0.6, and 3.6 times the maximum recommended human daily dosage (MRHD). In a pre- and post-natal development study, tramadol decreased pup body weight and increased pup mortality at 1.2 and 1.9 times the MRHD. In a published study, tramadol caused structural abnormalities in the brains of fetuses when administered to female Sprague Dawley rats from Gestation Days 10-21 at a dose comparable to the MRHD [see Data] . Based on animal data, advise pregnant women of the potential risk to a fetus.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in respiratory depression and physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

Neonatal opioid withdrawal syndrome can present as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms and signs of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings and Precautions ( 5.5)] .

Neonatal seizures, neonatal withdrawal syndrome, fetal death and still birth have been reported during postmarketing.

Labor or Delivery

Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Tramadol hydrochloride oral solution is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including tramadol hydrochloride oral solution, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.

Tramadol has been shown to cross the placenta. The mean ratio of serum tramadol in the umbilical veins compared to maternal veins was 0.83 for 40 women given tramadol during labor.

The effect of tramadol hydrochloride, if any, on the later growth, development, and functional maturation of the child is unknown.

Data

Animal Data

Tramadol has been shown to be embryotoxic and fetotoxic in mice, (120 mg/kg), rats (25 mg/kg) and rabbits (75 mg/kg) at maternally toxic dosages, but did not cause malformations at these dose levels. These doses on a mg/m 2basis are 1.4, 0.6, and 3.6 times the maximum recommended human daily dosage (MRHD) for mouse, rat and rabbit, respectively.

No drug-related malformations were observed in progeny of mice (up to 140 mg/kg), rats (up to 80 mg/kg) or rabbits (up to 300 mg/kg) treated with tramadol by various routes. Embryo and fetal toxicity consisted primarily of decreased fetal weights, decreased skeletal ossification and increased supernumerary ribs at maternally toxic dose levels. Transient delays in developmental or behavioral parameters were also seen in pups from rat dams allowed to deliver. Embryo and fetal lethality were reported only in one rabbit study at 300 mg/kg, a dose that would cause extreme maternal toxicity in the rabbit. The dosages listed for mouse, rat and rabbit are 1.7, 1.9 and 14.6 times the MRHD, respectively.

Tramadol was evaluated in pre- and post-natal studies in rats. Progeny of dams receiving oral (gavage) dose levels of 50 mg/kg (1.2 times the MRHD) or greater had decreased weights, and pup survival was decreased early in lactation at 80 mg/kg (1.9 times the MRHD).

Risk Summary

Tramadol hydrochloride oral solution is not recommended for obstetrical preoperative medication or for post-delivery analgesia in nursing mothers because its safety in infants and newborns has not been well studied.

Tramadol and its metabolite, O-desmethyltramadol (M1), are present in human milk. There is no information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The M1 metabolite is more potent than tramadol in mu opioid receptor binding [see Clinical Pharmacology ( 12)] . Published studies have reported tramadol and M1 in colostrum with administration of tramadol to nursing mothers in the early post-partum period. Women who are ultra-rapid metabolizers of tramadol may have higher than expected serum levels of M1, potentially leading to higher levels of M1 in breast milk that can be dangerous in their breastfed infants. In women with normal tramadol metabolism, the amount of tramadol secreted into human milk is low and dose-dependent. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with tramadol hydrochloride oral solution [see Warnings and Precautions ( 5.3, 5.5)] .

Clinical Considerations

If infants are exposed to tramadol hydrochloride oral solution through breast milk, they should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.

Data

Following a single IV 100 mg dose of tramadol, the cumulative excretion in breast milk within 16 hours post dose was 100 mcg of tramadol (0.1% of the maternal dose) and 27 mcg of M1.

Infertility

Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Adverse Reactions ( 6.2)] .

Published studies in adult male rodents report that tramadol, at clinically relevant doses, can produce adverse effects on male reproductive hormones and tissues [See Nonclinical Toxicology ( 13.1)] .

The safety and effectiveness of tramadol in pediatric patients have not been established.

Life-threatening respiratory depression and death have occurred in children who received tramadol [see Warnings and Precautions ( 5.3)] . In some of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and one of the children had evidence of being an ultra-rapid metabolizer of tramadol (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of tramadol. Because of the risk of life-threatening respiratory depression and death:

A total of 455 elderly (65 years of age or older) subjects were exposed to tramadol hydrochloride in controlled clinical trials. Of those, 145 subjects were 75 years of age and older.

In studies including geriatric patients, treatment-limiting adverse events were higher in subjects over 75 years of age compared to those under 65 years of age. Specifically, 30% of those over 75 years of age had gastrointestinal treatment-limiting adverse events compared to 17% of those under 65 years of age. Constipation resulted in discontinuation of treatment in 10% of those over 75.

Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of tramadol hydrochloride oral solution slowly in geriatric patients starting at the low end of the dosing range and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions ( 5.13)] .

Tramadol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.

Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, dosing reduction is recommended [see Dosage and Administration ( 2.3)] . Metabolism of tramadol and M1 is reduced in patients with severe hepatic impairment based on a study in patients with advanced cirrhosis of the liver. In patients with severe hepatic impairment, dosing reduction is recommended [see Dosage and Administration ( 2.3)] .

With the prolonged half-life in these conditions, achievement of steady-state is delayed, so that it may take several days for elevated plasma concentrations to develop.

Tramadol hydrochloride oral solution contains tramadol, a Schedule IV controlled substance.

Tramadol hydrochloride oral solution contains tramadol, a substance with potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see Warnings and Precautions ( 5.2)] .

Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed.

Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of tramadol hydrochloride oral solution increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of tramadol hydrochloride oral solution with alcohol and/or other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.

All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of tramadol hydrochloride oral solution abuse include those with a history of prolonged use of any opioid, including products containing tramadol, those with a history of drug or alcohol abuse, or those who use tramadol hydrochloride oral solution in combination with other abused drugs.

“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.

Tramadol hydrochloride oral solution, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of Tramadol Hydrochloride Oral Solution

Abuse of tramadol hydrochloride oral solution poses a risk of overdose and death. The risk is increased with concurrent use of tramadol hydrochloride oral solution with alcohol and/or other CNS depressants.

Tramadol hydrochloride oral solution is approved for oral use only.

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue tramadol hydrochloride oral solution in a patient physically dependent on opioids. Rapid tapering of tramadol hydrochloride oral solution in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug seeking for abuse.

When discontinuing tramadol hydrochloride oral solution, gradually taper the dosage using a patient specific plan that considers the following: the dose of tramadol hydrochloride oral solution the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage and Administration ( 2.5), and Warnings and Precautions ( 5.19)] .

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations ( 8.1)] .

Clinical Presentation

Acute overdosage with tramadol can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, QT prolongation, hypotension, partial or complete airway obstruction, atypical snoring, seizures, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

Deaths due to overdose have been reported with abuse and misuse of tramadol [see Warnings and Precautions ( 5.2), Drug Abuse and Dependence ( 9.2)] . Review of case reports has indicated that the risk of fatal overdose is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids.

Treatment of Overdose

In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or serious arrhythmias will require advanced life-supporting measures.

Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to tramadol overdose, administer an opioid antagonist.

While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals, convulsions following the administration of toxic doses of tramadol hydrochloride could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.

Because the duration of opioid reversal is expected to be less than the duration of action of tramadol in tramadol hydrochloride oral solution, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information.

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.

Tramadol hydrochloride oral solution is an opioid agonist. The chemical name for tramadol hydrochloride is (±) cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. The structural formula is:

{ "type": "p", "children": [], "text": "Tramadol hydrochloride oral solution is an opioid agonist. The chemical name for tramadol hydrochloride is (±)\n \n cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. The structural formula is:\n\n " }

The molecular formula of tramadol hydrochloride is C 16H 25NO 2 · HCl, and the molecular weight is 299.8. Tramadol hydrochloride is a white, bitter, crystalline and odorless powder. It is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7. Tramadol hydrochloride oral solution is a clear, grape flavored liquid containing 5 mg of tramadol hydrochloride per 1 mL (equivalent to tramadol 4.4 mg per 1 mL)

{ "type": "p", "children": [], "text": "The molecular formula of tramadol hydrochloride is C\n \n 16H\n \n 25NO\n \n 2 · HCl, and the molecular weight is 299.8. Tramadol hydrochloride is a white, bitter, crystalline and odorless powder. It is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7. Tramadol hydrochloride oral solution is a clear, grape flavored liquid containing 5 mg of tramadol hydrochloride per 1 mL (equivalent to tramadol 4.4 mg per 1 mL)\n\n " }

Inactive ingredients include: citric acid, glycerin, grape flavor, propylene glycol, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose.

{ "type": "p", "children": [], "text": "Inactive ingredients include: citric acid, glycerin, grape flavor, propylene glycol, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose." }

Tramadol hydrochloride oral solution contains tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re-uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to µ-opioid receptors and weak inhibition of re-uptake of norepinephrine and serotonin.

Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in µ-opioid binding. Tramadol-induced analgesia is only partially antagonized by the opioid antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human analgesia is dependent upon the plasma concentrations of each compound [see Clinical Pharmacology ( 12.2)] .

Analgesia in humans begins approximately within one hour after administration and reaches a peak in approximately two to three hours.

Effects on the Central Nervous System

Tramadol produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.

Tramadol administration may produce a constellation of symptoms including nausea and vomiting, dizziness, and somnolence.

Tramadol causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Effects on the Gastrointestinal Tract and Other Smooth Muscle

Tramadol causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Effects on the Cardiovascular System

Tramadol produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of peripheral vasodilation may include pruritus, flushing, red eyes, sweating and/or orthostatic hypotension.

The effect of oral tramadol on the QTcF interval was evaluated in a double-blind, randomized, four-way crossover, placebo- and positive- (moxifloxacin) controlled study in 68 adult male and female healthy subjects. At a 600 mg/day dose (1.5-fold the maximum immediate-release daily dose), the study demonstrated no significant effect on the QTcF interval.

Effects on the Endocrine System

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon [see Warnings and Precautions ( 5.14); Adverse Reactions ( 6)] .

Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [see Adverse Reactions ( 6)] .

Effects on the Immune System

Opioids have been shown to have a variety of effects on components of the immune system in in vitroand animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.

Concentration–Efficacy Relationships

The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists. The minimum effective analgesic concentration of tramadol for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome and/or the development of analgesic tolerance [see Dosage and Administration ( 2.1, 2.4)] .

Concentration–Adverse Reaction Relationships

There is a relationship between increasing tramadol plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions [see Dosage and Administration ( 2.1, 2.4)] .

The analgesic activity of tramadol hydrochloride oral solution is due to both parent drug and the M1 metabolite [see Clinical Pharmacology ( 12.1, 12.2)] . Tramadol is administered as a racemate and both the [-] and [+] forms of both tramadol and M1 are detected in the circulation. Linear pharmacokinetics have been observed following multiple doses of 50 and 100 mg to steady-state.

Absorption

Table 3shows the mean plasma concentrations of tramadol and M1 pharmacokinetic parameters following a single-dose administration of 50 mg tramadol hydrochloride oral solution and 50 mg immediate-release tramadol tablet under fasted conditions in healthy adult subjects.

<div class="scrollingtable"><table width="70%"> <caption> <span>Table 3: Summary of Tramadol and M1 Pharmacokinetic Parameters Following Single Dose Administration Under Fasted Condition in Healthy Adult Subjects</span> </caption> <col width="10%"/> <col width="15%"/> <col width="15%"/> <col width="15%"/> <col width="15%"/> <tfoot> <tr> <td align="left" colspan="5"> <dl class="Footnote"> <dt> <a href="#footnote-reference-2" name="footnote-2">*</a> </dt> <dd>median (min – max)</dd> </dl> </td> </tr> </tfoot> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" rowspan="3">Parameters</td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol Hydrochloride Oral Solution <br/> 50 mg <br/> Fasted </td><td align="center" class="Botrule Lrule Rrule Toprule">Immediate-release tramadol <br/> tablet <br/> 50 mg <br/> Fasted </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol Hydrochloride Oral Solution <br/> 50 mg <br/> Fasted </td><td align="center" class="Botrule Lrule Rrule Toprule">Immediate-release tramadol <br/> tablet <br/> 50 mg <br/> Fasted </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule" colspan="2">Tramadol</td><td align="center" class="Botrule Lrule Rrule Toprule" colspan="2">M1</td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule">Mean ± SD</td><td align="center" class="Botrule Lrule Rrule Toprule">Mean ± SD</td><td align="center" class="Botrule Lrule Rrule Toprule">Mean ± SD</td><td align="center" class="Botrule Lrule Rrule Toprule">Mean ± SD</td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule">T <span class="Sub">max</span><a class="Sup" href="#footnote-2" name="footnote-reference-2">*</a>(hr) </td><td align="center" class="Botrule Lrule Rrule Toprule">1.5 (0.50 2.50)</td><td align="center" class="Botrule Lrule Rrule Toprule">1.5 (0.75 3.0)</td><td align="center" class="Botrule Lrule Rrule Toprule">2.0 (0.50 5.00)</td><td align="center" class="Botrule Lrule Rrule Toprule">2.25 (1.25 10.00)</td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule">C <span class="Sub">max</span>(ng/mL) </td><td align="center" class="Botrule Lrule Rrule Toprule">180.20 ± 33.81</td><td align="center" class="Botrule Lrule Rrule Toprule">173.51 ± 29.59</td><td align="center" class="Botrule Lrule Rrule Toprule">47.77 ± 19.06</td><td align="center" class="Botrule Lrule Rrule Toprule">46.14 ± 18.28</td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule">AUC <span class="Sub">0-t</span>(hr*ng/mL) </td><td align="center" class="Botrule Lrule Rrule Toprule">1623.93 ± 502.43</td><td align="center" class="Botrule Lrule Rrule Toprule">1681.64 ± 578.06</td><td align="center" class="Botrule Lrule Rrule Toprule">624.12 ± 205.58</td><td align="center" class="Botrule Lrule Rrule Toprule">624.10 ± 199.82</td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule">AUC <span class="Sub">0-inf</span>(hr*ng/mL) </td><td align="center" class="Botrule Lrule Rrule Toprule">1658.31 ± 525.97</td><td align="center" class="Botrule Lrule Rrule Toprule">1721.47 ± 624.72</td><td align="center" class="Botrule Lrule Rrule Toprule">638.95 ± 207.13</td><td align="center" class="Botrule Lrule Rrule Toprule">639.26 ± 198.04</td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule Toprule">t <span class="Sub">1/2</span>(hr) </td><td align="center" class="Botrule Lrule Rrule Toprule">7.65 ± 1.63</td><td align="center" class="Botrule Lrule Rrule Toprule">7.61 ± 1.82</td><td align="center" class="Botrule Lrule Rrule Toprule">7.94 ± 1.65</td><td align="center" class="Botrule Lrule Rrule Toprule">8.06 ± 2.11</td> </tr> </tbody> </table></div>

The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults. In general, both enantiomers of tramadol and M1 follow a parallel time course in the body following single and multiple doses although small differences (~ 10%) exist in the absolute amount of each enantiomer present.

Steady-state plasma concentrations of both tramadol and M1 are achieved within two days with four-times-per-day dosing. There is no evidence of self-induction (see Figure 1and Table 4below).

Figure 1: Mean Tramadol and M1 Plasma Concentration Profiles after a Single 100 mg Oral Dose and after Twenty-Nine 100 mg Oral Doses of Tramadol HCl given four times per day.

<div class="scrollingtable"><table width="75%"> <caption> <span>Table 4: Mean (%CV) Pharmacokinetic Parameters for Racemic Tramadol and M1 Metabolite</span> </caption> <col align="left" valign="top" width="18%"/> <col align="center" valign="top" width="16%"/> <col align="center" valign="top" width="17%"/> <col align="center" valign="top" width="16%"/> <col align="center" valign="top" width="17%"/> <col align="center" valign="top" width="16%"/> <thead> <tr class="First First Last Last"> <th align="left" class="Botrule Lrule Rrule Toprule" valign="bottom">Population/Dosage Regimen <a class="Sup" href="#footnote-3" name="footnote-reference-3">*</a></th><th align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">Parent Drug/ Metabolite</th><th align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">Peak Conc.(ng/mL)</th><th align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">Time to Peak (hrs)</th><th align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">Clearance/F b <a class="Sup" href="#footnote-4" name="footnote-reference-4">†</a>(mL/min/Kg) </th><th align="center" class="Botrule Lrule Rrule Toprule" valign="bottom">t <span class="Sub">1/2</span>(hrs) </th> </tr> </thead> <tfoot> <tr> <td align="left" colspan="6"> <dl class="Footnote"> <dt> <a href="#footnote-reference-3" name="footnote-3">*</a> </dt> <dd>SD = Single dose, MD = Multiple dose, p.o.= Oral administration, i.v.= Intravenous administration, q.i.d. = Four times daily</dd> <dt> <a href="#footnote-reference-4" name="footnote-4">†</a> </dt> <dd>F represents the oral bioavailability of tramadol</dd> <dt> <a href="#footnote-reference-5" name="footnote-5">‡</a> </dt> <dd>Not applicable</dd> <dt> <a href="#footnote-reference-6" name="footnote-6">§</a> </dt> <dd>Not measured</dd> </dl> </td> </tr> </tfoot> <tbody> <tr class="First"> <td align="left" class="Botrule Lrule Rrule Toprule">Healthy Adults, <br/> 100 mg qid, MD p.o. </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol <br/> M1 </td><td align="center" class="Botrule Lrule Rrule Toprule">592 (30) <br/> 110 (29) </td><td align="center" class="Botrule Lrule Rrule Toprule">2.3 (61) <br/> 2.4 (46) </td><td align="center" class="Botrule Lrule Rrule Toprule">5.90 (25) <a class="Sup" href="#footnote-5" name="footnote-reference-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">6.7 (15) <br/> 7.0 (14) </td> </tr> <tr> <td align="left" class="Botrule Lrule Rrule Toprule">Healthy Adults, <br/> 100 mg SD p.o. </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol <br/> M1 </td><td align="center" class="Botrule Lrule Rrule Toprule">308 (25) <br/> 55.0 (36) </td><td align="center" class="Botrule Lrule Rrule Toprule">1.6 (63) <br/> 3.0 (51) </td><td align="center" class="Botrule Lrule Rrule Toprule">8.50 (31) <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">5.6 (20) <br/> 6.7 (16) </td> </tr> <tr> <td align="left" class="Botrule Lrule Rrule Toprule">Geriatric, (&gt;75 yrs) <br/> 50 mg SD p.o. </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol <br/> M1 </td><td align="center" class="Botrule Lrule Rrule Toprule">208 (31) <a class="Sup" href="#footnote-6" name="footnote-reference-6">§</a></td><td align="center" class="Botrule Lrule Rrule Toprule">2.1 (19) <a class="Sup" href="#footnote-6">§</a></td><td align="center" class="Botrule Lrule Rrule Toprule">6.89 (25) <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">7.0 (23) <a class="Sup" href="#footnote-6">§</a></td> </tr> <tr> <td align="left" class="Botrule Lrule Rrule Toprule">Hepatic Impaired, <br/> 50 mg SD p.o. </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol <br/> M1 </td><td align="center" class="Botrule Lrule Rrule Toprule">217 (11) <br/> 19.4 (12) </td><td align="center" class="Botrule Lrule Rrule Toprule">1.9 (16) <br/> 9.8 (20) </td><td align="center" class="Botrule Lrule Rrule Toprule">4.23 (56) <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">13.3 (11) <br/> 18.5 (15) </td> </tr> <tr> <td align="left" class="Botrule Lrule Rrule Toprule">Renal Impaired, <br/> CLcr1030 mL/min <br/> 100 mg SD i.v. </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol <br/> M1 </td><td align="center" class="Botrule Lrule Rrule Toprule"><a class="Sup" href="#footnote-5">‡</a> <br/> <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule"><a class="Sup" href="#footnote-5">‡</a> <br/> <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">4.23 (54) <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">10.6 (31) <br/> 11.5 (40) </td> </tr> <tr class="Last"> <td align="left" class="Botrule Lrule Rrule Toprule">Renal Impaired, <br/> CLcr&lt;5 mL/min <br/> 100 mg SD i.v. </td><td align="center" class="Botrule Lrule Rrule Toprule">Tramadol <br/> M1 </td><td align="center" class="Botrule Lrule Rrule Toprule"><a class="Sup" href="#footnote-5">‡</a> <br/> <a class="Sup" href="#footnote-5">‡</a></td><td align="center"><a class="Sup" href="#footnote-5">‡</a> <br/> <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">3.73 (17) <a class="Sup" href="#footnote-5">‡</a></td><td align="center" class="Botrule Lrule Rrule Toprule">11.0 (29) <br/> 16.9 (18) </td> </tr> </tbody> </table></div>

Food Effects

Oral administration of tramadol hydrochloride oral solution with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride oral solution can be administered without regard to food.

Distribution

The volume of distribution of tramadol was 2.6 and 2.9 liters/kg in male and female subjects, respectively, following a 100 mg intravenous dose. The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 mcg/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range.

Elimination

Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. The mean (%CV) apparent total clearance of tramadol after a single 100 mg oral dose is 8.50 (31) mL/min/kg. The mean terminal plasma elimination half-lives of racemic tramadol and racemic M1 are 6.3 ± 1.4 and 7.4 ± 1.4 hours, respectively. The plasma elimination half-life of racemic tramadol increased from approximately six hours to seven hours upon multiple dosing.

Metabolism

Tramadol is extensively metabolized after oral administration by a number of pathways, including CYP2D6 and CYP3A4, as well as by conjugation of parent and metabolites. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The remainder is excreted either as unidentified or as unextractable metabolites. The major metabolic pathways appear to be N- and O-demethylation and glucuronidation or sulfation in the liver. One metabolite ( O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. Formation of M1 is dependent on CYP2D6 and as such is subject to inhibition, which may affect the therapeutic response [Warnings and Precautions ( 5.7); Drug Interactions ( 7)] .

Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P-450. These individuals are "poor metabolizers" of debrisoquine, dextromethorphan, tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase I studies in healthy subjects, concentrations of tramadol were approximately 20% higher in "poor metabolizers" versus "extensive metabolizers", while M1 concentrations were 40% lower. Concomitant therapy with inhibitors of CYP2D6 such as fluoxetine, paroxetine and quinidine could result in significant drug interactions. In vitrodrug interaction studies in human liver microsomes indicate that inhibitors of CYP2D6 such as fluoxetine and its metabolite norfluoxetine, amitriptyline and quinidine inhibit the metabolism of tramadol to various degrees, suggesting that concomitant administration of these compounds could result in increases in tramadol concentrations and decreased concentrations of M1. The full pharmacological impact of these alterations in terms of either efficacy or safety is unknown. Concomitant use of serotonin re-uptake inhibitors and MAO inhibitors may enhance the risk of adverse events, including seizure and serotonin syndrome [see Warnings and Precautions ( 5.10), Drug Interactions ( 7)] .

Excretion

Tramadol metabolites are eliminated primarily by the kidneys. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The remainder is excreted either as unidentified or as unextractable metabolites.

Special Populations

Hepatic Impairment

Metabolism of tramadol and M1 is reduced in patients with severe hepatic impairment based on a study in patients with advanced cirrhosis of the liver, resulting in both a larger area under the concentration time curve for tramadol and longer tramadol and M1 elimination half-lives (13 hrs. for tramadol and 19 hrs. for M1). In patients with severe hepatic impairment, adjustment of the dosing regimen is recommended [see Dosage and Administration ( 2)] .

Renal Impairment

Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, adjustment of the dosing regimen is recommended [see Dosage and Administration ( 2)] . The total amount of tramadol and M1 removed during a 4-hour dialysis period is less than 7% of the administered dose.

Age: Geriatric

Healthy elderly subjects aged 65 to 75 years have plasma tramadol concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. In subjects over 75 years, maximum serum concentrations are elevated (208 vs. 162 ng/mL) and the elimination half-life is prolonged (7 vs. 6 hours) compared to subjects 65 to 75 years of age. Adjustment of the daily dose is recommended for patients older than 75 years [see Dosage and Administration ( 2.3)] .

Sex

The absolute bioavailability of tramadol was 73% in males and 79% in females. The plasma clearance was 6.4 mL/min/kg in males and 5.7 mL/min/kg in females following a 100 mg IV dose of tramadol. Following a single oral dose, and after adjusting for body weight, females had a 12% higher peak tramadol concentration and a 35% higher area under the concentration-time curve compared to males. The clinical significance of this difference is unknown.

Poor / Extensive Metabolizers, CYP2D6

The formation of the active metabolite, M1, is mediated by CYP2D6, a polymorphic enzyme. Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P450 metabolizing enzyme system. These individuals are "poor metabolizers" of debrisoquine, dextromethorphan and tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase 1 studies with IR tablets in healthy subjects, concentrations of tramadol were approximately 20% higher in "poor metabolizers" versus "extensive metabolizers," while M1 concentrations were 40% lower.

Carcinogenesis

A slight, but statistically significant, increase in two common murine tumors, pulmonary and hepatic, was observed in an NMRI mouse carcinogenicity study, particularly in aged mice. Mice were dosed orally up to 30 mg/kg in the drinking water (0.36 times the MRHD) for approximately two years, although the study was not done with the Maximum Tolerated Dose. This finding is not believed to suggest risk in humans. No evidence of carcinogenicity was noted in a rat 2-year carcinogenicity study testing oral doses of up to 30 mg/kg in the drinking water, 0.73 times the MRHD.

Mutagenesis

Tramadol was mutagenic in the presence of metabolic activation in the mouse lymphoma assay. Tramadol was not mutagenic in the in vitrobacterial reverse mutation assay using Salmonellaand E. coli(Ames), the mouse lymphoma assay in the absence of metabolic activation, the in vitrochromosomal aberration assay, or the in vivomicronucleus assay in bone marrow.

Impairment of Fertility

No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg in male rats and 75 mg/kg in female rats. These dosages are 1.2 and 1.8 times the maximum recommended human daily dose based on body surface area, respectively.

However, published studies report that treatment of adult male rats with tramadol (40 mg/kg, IP and SC for 30 and 60 days, respectively, 1.2x the MRHD based on BSA; or 4.5 to 135 mg/kg, SC for 18 weeks, 0.01x to 3.2x the MRHD based on BSA) produced adverse effects on male reproductive hormones and male reproductive tissues.

Titration Trials

In a randomized, blinded clinical study with 129 to 132 patients per group, a 10-day titration to a daily tramadol hydrochloride dose of 200 mg (50 mg four times per day), attained in 50 mg increments every 3 days, was found to result in fewer discontinuations due to dizziness or vertigo than titration over only 4 days or no titration. In a second study with 54 to 59 patients per group, patients who had nausea or vomiting when titrated over 4 days were randomized to re-initiate tramadol hydrochloride therapy using slower titration rates.

A 16-day titration schedule, starting with 25 mg every morning and using additional doses in 25 mg increments every third day to 100 mg/day (25 mg four times per day), followed by 50 mg increments in the total daily dose every third day to 200 mg/day (50 mg four times per day), resulted in fewer discontinuations due to nausea or vomiting and fewer discontinuations due to any cause than did a 10-day titration schedule (See Figure 2).

Figure 2:

Dispense in a tight container. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to30°C (59°F to 86°F). [see USP Controlled Room Temperature].

Store tramadol hydrochloride oral solution securely and dispose of properly [see Patient Counseling Information ( 17)].

Storage and Disposal

Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store tramadol hydrochloride oral solution securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving tramadol hydrochloride oral solution unsecured can pose a deadly risk to others in the home [see Warnings and Precautions ( 5.2, 5.3), Drug Abuse and Dependence ( 9.2)] .

Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines. If no take back programs or Drug Enforcement Administration (DEA)-registered collectors are available, instruct patients to dispose of tramadol hydrochloride oral solution by following these four steps:

Inform patients that they can visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

Medication Errors

Strongly advise patients and caregivers to always use a graduated oral syringe or measuring cup, with metric units of measurements (i.e., mL), to correctly measure the prescribed amount of medication.

Inform patients that oral dosing devices may be obtained from their pharmacy and to never use household teaspoons or tablespoons to measure tramadol hydrochloride oral solution [see Dosage and Administration ( 2.1), Warnings and Precautions ( 5.1)] .

Addiction, Abuse, and Misuse

Inform patients that the use of tramadol hydrochloride oral solution, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see Warnings and Precautions ( 5.2)] . Instruct patients not to share tramadol hydrochloride oral solution with others and to take steps to protect tramadol hydrochloride oral solution from theft or misuse.

Life-Threatening Respiratory Depression

Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting tramadol hydrochloride oral solution or when the dosage is increased, and that it can occur even at recommended dosages. Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Warnings and Precautions ( 5.3)] .

Accidental Ingestion

Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [see Warnings and Precautions ( 5.3)] .

Interactions with Benzodiazepines and Other CNS Depressants

Inform patients and caregivers that potentially fatal additive effects may occur if tramadol hydrochloride oral solution is used with benzodiazepines, CNS depressants, including alcohol, or some illicit drugs and not to use these concomitantly unless supervised by a healthcare provider [see Warnings and Precautions ( 5.4), Drug Interactions ( 7)] .

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with tramadol hydrochloride oral solution. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.3)] .

Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.

Explain to patients and caregivers that naloxone’s effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered [see Overdosage ( 10)] .

If naloxone is prescribed, also advise patients and caregivers:

Ultra-Rapid Metabolism of Tramadol and Other Risk Factors for Life-threatening Respiratory Depression in Children

Advise caregivers that tramadol hydrochloride oral solution is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Advise caregivers of children ages 12 to 18 years of age receiving tramadol hydrochloride oral solution to monitor for signs of respiratory depression [see Warnings and Precautions ( 5.7)] .

Hyperalgesia and Allodynia

Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see Warnings and Precautions ( 5.9), Adverse Reactions ( 6.2)] .

Maximum single-dose and 24-hour dose

Advise patients not to exceed the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in respiratory depression, seizures and death [see Dosage and Administration ( 2), Warnings and Precautions ( 5.3)] .

Serotonin Syndrome

Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome, and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications [see Warnings and Precautions ( 5.10)] .

Seizures

Inform patients that tramadol hydrochloride oral solution may cause seizures with concomitant use of serotonergic agents (including SSRIs, SNRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol [see Warnings and Precautions ( 5.11)] .

MAOI Interaction

Inform patients not to take tramadol hydrochloride oral solution while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking tramadol hydrochloride oral solution [see Drug Interactions ( 7)] .

Important Administration Instructions

Important Discontinuation Instructions

In order to avoid developing withdrawal symptoms, instruct patients not to discontinue tramadol hydrochloride oral solution without first discussing a tapering plan with the prescriber [see Dosage and Administration ( 2.5)] .

Driving or Operating Heavy Machinery

Inform patients that tramadol hydrochloride oral solution may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication [see Warnings and Precautions ( 5.20)] .

Constipation

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see Adverse Reactions ( 6)] .

Adrenal Insufficiency

Inform patients that opioids could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [see Warnings and Precautions ( 5.14)] .

Hypotension

Inform patients that tramadol hydrochloride oral solution may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see Warnings and Precautions ( 5.15)] .

Anaphylaxis

Inform patients that anaphylaxis has been reported with ingredients contained in tramadol hydrochloride oral solution. Advise patients how to recognize such a reaction and when to seek medical attention [see Contraindications ( 4), Warnings and Precautions ( 5.18), Adverse Reactions ( 6)] .

Pregnancy

Neonatal Opioid Withdrawal Syndrome

Inform female patients of reproductive potential that use of tramadol hydrochloride oral solution for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated and that the patient should inform their healthcare provider if they have used opioids at any time during their pregnancy, especially near the time of birth. [see Warnings and Precautions ( 5.5), Use in Specific Populations ( 8.1)] .

Embryo-Fetal Toxicity

Inform female patients of reproductive potential that tramadol hydrochloride oral solution may cause fetal harm and to inform the healthcare provider of a known or suspected pregnancy [see Use in Specific Populations ( 8.1)] .

Lactation

Advise women that breastfeeding is not recommended during treatment with tramadol hydrochloride oral solution [see Warnings and Precautions ( 5.5), Use in Specific Populations ( 8.2)] .

Infertility

Inform patients that use of opioids for an extended period of time may cause reduced fertility. It is not known whether these effects on fertility are reversible [see Use in Specific Populations ( 8.3)] .

Distributed by: Palmetto Pharmaceuticals, Inc. Greenville, SC 29615

Revised 12/2023 500529-02

<div class="scrollingtable"><table width="100%"> <col align="left" valign="top" width="50%"/> <col align="left" valign="top" width="50%"/> <tfoot> <tr class="First First Last Last"> <td align="left" colspan="2">Distributed by: Palmetto Pharmaceuticals, Inc., Greenville, SC 29615 . <br/> This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued/Revised: 12/2023 </td> </tr> </tfoot> <tbody class="Headless"> <tr class="Botrule First First"> <td align="center" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">MEDICATION GUIDE</span> <br/> <span class="Bold">Tramadol Hydrochloride Oral Solution, CIV</span> </p> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Tramadol hydrochloride oral solution is</span>: </p> <ul class="Disc"> <li>A strong prescription pain medicine that contains an opioid (narcotic) that is used for the management of pain in adults, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.</li> <li>An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Important information about tramadol hydrochloride oral solution:</span> </p> <ul class="Disc"> <li> <span class="Bold">Get emergency help right away if you take too much tramadol hydrochloride oral solution (overdose)</span>. When you first start taking tramadol hydrochloride oral solution, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. </li> <li>Taking tramadol hydrochloride oral solution with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</li> <li>Never give anyone else your tramadol hydrochloride oral solution. They could die from taking it. Selling or giving away tramadol hydrochloride oral solution is against the law.</li> <li>Store tramadol hydrochloride oral solution securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Important Information Guiding Use in Pediatric Patients:</span> </p> <ul class="Disc"> <li>Do not give tramadol hydrochloride oral solution to a child younger than 12 years of age.</li> <li>Do not give tramadol hydrochloride oral solution to anyone younger than 18 years of age after surgery to remove the tonsils, adenoids, or both.</li> <li>Avoid giving tramadol hydrochloride oral solution to children between 12 to 18 years of age who have risk factors for breathing problems such as obstructive sleep apnea, obesity, or underlying lung problems.</li> </ul> </td> </tr> <tr> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Do not take tramadol hydrochloride oral solution if you have:</span> </p> <ul class="Disc"> <li>Severe asthma, trouble breathing, or other lung problems.</li> <li>A bowel blockage or have narrowing of the stomach or intestines.</li> <li>An allergy to tramadol.</li> <li>Taken a Monoamine Oxidase Inhibitor, MAOI, (medicine used for depression) within the last 14 days.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule"> <p class="First">Before taking tramadol hydrochloride oral solution, tell your healthcare provider if you have a history of:</p> <ul class="Disc"> <li>head injury, seizures</li> <li>problems urinating</li> <li>abuse of street or prescription drugs, alcohol addiction, or mental health problems.</li> </ul> </td><td align="left" class="Rrule"> <ul class="Disc"> <li>liver, kidney, thyroid problems</li> <li>pancreas or gallbladder problems</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Tell your healthcare provider if you are:</span> </p> <ul class="Disc"> <li>noticing your pain getting worse. If your pain gets worse after you take tramadol hydrochloride oral solution, do not take more of tramadol hydrochloride oral solution without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking tramadol hydrochloride oral solution.</li> <li> <span class="Bold">pregnant or planning to become pregnant</span>. Use of tramadol hydrochloride oral solution for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated. </li> <li> <span class="Bold">breastfeeding</span>. Not recommended during treatment with tramadol hydrochloride oral solution; it may harm your baby. </li> <li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking tramadol hydrochloride oral solution with certain other medicines can cause serious side effects that could lead to death.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">When taking tramadol hydrochloride oral solution:</span> </p> <ul> <li>Do not change your dose. Take tramadol hydrochloride oral solution exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.</li> <li>For acute (short-term) pain, you may only need to take tramadol hydrochloride oral solution for a few days. You may have some tramadol hydrochloride oral solution left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused tramadol hydrochloride oral solution.</li> <li>Always use a calibrated oral syringe or other oral dosing device obtained from your doctor or pharmacist to <br/> correctly measure your dose. Never use a household teaspoon or tablespoon to measure tramadol hydrochloride oral solution. </li> <li>Take your prescribed dose as indicated by your healthcare provider. The maximum dosage is 10 mL to 20 mL every 4 to 6 hours, as needed for pain. Do not take more than your prescribed dose and do not take more than 80 mL per day. If you miss a dose, take your next dose at your usual time.</li> <li>Call your healthcare provider if the dose you are taking does not control your pain.</li> <li>If you have been taking tramadol hydrochloride oral solution regularly, do not stop taking tramadol hydrochloride oral solution without talking to your healthcare provider.</li> <li>Dispose of expired, unwanted, or unused tramadol hydrochloride oral solution by taking your drug to an authorized Drug Enforcement <br/> Administration (DEA)-registered collector or drug take-back program. If one is not available, you can dispose of <br/> tramadol hydrochloride oral solution by mixing tramadol hydrochloride oral solution with dirt, cat litter, or used coffee grounds; placing the mixture in a container such as a <br/> sealed plastic bag; and throwing the container in the household trash. Visit <a href="http://www.fda.gov/drugdisposal">www.fda.gov/drugdisposal</a>for additional information on disposal of unused medicines. </li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">While taking tramadol hydrochloride oral solution DO NOT:</span> </p> <ul> <li>Drive or operate heavy machinery, until you know how tramadol hydrochloride oral solution affects you. Tramadol hydrochloride oral solution can make you sleepy, dizzy, or lightheaded.</li> <li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with tramadol hydrochloride oral solution may cause you to overdose and die.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">The possible side effects of tramadol hydrochloride oral solution:</span> </p> <ul class="Disc"> <li>constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</li> </ul> </td> </tr> <tr class="Botrule Last Last"> <td align="left" class="Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Get emergency medical help if you have:</span> </p> <ul class="Disc"> <li>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</li> </ul>These are not all the possible side effects of tramadol hydrochloride oral solution. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <span class="Bold">For more information go to dailymed.nlm.nih.gov.</span></td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"100%\">\n<col align=\"left\" valign=\"top\" width=\"50%\"/>\n<col align=\"left\" valign=\"top\" width=\"50%\"/>\n<tfoot>\n<tr class=\"First First Last Last\">\n<td align=\"left\" colspan=\"2\">Distributed by: Palmetto Pharmaceuticals, Inc., Greenville, SC 29615 . \n <br/> This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued/Revised: 12/2023\n </td>\n</tr>\n</tfoot>\n<tbody class=\"Headless\">\n<tr class=\"Botrule First First\">\n<td align=\"center\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">MEDICATION GUIDE</span>\n<br/>\n<span class=\"Bold\">Tramadol Hydrochloride Oral Solution, CIV</span>\n</p>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Tramadol hydrochloride oral solution is</span>:\n \n </p>\n<ul class=\"Disc\">\n<li>A strong prescription pain medicine that contains an opioid (narcotic) that is used for the management of pain in adults, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.</li>\n<li>An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Important information about tramadol hydrochloride oral solution:</span>\n</p>\n<ul class=\"Disc\">\n<li>\n<span class=\"Bold\">Get emergency help right away if you take too much tramadol hydrochloride oral solution (overdose)</span>. When you first start taking tramadol hydrochloride oral solution, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur.\n \n </li>\n<li>Taking tramadol hydrochloride oral solution with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</li>\n<li>Never give anyone else your tramadol hydrochloride oral solution. They could die from taking it. Selling or giving away tramadol hydrochloride oral solution is against the law.</li>\n<li>Store tramadol hydrochloride oral solution securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Important Information Guiding Use in Pediatric Patients:</span>\n</p>\n<ul class=\"Disc\">\n<li>Do not give tramadol hydrochloride oral solution to a child younger than 12 years of age.</li>\n<li>Do not give tramadol hydrochloride oral solution to anyone younger than 18 years of age after surgery to remove the tonsils, adenoids, or both.</li>\n<li>Avoid giving tramadol hydrochloride oral solution to children between 12 to 18 years of age who have risk factors for breathing problems such as obstructive sleep apnea, obesity, or underlying lung problems.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Do not take tramadol hydrochloride oral solution if you have:</span>\n</p>\n<ul class=\"Disc\">\n<li>Severe asthma, trouble breathing, or other lung problems.</li>\n<li>A bowel blockage or have narrowing of the stomach or intestines.</li>\n<li>An allergy to tramadol.</li>\n<li>Taken a Monoamine Oxidase Inhibitor, MAOI, (medicine used for depression) within the last 14 days.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule\">\n<p class=\"First\">Before taking tramadol hydrochloride oral solution, tell your healthcare provider if you have a history of:</p>\n<ul class=\"Disc\">\n<li>head injury, seizures</li>\n<li>problems urinating</li>\n<li>abuse of street or prescription drugs, alcohol addiction, or mental health problems.</li>\n</ul>\n</td><td align=\"left\" class=\"Rrule\">\n<ul class=\"Disc\">\n<li>liver, kidney, thyroid problems</li>\n<li>pancreas or gallbladder problems</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Tell your healthcare provider if you are:</span>\n</p>\n<ul class=\"Disc\">\n<li>noticing your pain getting worse. If your pain gets worse after you take tramadol hydrochloride oral solution, do not take more of tramadol hydrochloride oral solution without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking tramadol hydrochloride oral solution.</li>\n<li>\n<span class=\"Bold\">pregnant or planning to become pregnant</span>. Use of tramadol hydrochloride oral solution for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.\n \n </li>\n<li>\n<span class=\"Bold\">breastfeeding</span>. Not recommended during treatment with tramadol hydrochloride oral solution; it may harm your baby.\n \n </li>\n<li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking tramadol hydrochloride oral solution with certain other medicines can cause serious side effects that could lead to death.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">When taking tramadol hydrochloride oral solution:</span>\n</p>\n<ul>\n<li>Do not change your dose. Take tramadol hydrochloride oral solution exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.</li>\n<li>For acute (short-term) pain, you may only need to take tramadol hydrochloride oral solution for a few days. You may have some tramadol hydrochloride oral solution left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused tramadol hydrochloride oral solution.</li>\n<li>Always use a calibrated oral syringe or other oral dosing device obtained from your doctor or pharmacist to \n <br/> correctly measure your dose. Never use a household teaspoon or tablespoon to measure tramadol hydrochloride oral solution.\n </li>\n<li>Take your prescribed dose as indicated by your healthcare provider. The maximum dosage is 10 mL to 20 mL every 4 to 6 hours, as needed for pain. Do not take more than your prescribed dose and do not take more than 80 mL per day. If you miss a dose, take your next dose at your usual time.</li>\n<li>Call your healthcare provider if the dose you are taking does not control your pain.</li>\n<li>If you have been taking tramadol hydrochloride oral solution regularly, do not stop taking tramadol hydrochloride oral solution without talking to your healthcare provider.</li>\n<li>Dispose of expired, unwanted, or unused tramadol hydrochloride oral solution by taking your drug to an authorized Drug Enforcement \n <br/> Administration (DEA)-registered collector or drug take-back program. If one is not available, you can dispose of \n <br/> tramadol hydrochloride oral solution by mixing tramadol hydrochloride oral solution with dirt, cat litter, or used coffee grounds; placing the mixture in a container such as a \n <br/> sealed plastic bag; and throwing the container in the household trash. Visit\n \n <a href=\"http://www.fda.gov/drugdisposal\">www.fda.gov/drugdisposal</a>for additional information on disposal of unused medicines.\n \n </li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">While taking tramadol hydrochloride oral solution DO NOT:</span>\n</p>\n<ul>\n<li>Drive or operate heavy machinery, until you know how tramadol hydrochloride oral solution affects you. Tramadol hydrochloride oral solution can make you sleepy, dizzy, or lightheaded.</li>\n<li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with tramadol hydrochloride oral solution may cause you to overdose and die.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">The possible side effects of tramadol hydrochloride oral solution:</span>\n</p>\n<ul class=\"Disc\">\n<li>constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule Last Last\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Get emergency medical help if you have:</span>\n</p>\n<ul class=\"Disc\">\n<li>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</li>\n</ul>These are not all the possible side effects of tramadol hydrochloride oral solution. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.\n \n <span class=\"Bold\">For more information go to dailymed.nlm.nih.gov.</span></td>\n</tr>\n</tbody>\n</table></div>" }

NDC 68134-402-05

{ "type": "p", "children": [], "text": "\nNDC 68134-402-05\n" }

Tramadol hydrochloride oral solution 5 mg/mL (equivalent to tramadol 4.4 mg per 1 mL) CIV

{ "type": "p", "children": [], "text": "\nTramadol hydrochloride oral solution 5 mg/mL (equivalent to tramadol 4.4 mg per 1 mL) CIV\n" }

Keep out of reach of children.

{ "type": "p", "children": [], "text": "\nKeep out of reach of children.\n" }

Rx only

{ "type": "p", "children": [], "text": "\nRx only\n" }

5 mL unit dose cup

{ "type": "p", "children": [], "text": "\n5 mL unit dose cup\n" }

NDC 68134-402-40

{ "type": "p", "children": [], "text": "\nNDC 68134-402-40\n" }

Tramadol hydrochloride oral solution 5 mg/mL (equivalent to tramadol 4.4 mg per 1 mL) CIV

{ "type": "p", "children": [], "text": "\nTramadol hydrochloride oral solution 5 mg/mL (equivalent to tramadol 4.4 mg per 1 mL) CIV\n" }

Keep out of reach of children.

{ "type": "p", "children": [], "text": "\nKeep out of reach of children.\n" }

Rx only

{ "type": "p", "children": [], "text": "\nRx only\n" }

Case containing 40 unit dose cups

{ "type": "p", "children": [], "text": "\nCase containing 40 unit dose cups\n" }

Limitation of Use

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Tramadol Hydrochloride Extended-Release Capsules [see Warnings and Precautions (5.2)].

Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of community-based program).

Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient [see Warnings and Precautions (5.1, 5.2, 5.8)].

Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.

Patients Not Currently on a Tramadol Product

The initial dose of Tramadol Hydrochloride Extended-Release Capsules is 100 mg once daily.

Patients Currently on Tramadol Immediate-Release (IR) Products

Calculate the 24-hour tramadol IR dose and initiate a total daily dose of Tramadol Hydrochloride Extended-Release Capsules rounded down to the next lowest 100 mg increment. The dose may subsequently be individualized according to patient need.

Due to limitations in flexibility of dose selection with Tramadol Hydrochloride Extended-Release Capsules, some patients maintained on tramadol IR products may not be able to convert to Tramadol Hydrochloride Extended-Release Capsules.

Conversion from Other Opioids to Tramadol Hydrochloride Extended-Release Capsules

When Tramadol Hydrochloride Extended-Release Capsules therapy is initiated, discontinue all other opioid analgesics other than those used on an as needed basis for breakthrough pain when appropriate. There are no established conversion ratios for conversion from other opioids to Tramadol Hydrochloride Extended-Release Capsules defined by clinical trials. Initiate dosing using Tramadol Hydrochloride Extended-Release Capsules 100 mg once a day.

It is safer to underestimate a patient's 24-hour tramadol requirements and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour tramadol dosage and manage an adverse reaction due to an overdose. While useful tables of opioid equivalents are readily available, there is inter-patient variability in the potency of opioid drugs and opioid formulations.

Close observation and frequent titration are warranted until pain management is stable on the new opioid. Monitor patients for signs and symptoms of opioid withdrawal and for signs of oversedation/toxicity after converting patients to Tramadol Hydrochloride Extended-Release Capsules.

Individually titrate Tramadol Hydrochloride Extended-Release Capsules by 100 mg every five days to a dose that provides adequate analgesia and minimizes adverse reactions. The maximum daily dose of Tramadol Hydrochloride Extended-Release Capsules is 300 mg per day.

Continually reevaluate patients receiving Tramadol Hydrochloride Extended-Release Capsules to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1, 5.18)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During use of opioid therapy for an extended period of time, periodically reassess the continued need for the use of opioid analgesics.

Patients who experience breakthrough pain may require a dosage adjustment of Tramadol Hydrochloride Extended-Release Capsules or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the Tramadol Hydrochloride Extended-Release Capsules dosage.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the Tramadol Hydrochloride Extended-Release Capsules dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Do not abruptly discontinue Tramadol Hydrochloride Extended-Release Capsules in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.

When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Tramadol Hydrochloride Extended-Release Capsules, there are a variety of factors that should be considered, including the total daily dose of opioid (including Tramadol Hydrochloride Extended-Release Capsules) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.

There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on Tramadol Hydrochloride Extended-Release Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.

It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.

When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see Warnings and Precautions (5.18), Drug Abuse and Dependence (9.3)].

Extended-release capsules are available as:

{ "type": "p", "children": [], "text": "Extended-release capsules are available as:" }

100 mg Capsules: White capsule imprinted with blue ink "G 252" on cap and "100" between lines on the body

{ "type": "p", "children": [], "text": "100 mg Capsules: White capsule imprinted with blue ink \"G 252\" on cap and \"100\" between lines on the body" }

200 mg Capsules: White capsule imprinted with violet ink "G 253" on cap and "200" between lines on the body

{ "type": "p", "children": [], "text": "200 mg Capsules: White capsule imprinted with violet ink \"G 253\" on cap and \"200\" between lines on the body" }

300 mg Capsules: White capsule imprinted with red ink "G 254" on cap and "300" between lines on the body

{ "type": "p", "children": [], "text": "300 mg Capsules: White capsule imprinted with red ink \"G 254\" on cap and \"300\" between lines on the body" }

Tramadol Hydrochloride Extended-Release Capsules is contraindicated for:

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride Extended-Release Capsules is contraindicated for:" }

{ "type": "ul", "children": [ "All children younger than 12 years of age [see Warnings and Precautions (5.6)]\n", "Postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Warnings and Precautions (5.6)]\n" ], "text": "" }

Tramadol Hydrochloride Extended-Release Capsules is also contraindicated in patients with:

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride Extended-Release Capsules is also contraindicated in patients with:" }

{ "type": "ul", "children": [ "Significant respiratory depression [see Warnings and Precautions (5.12)]\n", "Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.12)]\n", "Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.16)]\n", "Hypersensitivity to tramadol (e.g., anaphylaxis) [see Warnings and Precautions (5.17), Adverse Reactions (6)]\n", "Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days [see Drug Interactions (7)]\n" ], "text": "" }

Tramadol Hydrochloride Extended-Release Capsules contains tramadol, a Schedule IV controlled substance. As an opioid, Tramadol Hydrochloride Extended-Release Capsules exposes users to the risks of addiction, abuse and misuse. Because extended-release products such as Tramadol Hydrochloride Extended-Release Capsules deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of tramadol present [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Tramadol Hydrochloride Extended-Release Capsules. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing Tramadol Hydrochloride Extended-Release Capsules, and reassess all patients receiving Tramadol Hydrochloride Extended-Release Capsules for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as Tramadol Hydrochloride Extended-Release Capsules but use in such patients necessitates intensive counseling about the risks and proper use of Tramadol Hydrochloride Extended-Release Capsules along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Abuse or misuse of Tramadol Hydrochloride Extended-Release Capsules by splitting, breaking, chewing, crushing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of tramadol and can result in overdose and death [see Overdosage (10)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing Tramadol Hydrochloride Extended-Release Capsules. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see Overdosage (10)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Tramadol Hydrochloride Extended-Release Capsules, the risk is greatest during the initiation of therapy or following a dosage increase.

To reduce the risk of respiratory depression, proper dosing and titration of Tramadol Hydrochloride Extended-Release Capsules are essential [see Dosage and Administration (2)]. Overestimating the Tramadol Hydrochloride Extended-Release Capsules dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.

Accidental ingestion of even one dose of Tramadol Hydrochloride Extended-Release Capsules, especially by children, can result in respiratory depression and death due to an overdose of tramadol.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose.

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.5)].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Tramadol Hydrochloride Extended-Release Capsules. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered.

Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone [see Dosage and Administration (2.2), Warnings and Precautions (5.1, 5.3), Overdosage (10)].

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Tramadol Hydrochloride Extended-Release Capsules with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions (7)].

If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2), Overdosage (10)].

Advise both patients and caregivers about the risks of respiratory depression and sedation when Tramadol Hydrochloride Extended-Release Capsules is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressants have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions (7)].

Use of Tramadol Hydrochloride Extended-Release Capsules for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations (8.1)].

To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following:

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com. The FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint.

Life-threatening respiratory depression and death have occurred in children who received tramadol. Tramadol and codeine are subject to variability in metabolism based upon CYP2D6 genotype (described below), which can lead to increased exposure to an active metabolite. Based upon postmarketing reports with tramadol or with codeine, children younger than 12 years of age may be more susceptible to the respiratory depressant effects of tramadol. Furthermore, children with obstructive sleep apnea who are treated with opioids for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to their respiratory depressant effect. Because of the risk of life-threatening respiratory depression and death:

Nursing Mothers

Tramadol is subject to the same polymorphic metabolism as codeine, with ultra-rapid metabolizers of CYP2D6 substrates being potentially exposed to life-threatening levels of O-desmethyltramadol (M1). At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. A baby nursing from an ultra-rapid metabolizer mother taking Tramadol Hydrochloride Extended-Release Capsules could potentially be exposed to high levels of M1, and experience life-threatening respiratory depression. For this reason, breastfeeding is not recommended during treatment with Tramadol Hydrochloride Extended-Release Capsules [see Use in Specific Populations (8.2)].

CYP2D6 Genetic Variability: Ultra-rapid metabolizer

Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1×N or *1/*2×N). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 1 to 10% for Whites (European, North American), 3 to 4% for Blacks (African Americans), 1 to 2% for East Asians (Chinese, Japanese, Korean), and may be greater than 10% in certain racial/ethnic groups (i.e., Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican).

These individuals convert tramadol into its active metabolite, O-desmethyltramadol (M1), more rapidly and completely than other people. This rapid conversion results in higher than expected serum M1 levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) [see Overdosage (10)]. Therefore, individuals who are ultra-rapid metabolizers should not use Tramadol Hydrochloride Extended-Release Capsules.

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors on levels of tramadol and M1 from Tramadol Hydrochloride Extended-Release Capsules are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with Tramadol Hydrochloride Extended-Release Capsules requires careful consideration of the effects on the parent drug, tramadol which is a weak serotonin and norepinephrine reuptake inhibitor and mu-opioid agonist, and the active metabolite, M1, which is more potent than tramadol in mu-opioid receptor binding [see Drug Interactions (7)].

Risks of Concomitant Use or Discontinuation of Cytochrome P450 2D6 Inhibitors

The concomitant use of Tramadol Hydrochloride Extended-Release Capsules with all cytochrome P450 2D6 inhibitors (e.g., amiodarone, quinidine) may result in an increase in tramadol plasma levels and a decrease in the levels of the active metabolite, M1. A decrease in M1 exposure in patients who have developed physical dependence to tramadol, may result in signs and symptoms of opioid withdrawal and reduced efficacy. The effect of increased tramadol levels may be an increased risk for serious adverse events including seizures and serotonin syndrome.

Discontinuation of a concomitantly used cytochrome P450 2D6 inhibitor may result in a decrease in tramadol plasma levels and an increase in active metabolite M1 levels, which could increase or prolong adverse reactions related to opioid toxicity and may cause potentially fatal respiratory depression.

Evaluate patients receiving Tramadol Hydrochloride Extended-Release Capsules and any CYP2D6 inhibitor at frequent intervals for the risk of serious adverse events including seizures and serotonin syndrome, signs and symptoms that may reflect opioid toxicity, and opioid withdrawal when Tramadol Hydrochloride Extended-Release Capsules is used in conjunction with inhibitors of CYP2D6 [see Drug Interactions (7)].

Cytochrome P450 3A4 Interaction

The concomitant use of Tramadol Hydrochloride Extended-Release Capsules with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations, which could increase or prolong adverse reactions, increase the risk for serious adverse events including seizures and serotonin syndrome, and may cause potentially fatal respiratory depression.

The concomitant use of Tramadol Hydrochloride Extended-Release Capsules with all cytochrome P450 3A4 inducers or discontinuation of a cytochrome P450 3A4 inhibitor may result in lower tramadol levels. This may be associated with a decrease in efficacy, and in some patients, may result in signs and symptoms of opioid withdrawal.

Evaluate patients receiving Tramadol Hydrochloride Extended-Release Capsules and any CYP3A4 inhibitor or inducer at frequent intervals for the risk for serious adverse events including seizures and serotonin syndrome, signs and symptoms that may reflect opioid toxicity and opioid withdrawal when Tramadol Hydrochloride Extended-Release Capsules is used in conjunction with inhibitors and inducers of CYP3A4 [see Drug Interactions (7)].

Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see Dependence (9.3)]. Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.

Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see Dosage and Administration (2.5), Warnings and Precautions (5.18)].

Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol products, including Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions (7)]. This may occur within the recommended dosage range.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms generally occurs within several hours to a few days of concomitant use but may occur later than that. Discontinue Tramadol Hydrochloride Extended-Release Capsules if serotonin syndrome is suspected.

Seizures have been reported in patients receiving tramadol within the recommended dosage range. Spontaneous post-marketing reports indicate that seizure risk is increased with doses of tramadol above the recommended range.

Concomitant use of tramadol increases the seizure risk in patients taking: [see Drug Interactions (7)]

Risk of seizures may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections).

In tramadol overdose, naloxone administration may increase the risk of seizure.

The use of Tramadol Hydrochloride Extended-Release Capsules in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients with Chronic Pulmonary Disease: Tramadol Hydrochloride Extended-Release Capsules treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Tramadol Hydrochloride Extended-Release Capsules [see Warnings and Precautions (5.2)].

Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see Warnings and Precautions (5.2)].

Regularly evaluate patients, particularly when initiating and titrating Tramadol Hydrochloride Extended-Release Capsules and when Tramadol Hydrochloride Extended-Release Capsules is given concomitantly with other drugs that depress respiration [see Warnings and Precautions (5.2, 5.7)]. Alternatively, consider the use of non-opioid analgesics in these patients.

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Tramadol Hydrochloride Extended-Release Capsules may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see Drug Interactions (7)]. Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of Tramadol Hydrochloride Extended-Release Capsules. In patients with circulatory shock, Tramadol Hydrochloride Extended-Release Capsules may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of Tramadol Hydrochloride Extended-Release Capsules in patients with circulatory shock.

In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), Tramadol Hydrochloride Extended-Release Capsules may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with Tramadol Hydrochloride Extended-Release Capsules.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of Tramadol Hydrochloride Extended-Release Capsules in patients with impaired consciousness or coma.

Tramadol Hydrochloride Extended-Release Capsules is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.

The tramadol in Tramadol Hydrochloride Extended-Release Capsules may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.

Serious and rarely fatal hypersensitive reactions have been reported in patients receiving therapy with tramadol. When these events do occur, it is often following the first dose. Other reported hypersensitivity reactions include pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis and Stevens-Johnson syndrome. Patients with a history of hypersensitivity reactions to tramadol and other opioids may be at increased risk and therefore should not receive Tramadol Hydrochloride Extended-Release Capsules. If anaphylaxis or other hypersensitivity occurs, stop administration of Tramadol Hydrochloride Extended-Release Capsules immediately, discontinue Tramadol Hydrochloride Extended-Release Capsules permanently, and do not rechallenge with any formulation of tramadol. Advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction [see Contraindications (4)].

Do not abruptly discontinue Tramadol Hydrochloride Extended-Release Capsules in a patient physically dependent on opioids. When discontinuing Tramadol Hydrochloride Extended-Release Capsules in a physically dependent patient, gradually taper the dosage. Rapid tapering of tramadol in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see Dosage and Administration (2.5), Drug Abuse and Dependence (9.3)].

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Tramadol Hydrochloride Extended-Release Capsules. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms [see Drug Interactions (7)].

When discontinuing Tramadol Hydrochloride Extended-Release Capsules, gradually taper the dosage [see Dosage and Administration (2.5)]. Do not abruptly discontinue Tramadol Hydrochloride Extended-Release Capsules [see Drug Abuse and Dependence (9.3)].

Tramadol Hydrochloride Extended-Release Capsules may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of Tramadol Hydrochloride Extended-Release Capsules and know how they will react to the medication.

Hyponatremia (serum sodium <135 mmol/L) has been reported with the use of tramadol, and many cases are severe (sodium level <120 mmol/L). Most cases of hyponatremia occurred in females over the age of 65 and within the first week of therapy. In some reports, hyponatremia resulted from the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Assess patients for signs and symptoms of hyponatremia (e.g., confusion, disorientation) during treatment with Tramadol Hydrochloride Extended-Release Capsules, especially during initiation of therapy. If signs and symptoms of hyponatremia are present, initiate appropriate treatment (e.g., fluid restriction) and discontinue Tramadol Hydrochloride Extended-Release Capsules [see Dosage and Administration (2.5)].

Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization. In most cases, patients had predisposing risk factors (e.g., diabetes). If hypoglycemia is suspected, monitor blood glucose levels and consider drug discontinuation as appropriate [see Dosage and Administration (2.5)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tramadol Hydrochloride Extended-Release Capsules were administered to a total of 1987 patients in clinical trials. These included four double-blind and one long-term, open-label study in patients with osteoarthritis of the hip and knee. A total of 812 patients were 65 years or older. Adverse reactions with doses from 100 mg to 300 mg in the four pooled, randomized, double-blind, placebo-controlled studies in patients with chronic non-malignant pain are presented in the following table (see Table 1).

<div class="scrollingtable"><table width="85%"> <caption> <span>Table 1: Incidence (%) of Patients with Adverse Reaction Rates ≥5% from Four Double-Blind, Placebo-Controlled Studies in Patients with Moderate to Moderately Severe Chronic Pain by Dose (N=1917)</span> </caption> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <thead> <tr class="Botrule First"> <th align="left" class="Lrule Rrule" rowspan="2">Preferred Term</th><th align="center" class="Rrule" colspan="3">Tramadol Hydrochloride Extended-Release Capsules</th><th align="center" class="Rrule">Placebo</th> </tr> <tr class="Botrule Last"> <th align="left" class="Rrule">100 mg<br/>(N=429)<br/>n (%)</th><th align="left" class="Rrule">200 mg<br/>(N=434)<br/>n (%)</th><th align="left" class="Rrule">300 mg<br/>(N=1054)<br/>n (%)</th><th align="left" class="Rrule">(N=646)<br/>n (%)</th> </tr> </thead> <tbody> <tr class="Botrule First"> <td align="left" class="Lrule Rrule">Headache</td><td align="left" class="Rrule">99 (23.1)</td><td align="left" class="Rrule">96 (22.1)</td><td align="left" class="Rrule">200 (19.0)</td><td align="left" class="Rrule">128 (19.8)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Nausea</td><td align="left" class="Rrule">69 (16.1)</td><td align="left" class="Rrule">93 (21.4)</td><td align="left" class="Rrule">265 (25.1)</td><td align="left" class="Rrule">37 (5.7)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Somnolence</td><td align="left" class="Rrule">50 (11.7)</td><td align="left" class="Rrule">60 (13.8)</td><td align="left" class="Rrule">170 (16.1)</td><td align="left" class="Rrule">26 (4.0)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Dizziness</td><td align="left" class="Rrule">41 (9.6)</td><td align="left" class="Rrule">54 (12.4)</td><td align="left" class="Rrule">143 (13.6)</td><td align="left" class="Rrule">31 (4.8)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Constipation</td><td align="left" class="Rrule">40 (9.3)</td><td align="left" class="Rrule">59 (13.6)</td><td align="left" class="Rrule">225 (21.3)</td><td align="left" class="Rrule">27 (4.2)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Vomiting</td><td align="left" class="Rrule">28 (6.5)</td><td align="left" class="Rrule">45 (10.4)</td><td align="left" class="Rrule">98 (9.3)</td><td align="left" class="Rrule">12 (1.9)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Arthralgia</td><td align="left" class="Rrule">23 (5.4)</td><td align="left" class="Rrule">20 (4.6)</td><td align="left" class="Rrule">53 (5.0)</td><td align="left" class="Rrule">33 (5.1)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Dry Mouth</td><td align="left" class="Rrule">20 (4.7)</td><td align="left" class="Rrule">36 (8.3)</td><td align="left" class="Rrule">138 (13.1)</td><td align="left" class="Rrule">22 (3.4)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Sweating</td><td align="left" class="Rrule">18 (4.2)</td><td align="left" class="Rrule">23 (5.3)</td><td align="left" class="Rrule">71 (6.7)</td><td align="left" class="Rrule">4 (0.6)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Asthenia</td><td align="left" class="Rrule">15 (3.5)</td><td align="left" class="Rrule">26 (6.0)</td><td align="left" class="Rrule">91 (8.6)</td><td align="left" class="Rrule">17 (2.6)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Pruritus</td><td align="left" class="Rrule">13 (3.0)</td><td align="left" class="Rrule">25 (5.8)</td><td align="left" class="Rrule">77 (7.3)</td><td align="left" class="Rrule">12 (1.9)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Anorexia</td><td align="left" class="Rrule">9 (2.1)</td><td align="left" class="Rrule">23 (5.3)</td><td align="left" class="Rrule">60 (5.7)</td><td align="left" class="Rrule">1 (0.2)</td> </tr> <tr class="Last"> <td align="left" class="Lrule Rrule">Insomnia</td><td align="left" class="Rrule">9 (2.1)</td><td align="left" class="Rrule">9 (2.1)</td><td align="left" class="Rrule">53 (5.0)</td><td align="left" class="Rrule">11 (1.7)</td> </tr> </tbody> </table></div>

The following adverse reactions were reported from all chronic pain studies (N=1917). The lists below include adverse reactions not otherwise noted in Table 1.

Adverse reactions with incidence rates of 1.0% to <5.0%

Cardiac disorders: hypertension

Gastrointestinal disorders: dyspepsia, flatulence

General disorders: abdominal pain, accidental injury, chills, fever, flu syndrome, neck pain, pelvic pain

Investigations: hyperglycemia, urine abnormality

Metabolism and nutrition disorders: peripheral edema, weight loss

Musculoskeletal, connective tissue and bone disorders: myalgia

Nervous system disorders: paresthesia, tremor, withdrawal syndrome

Psychiatric disorders: agitation, anxiety, apathy, confusion, depersonalization, depression, euphoria, nervousness

Respiratory, thoracic and mediastinal disorders: bronchitis, pharyngitis, rhinitis, sinusitis

Skin and subcutaneous tissue disorders: rash

Urogenital disorders: prostatic disorder, urinary tract infection

Vascular disorders: vasodilatation

Adverse reactions with incidence rates of 0.5% to <1.0% at any dose and serious adverse reactions reported in at least two patients

Cardiac disorders: EKG abnormal, hypotension, tachycardia

Gastrointestinal disorders: gastroenteritis

General disorders: neck rigidity, viral infection

Hematologic/Lymphatic disorders: anemia, ecchymoses

Metabolism and nutrition disorders: blood urea nitrogen increased, GGT increased, gout, SGPT increased

Musculoskeletal disorders: arthritis, arthrosis, joint disorder, leg cramps

Nervous system disorders: emotional lability, hyperkinesia, hypertonia, thinking abnormal, twitching, vertigo

Respiratory disorders: pneumonia

Skin and subcutaneous tissue disorders: hair disorder, skin disorder, urticaria

Special Senses: eye disorder, lacrimation disorder

Urogenital disorders: cystitis, dysuria, sexual function abnormality, urinary retention

The following adverse reactions have been identified during post approval use of tramadol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.

Anaphylaxis: Anaphylaxis has been reported with ingredients contained in Tramadol Hydrochloride Extended-Release Capsules.

Androgen deficiency: Cases of androgen deficiency have occurred with use of opioids for an extended period of time [see Clinical Pharmacology (12.2)].

Hyperalgesia and Allodynia: Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see Warnings and Precautions (5.8)].

QT prolongation/torsade de pointes: Cases of QT prolongation and/or torsade de pointes have been reported with tramadol use. Many of these cases were reported in patients taking another drug labeled for QT prolongation, in patients with a risk factor for QT prolongation (e.g., hypokalemia), or in overdose setting.

Metabolism and nutrition disorders

Hyponatremia: Cases of severe hyponatremia and/or SIADH have been reported in patients taking tramadol, most often in females over the age of 65, and within the first week of therapy [see Warnings and Precautions (5.20)].

Hypoglycemia: Cases of hypoglycemia have been reported in patients taking tramadol. Most reports were in patients with predisposing risk factors, including diabetes or renal insufficiency, or in elderly patients [see Warnings and Precautions (5.21)].

Table 2 includes clinically significant drug interactions with Tramadol Hydrochloride Extended-Release Capsules.

{ "type": "p", "children": [], "text": "Table 2 includes clinically significant drug interactions with Tramadol Hydrochloride Extended-Release Capsules." }

<div class="scrollingtable"><table width="85%"> <caption> <span>Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Extended-Release Capsules</span> </caption> <col align="left" valign="top" width="25%"/> <col align="left" valign="top" width="75%"/> <tbody class="Headless"> <tr class="Botrule First"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Inhibitors of CYP2D6</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">The concomitant use of Tramadol Hydrochloride Extended-Release Capsules and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of Tramadol Hydrochloride Extended-Release Capsules is achieved. Since M1 is a more potent mu-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome.<br/>After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase which could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, and may cause potentially fatal respiratory depression <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures, and serotonin syndrome.<br/>If a CYP2D6 inhibitor is discontinued, consider lowering Tramadol Hydrochloride Extended-Release Capsules dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Quinidine, fluoxetine, paroxetine, and bupropion</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Inhibitors of CYP3A4</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact: </td><td align="left" class="Rrule">The concomitant use of Tramadol Hydrochloride Extended-Release Capsules and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of Tramadol Hydrochloride Extended-Release Capsules is achieved.<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>, resulting in decreased opioid efficacy and possibly signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">If concomitant use is necessary, consider dosage reduction of Tramadol Hydrochloride Extended-Release Capsules until stable drug effects are achieved. Evaluate patients at frequent intervals for seizures and serotonin syndrome, and signs of respiratory depression and sedation.<br/>If a CYP3A4 inhibitor is discontinued, consider increasing the Tramadol Hydrochloride Extended-Release Capsules dosage until stable drug effects are achieved and evaluate patients for signs and symptoms of opioid withdrawal.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">CYP3A4 Inducers</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">The concomitant use of Tramadol Hydrochloride Extended-Release Capsules and CYP3A4 inducers can decrease the plasma concentration of tramadol <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>, which could increase or prolong both the therapeutic effects and adverse reactions and may cause seizures and serotonin syndrome, and potentially fatal respiratory depression.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">If concomitant use is necessary, consider increasing the Tramadol Hydrochloride Extended-Release Capsules dosage until stable drug effects are achieved. Evaluate patients for signs of opioid withdrawal.<br/>If a CYP3A4 inducer is discontinued, consider Tramadol Hydrochloride Extended-Release Capsules dosage reduction and evaluate patients at frequent intervals for seizures and serotonin syndrome, and signs of respiratory depression and sedation.<br/>Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of Tramadol Hydrochloride Extended-Release Capsules and carbamazepine is not recommended.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Rifampin, carbamazepine, phenytoin</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a></span>, <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1</a></span>, <span class="Italics"><a href="#S5.2">5.2</a></span>, <span class="Italics"><a href="#S5.3">5.3)</a>]</span>.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Serotonergic Drugs</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>].</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue Tramadol Hydrochloride Extended-Release Capsules if serotonin syndrome is suspected.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Monoamine Oxidase Inhibitors (MAOIs)</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">MAOI interactions with opioids may manifest as serotonin syndrome <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span> or opioid toxicity (e.g., respiratory depression, coma) <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Do not use Tramadol Hydrochloride Extended-Release Capsules in patients taking MAOIs or within 14 days of stopping such treatment.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Phenelzine, tranylcypromine, linezolid</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">May reduce the analgesic effect of Tramadol Hydrochloride Extended-Release Capsules and/or precipitate withdrawal symptoms.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Avoid concomitant use.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Examples:</td><td align="left" class="Rrule">Butorphanol, nalbuphine, pentazocine, buprenorphine</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Muscle Relaxants</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Because respiratory depression may be greater than otherwise expected, decrease the dosage of Tramadol Hydrochloride Extended-Release Capsules and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a></span>, <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.3">5.3)</a>]</span>.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Diuretics</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Anticholinergic Drugs</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Evaluate patients for signs of urinary retention or reduced gastric motility when Tramadol Hydrochloride Extended-Release Capsules is used concomitantly with anticholinergic drugs.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Digoxin</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Evaluate patients at frequent intervals for signs of digoxin toxicity and adjust dosage of digoxin as needed.</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="2"><span class="Bold">Warfarin</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">Clinical Impact:</td><td align="left" class="Rrule">Post-marketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.</td> </tr> <tr class="Last"> <td align="left" class="Lrule Rrule">Intervention:</td><td align="left" class="Rrule">Frequently reevaluate the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.</td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"85%\">\n<caption>\n<span>Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Extended-Release Capsules</span>\n</caption>\n<col align=\"left\" valign=\"top\" width=\"25%\"/>\n<col align=\"left\" valign=\"top\" width=\"75%\"/>\n<tbody class=\"Headless\">\n<tr class=\"Botrule First\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Inhibitors of CYP2D6</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">The concomitant use of Tramadol Hydrochloride Extended-Release Capsules and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of Tramadol Hydrochloride Extended-Release Capsules is achieved. Since M1 is a more potent mu-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome.<br/>After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase which could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, and may cause potentially fatal respiratory depression <span class=\"Italics\">[see <a href=\"#S12.3\">Clinical Pharmacology (12.3)</a>]</span>.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures, and serotonin syndrome.<br/>If a CYP2D6 inhibitor is discontinued, consider lowering Tramadol Hydrochloride Extended-Release Capsules dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Quinidine, fluoxetine, paroxetine, and bupropion</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Inhibitors of CYP3A4</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact: \t\t\t\t\t\t\t\t\t</td><td align=\"left\" class=\"Rrule\">The concomitant use of Tramadol Hydrochloride Extended-Release Capsules and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of Tramadol Hydrochloride Extended-Release Capsules is achieved.<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <span class=\"Italics\">[see <a href=\"#S12.3\">Clinical Pharmacology (12.3)</a>]</span>, resulting in decreased opioid efficacy and possibly signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">If concomitant use is necessary, consider dosage reduction of Tramadol Hydrochloride Extended-Release Capsules until stable drug effects are achieved. Evaluate patients at frequent intervals for seizures and serotonin syndrome, and signs of respiratory depression and sedation.<br/>If a CYP3A4 inhibitor is discontinued, consider increasing the Tramadol Hydrochloride Extended-Release Capsules dosage until stable drug effects are achieved and evaluate patients for signs and symptoms of opioid withdrawal.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir)</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">CYP3A4 Inducers</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">The concomitant use of Tramadol Hydrochloride Extended-Release Capsules and CYP3A4 inducers can decrease the plasma concentration of tramadol <span class=\"Italics\">[see <a href=\"#S12.3\">Clinical Pharmacology (12.3)</a>]</span>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol <span class=\"Italics\">[see <a href=\"#S5.7\">Warnings and Precautions (5.7)</a>]</span>.<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <span class=\"Italics\">[see <a href=\"#S12.3\">Clinical Pharmacology (12.3)</a>]</span>, which could increase or prolong both the therapeutic effects and adverse reactions and may cause seizures and serotonin syndrome, and potentially fatal respiratory depression.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">If concomitant use is necessary, consider increasing the Tramadol Hydrochloride Extended-Release Capsules dosage until stable drug effects are achieved. Evaluate patients for signs of opioid withdrawal.<br/>If a CYP3A4 inducer is discontinued, consider Tramadol Hydrochloride Extended-Release Capsules dosage reduction and evaluate patients at frequent intervals for seizures and serotonin syndrome, and signs of respiratory depression and sedation.<br/>Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of Tramadol Hydrochloride Extended-Release Capsules and carbamazepine is not recommended.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Rifampin, carbamazepine, phenytoin</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Benzodiazepines and Other Central Nervous System (CNS) Depressants</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death <span class=\"Italics\">[see <a href=\"#S5.3\">Warnings and Precautions (5.3)</a>]</span>.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <span class=\"Italics\">[see <a href=\"#S2.2\">Dosage and Administration (2.2)</a></span>, <span class=\"Italics\"><a href=\"#S5.1\">Warnings and Precautions (5.1</a></span>, <span class=\"Italics\"><a href=\"#S5.2\">5.2</a></span>, <span class=\"Italics\"><a href=\"#S5.3\">5.3)</a>]</span>.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Serotonergic Drugs</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <span class=\"Italics\">[see <a href=\"#S5.9\">Warnings and Precautions (5.9)</a>].</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue Tramadol Hydrochloride Extended-Release Capsules if serotonin syndrome is suspected.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Monoamine Oxidase Inhibitors (MAOIs)</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">MAOI interactions with opioids may manifest as serotonin syndrome <span class=\"Italics\">[see <a href=\"#S5.9\">Warnings and Precautions (5.9)</a>]</span> or opioid toxicity (e.g., respiratory depression, coma) <span class=\"Italics\">[see <a href=\"#S5.2\">Warnings and Precautions (5.2)</a>]</span>.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Do not use Tramadol Hydrochloride Extended-Release Capsules in patients taking MAOIs or within 14 days of stopping such treatment.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Phenelzine, tranylcypromine, linezolid</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">May reduce the analgesic effect of Tramadol Hydrochloride Extended-Release Capsules and/or precipitate withdrawal symptoms.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Avoid concomitant use.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Examples:</td><td align=\"left\" class=\"Rrule\">Butorphanol, nalbuphine, pentazocine, buprenorphine</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Muscle Relaxants</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Because respiratory depression may be greater than otherwise expected, decrease the dosage of Tramadol Hydrochloride Extended-Release Capsules and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <span class=\"Italics\">[see <a href=\"#S2.2\">Dosage and Administration (2.2)</a></span>, <span class=\"Italics\"><a href=\"#S5.2\">Warnings and Precautions (5.2</a>, <a href=\"#S5.3\">5.3)</a>]</span>.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Diuretics</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Anticholinergic Drugs</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Evaluate patients for signs of urinary retention or reduced gastric motility when Tramadol Hydrochloride Extended-Release Capsules is used concomitantly with anticholinergic drugs.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Digoxin</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Evaluate patients at frequent intervals for signs of digoxin toxicity and adjust dosage of digoxin as needed.</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"2\"><span class=\"Bold\">Warfarin</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">Clinical Impact:</td><td align=\"left\" class=\"Rrule\">Post-marketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.</td>\n</tr>\n<tr class=\"Last\">\n<td align=\"left\" class=\"Lrule Rrule\">Intervention:</td><td align=\"left\" class=\"Rrule\">Frequently reevaluate the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.</td>\n</tr>\n</tbody>\n</table></div>" }

Risk Summary

Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.4)]. Available data with Tramadol Hydrochloride Extended-Release Capsules in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.

In animal reproduction studies, tramadol administration during organogenesis decreased fetal weights and reduced ossification in mice, rats, and rabbits at 1.4, 0.6, and 3.6 times the maximum recommended human daily dosage (MRHD). Tramadol decreased pup body weight and increased pup mortality at 1.2 and 1.9 times the MRHD [see Data]. Based on animal data, advise pregnant women of the potential risk to a fetus.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings and Precautions (5.4)].

Neonatal seizures, neonatal withdrawal syndrome, fetal death and still birth have been reported with tramadol during post-approval use of tramadol immediate-release products.

Labor or Delivery

Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Tramadol Hydrochloride Extended-Release Capsules is not recommended for use in pregnant women during or immediately prior to labor, when use of shorter-acting analgesics or other analgesic techniques are more appropriate. Opioid analgesics, including Tramadol Hydrochloride Extended-Release Capsules can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.

Tramadol has been shown to cross the placenta. The mean ratio of serum tramadol in the umbilical veins compared to maternal veins was 0.83 for 40 women given tramadol during labor.

The effect of Tramadol Hydrochloride Extended-Release Capsules, if any, on the later growth, development, and functional maturation of the child is unknown.

Data

Animal Data

Tramadol has been shown to be embryotoxic and fetotoxic in mice, (120 mg/kg), rats (25 mg/kg) and rabbits (75 mg/kg) at maternally toxic dosages but was not teratogenic at these dose levels. These doses on a mg/m2 basis are 1.9, 0.8, and 4.9 times the maximum recommended human daily dosage (MRHD) for mouse, rat and rabbit, respectively.

No drug-related teratogenic effects were observed in progeny of mice (up to 140 mg/kg), rats (up to 80 mg/kg) or rabbits (up to 300 mg/kg) treated with tramadol by various routes. Embryo and fetal toxicity consisted primarily of decreased fetal weights, decreased skeletal ossification, and increased supernumerary ribs at maternally toxic dose levels. Transient delays in developmental or behavioral parameters were also seen in pups from rat dams allowed to deliver. Embryo and fetal lethality were reported only in one rabbit study at 300 mg/kg, a dose that would cause extreme maternal toxicity in the rabbit. The dosages listed for mouse, rat, and rabbit are 2.3, 2.6, and 19 times the MRHD, respectively.

Tramadol was evaluated in pre- and post-natal studies in rats. Progeny of dams receiving oral (gavage) dose levels of 50 mg/kg (1.6 times the MRHD) or greater had decreased weights, and pup survival was decreased early in lactation at 80 mg/kg (2.6 times the MRHD).

Risk Summary

Tramadol Hydrochloride Extended-Release Capsules is not recommended for obstetrical preoperative medication or for post-delivery analgesia in nursing mothers because its safety in infants and newborns has not been studied.

Tramadol and its metabolite, O-desmethyltramadol (M1), are present in human milk. There is no information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The M1 metabolite is more potent than tramadol in mu-opioid receptor binding [see Clinical Pharmacology (12.1)]. Published studies have reported tramadol and M1 in colostrum with administration of tramadol to nursing mothers in the early post-partum period. Women who are ultra-rapid metabolizers of tramadol may have higher than expected serum levels of M1, potentially leading to higher levels of M1 in breast milk that can be dangerous in their breastfed infants. In women with normal tramadol metabolism, the amount of tramadol secreted into human milk is low and dose dependent. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with Tramadol Hydrochloride Extended-Release Capsules.

Clinical Considerations

Monitor infants exposed to Tramadol Hydrochloride Extended-Release Capsules through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.

Data

Following a single IV 100 mg dose of tramadol, the cumulative excretion in breast milk within 16 hours post dose was 100 mcg of tramadol (0.1% of the maternal dose) and 27 mcg of M1.

Infertility

Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Adverse Reactions (6.2), Clinical Pharmacology (12.2), Nonclinical Toxicology (13.1)].

The safety and effectiveness of Tramadol Hydrochloride Extended-Release Capsules in pediatric patients have not been established.

Life-threatening respiratory depression and death have occurred in children who received tramadol [see Warnings and Precautions (5.6)]. In some of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and one of the children had evidence of being an ultra-rapid metabolizer of tramadol (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of tramadol. Because of the risk of life-threatening respiratory depression and death:

Eight hundred and twelve elderly (65 years of age or older) subjects were exposed to Tramadol Hydrochloride Extended-Release Capsules in clinical trials. Of those subjects, two hundred and forty were 75 years of age and older. In general, higher incidence rates of adverse events were observed for patients older than 65 years of age compared with patients 65 years and younger, particularly for the following adverse events: nausea, constipation, somnolence, dizziness, dry mouth, vomiting, asthenia, pruritus, anorexia, sweating, fatigue, weakness, postural hypotension and dyspepsia. For this reason, Tramadol Hydrochloride Extended-Release Capsules should be used with great caution in patients older than 75 years of age [see Dosage and Administration (2.3)].

Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Tramadol Hydrochloride Extended-Release Capsules slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.12)].

Tramadol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.

Metabolism of tramadol and M1 is reduced in patients with advanced cirrhosis of the liver. Tramadol Hydrochloride Extended-Release Capsules has not been studied in patients with hepatic impairment. The limited availability of dose strengths of Tramadol Hydrochloride Extended-Release Capsules does not permit the dosing flexibility required for safe use in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, Tramadol Hydrochloride Extended-Release Capsules should not be used in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].

Tramadol Hydrochloride Extended-Release Capsules has not been studied in patients with renal impairment. Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. The limited availability of dose strengths of Tramadol Hydrochloride Extended-Release Capsules does not permit the dosing flexibility required for safe use in patients with severe renal impairment (Child-Pugh Class C). Therefore, Tramadol Hydrochloride Extended-Release Capsules should not be used in patients with severe renal impairment [see Clinical Pharmacology (12.3)].

Tramadol Hydrochloride Extended-Release Capsules contains tramadol, a Schedule IV controlled substance.

Tramadol Hydrochloride Extended-Release Capsules contains tramadol, a substance with potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see Warnings and Precautions (5.1)].

Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed.

Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of Tramadol Hydrochloride Extended-Release Capsules increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of Tramadol Hydrochloride Extended-Release Capsules with alcohol and/or other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.

All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of Tramadol Hydrochloride Extended-Release Capsules abuse include those with a history of prolonged use of any opioid, including products containing tramadol, those with a history of drug or alcohol abuse, or those who use Tramadol Hydrochloride Extended-Release Capsules in combination with other abused drugs.

"Drug-seeking" behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated "loss" of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.

Tramadol Hydrochloride Extended-Release Capsules, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of Tramadol Hydrochloride Extended-Release Capsules

Abuse of Tramadol Hydrochloride Extended-Release Capsules poses a risk of overdose and death. This risk is increased with concurrent use of Tramadol Hydrochloride Extended-Release Capsules with alcohol and/or other CNS depressants [see Warnings and Precautions (5.1, 5.3), Drug Interactions (7)].

Tramadol Hydrochloride Extended-Release Capsules is approved for oral use only. With parental abuse, the inactive ingredients in Tramadol Hydrochloride Extended-Release Capsules can result in local tissue necrosis, infection, pulmonary granulomas, increased risk of endocarditis and valvular heart injury, embolism, and death.

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue Tramadol Hydrochloride Extended-Release Capsules in a patient physically dependent on opioids. Rapid tapering of Tramadol Hydrochloride Extended-Release Capsules in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing Tramadol Hydrochloride Extended-Release Capsules, gradually taper the dosage using a patient-specific plan that considers the following: the dose of Tramadol Hydrochloride Extended-Release Capsules the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage and Administration (2.5), Warnings and Precautions (5.18)].

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1)].

Clinical Presentation

Acute overdosage with tramadol can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, QT prolongation, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations. [see Clinical Pharmacology (12.2)].

Treatment of Overdose

In case of overdosage, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support measures.

Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid antagonist.

While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals, convulsions following the administration of toxic doses of Tramadol Hydrochloride Extended-Release Capsules could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.

Because the duration of opioid reversal is expected to be less than the duration of action of tramadol in Tramadol Hydrochloride Extended-Release Capsules, carefully monitor the patient until spontaneous respiration is reliably reestablished. Tramadol Hydrochloride Extended-Release Capsules will continue to release tramadol and add to the tramadol load for 24 to 48 hours or longer following ingestion, necessitating prolonged monitoring. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information.

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.

Tramadol Hydrochloride Extended-Release Capsules is an opioid agonist in an extended-release oral formulation. The chemical name for tramadol hydrochloride USP is (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride Extended-Release Capsules is an opioid agonist in an extended-release oral formulation. The chemical name for tramadol hydrochloride USP is (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:" }

Figure 1

{ "type": "p", "children": [], "text": "\nFigure 1\n" }

{ "type": "", "children": [], "text": "" }

The molecular weight of tramadol hydrochloride USP is 299.8. It is a white, bitter, crystalline and odorless powder that is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7.

{ "type": "p", "children": [], "text": "The molecular weight of tramadol hydrochloride USP is 299.8. It is a white, bitter, crystalline and odorless powder that is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7." }

Tramadol Hydrochloride Extended-Release Capsules contain a total dose of tramadol hydrochloride 100, 200, and 300 mg in a combination of immediate-release and extended-release components.

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride Extended-Release Capsules contain a total dose of tramadol hydrochloride 100, 200, and 300 mg in a combination of immediate-release and extended-release components." }

<div class="scrollingtable"><table width="65%"> <col align="left" valign="top" width="34%"/> <col align="left" valign="top" width="33%"/> <col align="left" valign="top" width="33%"/> <thead> <tr class="First Last"> <th align="left" class="Lrule Rrule">Dosage</th><th align="left" class="Rrule">Immediate-release</th><th align="left" class="Rrule">Extended-release</th> </tr> </thead> <tbody> <tr class="Botrule First"> <td align="left" class="Lrule Rrule">100 mg</td><td align="left" class="Rrule">25 mg</td><td align="left" class="Rrule">75 mg</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">200 mg</td><td align="left" class="Rrule">50 mg</td><td align="left" class="Rrule">150 mg</td> </tr> <tr class="Last"> <td align="left" class="Lrule Rrule">300 mg</td><td align="left" class="Rrule">50 mg</td><td align="left" class="Rrule">250 mg</td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"65%\">\n<col align=\"left\" valign=\"top\" width=\"34%\"/>\n<col align=\"left\" valign=\"top\" width=\"33%\"/>\n<col align=\"left\" valign=\"top\" width=\"33%\"/>\n<thead>\n<tr class=\"First Last\">\n<th align=\"left\" class=\"Lrule Rrule\">Dosage</th><th align=\"left\" class=\"Rrule\">Immediate-release</th><th align=\"left\" class=\"Rrule\">Extended-release</th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"Botrule First\">\n<td align=\"left\" class=\"Lrule Rrule\">100 mg</td><td align=\"left\" class=\"Rrule\">25 mg</td><td align=\"left\" class=\"Rrule\">75 mg</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\">200 mg</td><td align=\"left\" class=\"Rrule\">50 mg</td><td align=\"left\" class=\"Rrule\">150 mg</td>\n</tr>\n<tr class=\"Last\">\n<td align=\"left\" class=\"Lrule Rrule\">300 mg</td><td align=\"left\" class=\"Rrule\">50 mg</td><td align=\"left\" class=\"Rrule\">250 mg</td>\n</tr>\n</tbody>\n</table></div>" }

Tramadol Hydrochloride Extended-Release Capsules are white in color. Inactive ingredients include gelatin, titanium dioxide, shellac, FD & C Blue #2 aluminum lake (E132) (100 and 200 mg capsules), D & C Red #7 calcium lake (E180) (200 and 300 mg capsules), D & C Yellow #10 aluminum lake (300 mg capsule), lactose monohydrate 200 mesh, microcrystalline cellulose, povidone K30, corn starch, sodium starch glycolate, magnesium stearate, sucrose stearate, hypromellose, talc, polysorbate 80, Eudragit NE 30D, and simethicone emulsion.

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride Extended-Release Capsules are white in color. Inactive ingredients include gelatin, titanium dioxide, shellac, FD & C Blue #2 aluminum lake (E132) (100 and 200 mg capsules), D & C Red #7 calcium lake (E180) (200 and 300 mg capsules), D & C Yellow #10 aluminum lake (300 mg capsule), lactose monohydrate 200 mesh, microcrystalline cellulose, povidone K30, corn starch, sodium starch glycolate, magnesium stearate, sucrose stearate, hypromellose, talc, polysorbate 80, Eudragit NE 30D, and simethicone emulsion." }

Tramadol Hydrochloride Extended-Release Capsules contains tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to mu-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin.

Opioid activity of tramadol is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to mu-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in mu-opioid binding. Tramadol-induced analgesia is only partially antagonized by the opioid antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human analgesia is dependent upon the plasma concentrations of each compound.

Tramadol has been shown to inhibit reuptake of norepinephrine and serotonin in vitro, as have some other opioid analgesics. These mechanisms may contribute independently to the overall analgesic profile of tramadol. The relationship between exposure of tramadol and M1 and efficacy has not been evaluated in clinical studies.

Apart from analgesia, tramadol administration may produce a constellation of symptoms (including dizziness, somnolence, nausea, constipation, sweating and pruritus) similar to that of other opioids. In contrast to morphine, tramadol has not been shown to cause histamine release. At therapeutic doses, tramadol has no effect on heart rate, left ventricular function or cardiac index. Orthostatic hypotension has been observed.

Effects on the Central Nervous System

Tramadol produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.

Tramadol causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Effects on the Gastrointestinal Tract and Other Smooth Muscle

Tramadol causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone is increased to the point of spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Effects on the Cardiovascular System

Tramadol produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

The effect of oral tramadol on the QTcF interval was evaluated in a double-blind, randomized, four-way crossover, placebo- and positive- (moxifloxacin) controlled study in 68 adult male and female healthy subjects. At a 600 mg/day dose (1.5-fold the maximum immediate-release daily dose), the study demonstrated no significant effect on the QTcF interval.

Effects on the Endocrine System

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [see Adverse Reactions (6.2)]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.

Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [see Adverse Reactions (6.2)].

Effects on the Immune System

Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.

Concentration–Efficacy Relationships

The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists. The minimum effective analgesic concentration of tramadol for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the development of analgesic tolerance [see Dosage and Administration (2.1, 2.4)].

Concentration–Adverse Reaction Relationships

There is a relationship between increasing tramadol plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions [see Dosage and Administration (2.1, 2.3, 2.4)].

The analgesic activity of tramadol is due to both parent drug and the M1 metabolite. Tramadol Hydrochloride Extended-Release Capsules is administered as a racemate and both tramadol and M1 are detected in the circulation. The Cmax and AUC of Tramadol Hydrochloride Extended-Release Capsules have been observed to be dose-proportional over an oral dose range of 100 to 300 mg in healthy subjects.

Absorption

After a single dose administration of Tramadol Hydrochloride Extended-Release Capsules, Tmax occurs around 10-12 hours.

The mean Cmax and AUC of Tramadol Hydrochloride Extended-Release Capsules after a 300 mg single dose was 308 ng/mL and 6777 ng.hr/mL, respectively under fasting conditions. Tramadol Hydrochloride Extended-Release Capsules is bioequivalent to a reference extended-release tramadol product following a single 300 mg dose under fasting conditions.

At steady-state, Tramadol Hydrochloride Extended-Release Capsules at 200 mg has been observed to be bioequivalent to a reference extended-release tramadol product at 200 mg under fasting conditions (Table 3). Following administration of Tramadol Hydrochloride Extended-Release Capsules 200 mg capsules, steady-state plasma concentrations of both tramadol and M1 are achieved within four days of once daily dosing.

<div class="scrollingtable"><table width="85%"> <caption> <span>Table 3</span> </caption> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <col align="left" valign="middle" width="20%"/> <thead> <tr class="Botrule First"> <th align="left" class="Lrule Rrule" colspan="5">Mean (%CV) Steady-State Pharmacokinetic Parameter Values (N= 38)</th> </tr> <tr class="Botrule"> <th align="left" class="Lrule Rrule"></th><th align="center" class="Rrule" colspan="2">Tramadol</th><th align="center" class="Rrule" colspan="2">O-Desmethyltramadol<br/>(M1 Metabolite)</th> </tr> <tr class="Last"> <th align="left" class="Lrule Rrule">Parameter</th><th align="left" class="Rrule">Tramadol Hydrochloride Extended- Release Capsules<br/>200 mg</th><th align="left" class="Rrule">A Reference Extended-Release Tramadol Product<br/>200 mg</th><th align="left" class="Rrule">Tramadol Hydrochloride Extended-Release Capsules<br/>200 mg</th><th align="left" class="Rrule">A Reference Extended-Release Tramadol Product<br/>200 mg</th> </tr> </thead> <tfoot> <tr class="First Last"> <td align="left" colspan="5" valign="top">AUC<span class="Sub">0-24</span>: Area Under the Curve in a 24-hour dosing interval<br/>C<span class="Sub">max</span>: Peak Concentration in a 24-hour dosing interval<br/>C<span class="Sub">min</span>: Trough Concentration in a 24-hour dosing interval<br/>T<span class="Sub">max</span>: Time to Peak Concentration</td> </tr> </tfoot> <tbody> <tr class="Botrule First"> <td align="left" class="Lrule Rrule">AUC<span class="Sub">0-24</span> (ng.hr/mL)</td><td align="left" class="Rrule">5678 (27%)</td><td align="left" class="Rrule">5563 (32%)</td><td align="left" class="Rrule">1319 (34%)</td><td align="left" class="Rrule">1302 (40%)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">C<span class="Sub">max</span> (ng/mL)</td><td align="left" class="Rrule">332 (25%)</td><td align="left" class="Rrule">350 (31%)</td><td align="left" class="Rrule">70 (34%)</td><td align="left" class="Rrule">74 (41%)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">C<span class="Sub">min</span> (ng/mL)</td><td align="left" class="Rrule">128 (39%)</td><td align="left" class="Rrule">125 (45%)</td><td align="left" class="Rrule">35 (34%)</td><td align="left" class="Rrule">33 (42%)</td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule">T<span class="Sub">max</span></td><td align="left" class="Rrule">5.9 (66%)</td><td align="left" class="Rrule">10 (30%)</td><td align="left" class="Rrule">11 (37%)</td><td align="left" class="Rrule">13 (29%)</td> </tr> <tr class="Last"> <td align="left" class="Lrule Rrule">% Fluctuation</td><td align="left" class="Rrule">88 (19%)</td><td align="left" class="Rrule">101 (30%)</td><td align="left" class="Rrule">64 (22%)</td><td align="left" class="Rrule">76 (30%)</td> </tr> </tbody> </table></div>

Food Effect

The rate and extent of absorption of Tramadol Hydrochloride Extended-Release Capsules (300 mg) are similar following oral administration with or without food. Therefore, Tramadol Hydrochloride Extended-Release Capsules can be administered without regard to meals.

Distribution

The volume of distribution of tramadol was 2.6 and 2.9 liters/kg in male and female subjects, respectively, following a 100 mg intravenous tramadol dose. The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 mcg/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range.

Elimination

Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. The mean plasma elimination half-lives of racemic tramadol and racemic M1 after administration of Tramadol Hydrochloride Extended-Release Capsules are approximately 10 and 11 hours, respectively.

Metabolism

Tramadol is extensively metabolized after oral administration. The major metabolic pathways appear to be N- (mediated by CYP3A4 and CYP2B6) and O- (mediated by CYP2D6) demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. Formation of M1 is dependent on CYP2D6 and as such is subject to inhibition and polymorphism, which may affect the therapeutic response [see Drug Interactions (7)].

Excretion

Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The remainder is excreted either as unidentified or as unextractable metabolites.

Special Populations

Hepatic Impairment

Pharmacokinetics of tramadol was studied in patients with mild or moderate hepatic impairment after receiving multiple doses of an extended-release tramadol product at 100 mg. The exposure of (+)- and (-)-tramadol was similar in mild and moderate hepatic impairment patients in comparison to patients with normal hepatic function. However, exposure of (+)- and (-)-M1 decreased ~50% with increased severity of the hepatic impairment (from normal to mild and moderate). The pharmacokinetics of tramadol has not been studied in patients with severe hepatic impairment. After the administration of tramadol immediate-release tablets to patients with advanced cirrhosis of the liver, tramadol area under the plasma concentration time curve was larger and the tramadol and M1 half-lives were longer than subjects with normal hepatic function. The limited availability of dose strengths of Tramadol Hydrochloride Extended-Release Capsules does not permit the dosing flexibility required for safe use in patients with severe hepatic impairment. Therefore, Tramadol Hydrochloride Extended-Release Capsules should not be used in patients with severe hepatic impairment [see Use in Specific Populations (8.6)].

Renal Impairment

Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. The pharmacokinetics of tramadol was studied in patients with mild or moderate renal impairment after receiving multiple doses of an extended-release tramadol product at 100 mg. There is no consistent trend observed for tramadol exposure related to renal function in patients with mild (CLcr: 50-80 mL/min) or moderate (CLcr: 30-50 mL/min) renal impairment in comparison to patients with normal renal function (CLcr > 80 mL/min). However, exposure of M1 increased 20-40% with increased severity of the renal impairment (from normal to mild and moderate). The pharmacokinetics of tramadol has not been studied in patients with severe renal impairment (CLcr < 30 mL/min). The limited availability of dose strengths of Tramadol Hydrochloride Extended-Release Capsules does not permit the dosing flexibility required for safe use in patients with severe renal impairment. Therefore, Tramadol Hydrochloride Extended-Release Capsules should not be used in patients with severe renal impairment. The total amount of tramadol and M1 removed during a 4-hour dialysis period is less than 7% of the administered dose [see Use in Specific Populations (8.6)].

Sex

Based on pooled multiple-dose pharmacokinetics studies for an extended-release tramadol product in 166 healthy subjects (111 males and 55 females), the dose-normalized AUC values for tramadol were somewhat higher in females than in males. There was a considerable degree of overlap in values between male and female groups. Dosage adjustment based on sex is not recommended.

Age: Geriatric Population

The effect of age on pharmacokinetics of Tramadol Hydrochloride Extended-Release Capsules has not been studied. Healthy elderly subjects aged 65 to 75 years administered an immediate-release formulation of tramadol, have plasma concentrations and elimination half-lives comparable to those observed in healthy subjects younger than 65 years of age. In subjects over 75 years, mean maximum plasma concentrations are elevated (208 vs. 162 ng/mL) and the mean elimination half-life is prolonged (7 vs. 6 hours) compared to subjects 65 to 75 years of age. Adjustment of the daily dose is recommended for patients older than 75 years [see Dosage and Administration (2.3)].

Drug Interaction Studies

Potential for Tramadol to Affect Other Drugs

In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data.

Poor / Extensive Metabolizers, CYP2D6

The formation of the active metabolite, M1, is mediated by CYP2D6, a polymorphic enzyme. Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P-450 metabolizing enzyme system. These individuals are "poor metabolizers" of debrisoquine, dextromethorphan and tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase 1 studies with IR tablets in healthy subjects, concentrations of tramadol were approximately 20% higher in "poor metabolizers" versus "extensive metabolizers", while M1 concentrations were 40% lower.

CYP2D6 Inhibitors

In vitro drug interaction studies in human liver microsomes indicate that concomitant administration with inhibitors of CYP2D6 such as fluoxetine, paroxetine, and amitriptyline could result in some inhibition of the metabolism of tramadol.

Quinidine

Tramadol is metabolized to active metabolite M1 by CYP2D6. Coadministration of quinidine, a selective inhibitor of CYP2D6, with tramadol ER resulted in a 50-60% increase in tramadol exposure and a 50-60% decrease in M1 exposure. The clinical consequences of these findings are unknown.

To evaluate the effect of tramadol, a CYP2D6 substrate on quinidine, an in vitro drug interaction study in human liver microsomes was conducted. The results from this study indicate that tramadol has no effect on quinidine metabolism [see Warnings and Precautions (5.1, 5.7), Drug Interactions (7)].

CYP3A4 Inhibitors and Inducers

Since tramadol is also metabolized by CYP3A4, administration of CYP3A4 inhibitors, such as ketoconazole and erythromycin, or CYP3A4 inducers, such as rifampin and St. John's Wort, with Tramadol Hydrochloride Extended-Release Capsules may affect the metabolism of tramadol leading to altered tramadol exposure [see Warnings and Precautions (5.1, 5.7), Drug Interactions (7)].

Cimetidine

Concomitant administration of tramadol immediate-release tablets with cimetidine, a weak CPY3A4 inhibitor, does not result in clinically significant changes in tramadol pharmacokinetics. No alteration of the Tramadol Hydrochloride Extended-Release Capsules dosage regimen with cimetidine is recommended.

Carbamazepine

Carbamazepine, a CYP3A4 inducer, increases tramadol metabolism. Patients taking carbamazepine may have a significantly reduced analgesic effect of tramadol. Concomitant administration of Tramadol Hydrochloride Extended-Release Capsules and carbamazepine is not recommended.

Carcinogenesis

Carcinogenicity assessment has been conducted in mice, rats and p53(+/-) heterozygous mice. A slight but statistically significant increase in two common murine tumors, pulmonary and hepatic, was observed in an NMRI mouse carcinogenicity study, particularly in aged mice. Mice were dosed orally up to 30 mg/kg in the drinking water (0.5 times the maximum recommended daily human dosage or MRHD) for approximately two years, although the study was not done with the Maximum Tolerated Dose. This finding is not believed to suggest risk in humans.

No evidence of carcinogenicity was noted in a rat 2-year carcinogenicity study testing oral doses of up to 30 mg/kg in the drinking water (1 times the MRHD). In a second rat study, no evidence of carcinogenicity was noted in rats at oral doses up to 75 mg/kg/day for males and 100 mg/kg/day for females (approximately 2 fold the maximum recommended human daily dose MRHD) for two years. However, the excessive decrease in body weight gain observed in the rat study might have reduced their sensitivity to any potential carcinogenic effect of the drug. No carcinogenic effect of tramadol was observed in p53(+/−)-heterozygous mice at oral doses up to 150 mg/kg/day for 26 weeks.

Mutagenesis

Tramadol was mutagenic in the presence of metabolic activation in the mouse lymphoma assay. Tramadol was not mutagenic in the in vitro bacterial reverse mutation assay using Salmonella and E. coli (Ames), the mouse lymphoma assay in the absence of metabolic activation, the in vitro chromosomal aberration assay, or the in vivo micronucleus assay in bone marrow.

Impairment of Fertility

No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg in male rats and 75 mg/kg in female rats. These dosages are 1.2 and 1.8 times the maximum recommended human daily dose based on body surface area, respectively.

Tramadol Hydrochloride Extended-Release Capsules is bioequivalent under fasting conditions to another extended-release tramadol product [see Clinical Pharmacology (12.3)] which demonstrated efficacy in two of four clinical trials of patients with chronic pain. To qualify for inclusion into these studies, patients were required to have moderate to moderately severe pain as defined by a pain intensity score of ≥40 mm, off previous medications, on a 0 - 100 mm visual analog scale (VAS).

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride Extended-Release Capsules is bioequivalent under fasting conditions to another extended-release tramadol product [see Clinical Pharmacology (12.3)] which demonstrated efficacy in two of four clinical trials of patients with chronic pain. To qualify for inclusion into these studies, patients were required to have moderate to moderately severe pain as defined by a pain intensity score of ≥40 mm, off previous medications, on a 0 - 100 mm visual analog scale (VAS). " }

In one 12-week randomized, double-blind, placebo-controlled study, patients with moderate to moderately severe pain due to osteoarthritis of the knee and/or hip were administered doses from 100 mg to 400 mg daily. Treatment with the extended-release tramadol product was initiated at 100 mg once daily for four days then increased by 100 mg per day increments every five days to the randomized fixed dose. Between 51% and 59% of patients in active treatment groups completed the study and 56% of patients in the placebo group completed the study. Discontinuations due to adverse events were more common in the extended-release tramadol product 200 mg, 300 mg and 400 mg treatment groups (20%, 27%, and 30% of discontinuations, respectively) compared to 14% of the patients treated with the extended-release tramadol product 100 mg and 10% of patients treated with placebo.

{ "type": "p", "children": [], "text": "In one 12-week randomized, double-blind, placebo-controlled study, patients with moderate to moderately severe pain due to osteoarthritis of the knee and/or hip were administered doses from 100 mg to 400 mg daily. Treatment with the extended-release tramadol product was initiated at 100 mg once daily for four days then increased by 100 mg per day increments every five days to the randomized fixed dose. Between 51% and 59% of patients in active treatment groups completed the study and 56% of patients in the placebo group completed the study. Discontinuations due to adverse events were more common in the extended-release tramadol product 200 mg, 300 mg and 400 mg treatment groups (20%, 27%, and 30% of discontinuations, respectively) compared to 14% of the patients treated with the extended-release tramadol product 100 mg and 10% of patients treated with placebo." }

Pain, as assessed by the WOMAC Pain subscale, was measured at 1, 2, 3, 6, 9, and 12 weeks and change from baseline assessed. A responder analysis based on the percent change in WOMAC Pain subscale demonstrated a statistically significant improvement in pain for the 100 mg and 200 mg treatment groups compared to placebo (see Figure 2).

{ "type": "p", "children": [], "text": "Pain, as assessed by the WOMAC Pain subscale, was measured at 1, 2, 3, 6, 9, and 12 weeks and change from baseline assessed. A responder analysis based on the percent change in WOMAC Pain subscale demonstrated a statistically significant improvement in pain for the 100 mg and 200 mg treatment groups compared to placebo (see Figure 2)." }

Figure 2

{ "type": "p", "children": [], "text": "\nFigure 2\n" }

In one 12-week randomized, double-blind, placebo-controlled flexible-dosing trial of the extended-release tramadol product in patients with osteoarthritis of the knee, patients titrated to an average daily dose of approximately 270 mg/day. Forty-nine percent of patients randomized to the active treatment group completed the study, while 52% of patients randomized to placebo completed the study. Most of the early discontinuations in the active treatment group were due to adverse events, accounting for 27% of the early discontinuations in contrast to 7% of the discontinuations from the placebo group. Thirty-seven percent of the placebo-treated patients discontinued the study due to lack of efficacy compared to 15% of active-treated patients. The active treatment group demonstrated a statistically significant decrease in the mean Visual Analog Scale (VAS) score, and a statistically significant difference in the responder rate, based on the percent change from baseline in the VAS score, measured at 1, 2, 4, 8, and 12 weeks, between patients receiving the extended-release tramadol product and placebo (see Figure 3).

{ "type": "p", "children": [], "text": "In one 12-week randomized, double-blind, placebo-controlled flexible-dosing trial of the extended-release tramadol product in patients with osteoarthritis of the knee, patients titrated to an average daily dose of approximately 270 mg/day. Forty-nine percent of patients randomized to the active treatment group completed the study, while 52% of patients randomized to placebo completed the study. Most of the early discontinuations in the active treatment group were due to adverse events, accounting for 27% of the early discontinuations in contrast to 7% of the discontinuations from the placebo group. Thirty-seven percent of the placebo-treated patients discontinued the study due to lack of efficacy compared to 15% of active-treated patients. The active treatment group demonstrated a statistically significant decrease in the mean Visual Analog Scale (VAS) score, and a statistically significant difference in the responder rate, based on the percent change from baseline in the VAS score, measured at 1, 2, 4, 8, and 12 weeks, between patients receiving the extended-release tramadol product and placebo (see Figure 3)." }

Figure 3

{ "type": "p", "children": [], "text": "\nFigure 3\n" }

Four randomized, placebo-controlled clinical trials of Tramadol Hydrochloride Extended-Release Capsules were conducted, none of which demonstrated efficacy but which differed in design from the preceding clinical studies described. Two trials were 12-week randomized placebo-controlled trials of Tramadol Hydrochloride Extended-Release Capsules 100 mg/day, 200 mg/day, and 300 mg/day versus placebo in patients with moderate to moderately severe osteoarthritis pain of the hip and knee. The other two 12 week trials were similar in design, but only studied Tramadol Hydrochloride Extended-Release Capsules 300 mg/day. In this fixed-dose design, subjects were required to titrate to a fixed dose, even if their pain responded to a lower titration dose.

{ "type": "p", "children": [], "text": "Four randomized, placebo-controlled clinical trials of Tramadol Hydrochloride Extended-Release Capsules were conducted, none of which demonstrated efficacy but which differed in design from the preceding clinical studies described. Two trials were 12-week randomized placebo-controlled trials of Tramadol Hydrochloride Extended-Release Capsules 100 mg/day, 200 mg/day, and 300 mg/day versus placebo in patients with moderate to moderately severe osteoarthritis pain of the hip and knee. The other two 12 week trials were similar in design, but only studied Tramadol Hydrochloride Extended-Release Capsules 300 mg/day. In this fixed-dose design, subjects were required to titrate to a fixed dose, even if their pain responded to a lower titration dose. " }

Dispense in a tight container. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.

Store Tramadol Hydrochloride Extended-Release Capsules securely and dispose of properly.

Storage and Disposal

Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store Tramadol Hydrochloride Extended-Release Capsules securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving Tramadol Hydrochloride Extended-Release Capsules unsecured can pose a deadly risk to others in the home [see Warnings and Precautions (5.1, 5.2), Drug Abuse and Dependence (9.2)].

Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines. If no take back programs or DEA-registered collectors are available, instruct patients to dispose of Tramadol Hydrochloride Extended-Release Capsules by following these four steps:

Inform patients that they can visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

Addiction, Abuse, and Misuse

Inform patients that the use of Tramadol Hydrochloride Extended-Release Capsules even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see Warnings and Precautions (5.1)]. Instruct patients not to share Tramadol Hydrochloride Extended-Release Capsules with others and to take steps to protect Tramadol Hydrochloride Extended-Release Capsules from theft or misuse.

Life-Threatening Respiratory Depression

Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting Tramadol Hydrochloride Extended-Release Capsules or when the dosage is increased, and that it can occur even at recommended dosages.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Warnings and Precautions (5.2), Overdosage (10)].

Accidental Ingestion

Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [see Warnings and Precautions (5.2)]. Instruct patients to take steps to store Tramadol Hydrochloride Extended-Release Capsules securely and to dispose of unused Tramadol Hydrochloride Extended-Release Capsules in accordance with the local state guidelines and/or regulations.

Interactions with Benzodiazepines and Other CNS Depressants

Inform patients and caregivers that potentially fatal additive effects may occur if Tramadol Hydrochloride Extended-Release Capsules is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider [see Warnings and Precautions (5.3), Drug Interactions (7)].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with Tramadol Hydrochloride Extended-Release Capsules. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.

Explain to patients and caregivers that naloxone's effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered [see Overdosage (10)].

If naloxone is prescribed, also advise patients and caregivers:

Ultra-Rapid Metabolism of Tramadol and Other Risk Factors for Life-Threatening Respiratory Depression in Children

Advise caregivers that Tramadol Hydrochloride Extended-Release Capsules is contraindicated in all children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Advise caregivers of children ages 12 to 18 years of age receiving Tramadol Hydrochloride Extended-Release Capsules to watch for signs of respiratory depression [see Warnings and Precautions (5.6)].

Hyperalgesia and Allodynia

Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see Warnings and Precautions (5.8), Adverse Reactions (6.2)].

Serotonin Syndrome

Inform patients that tramadol could cause a rare but potentially life-threatening condition called serotonin syndrome, particularly during concomitant use with serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications [see Warnings and Precautions (5.9), Drug Interactions (7)].

Seizures

Inform patients that Tramadol Hydrochloride Extended-Release Capsules may cause seizures with concomitant use of serotonergic agents (including SSRIs, SNRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol [see Warnings and Precautions (5.10)].

MAOI Interaction

Inform patients not to take Tramadol Hydrochloride Extended-Release Capsules while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking Tramadol Hydrochloride Extended-Release Capsules [see Drug Interactions (7)].

Important Administration Instructions

Instruct patients how to properly take Tramadol Hydrochloride Extended-Release Capsules, including the following:

Important Discontinuation Instructions

In order to avoid developing withdrawal symptoms, instruct patients not to discontinue Tramadol Hydrochloride Extended-Release Capsules without first discussing a tapering plan with the prescriber [see Dosage and Administration (2.5)].

Driving or Operating Heavy Machinery

Inform patients that Tramadol Hydrochloride Extended-Release Capsules may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication [see Warnings and Precautions (5.19)].

Constipation

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see Adverse Reactions (6), Clinical Pharmacology (12.1)].

Adrenal Insufficiency

Inform patients that Tramadol Hydrochloride Extended-Release Capsules could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [see Warnings and Precautions (5.13)].

Hypotension

Inform patients that Tramadol Hydrochloride Extended-Release Capsules may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see Warnings and Precautions (5.14)].

Anaphylaxis

Inform patients that anaphylaxis has been reported with ingredients contained in Tramadol Hydrochloride Extended-Release Capsules. Advise patients how to recognize such a reaction and when to seek medical attention [see Contraindications (4), Adverse Reactions (6)].

Pregnancy

Neonatal Opioid Withdrawal Syndrome

Inform female patients of reproductive potential that use of Tramadol Hydrochloride Extended-Release Capsules for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see Warnings and Precautions (5.5), Use in Specific Populations (8.1)].

Embryo-Fetal Toxicity

Inform female patients of reproductive potential that Tramadol Hydrochloride Extended-Release Capsules can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)].

Lactation

Advise women that breastfeeding is not recommended during treatment with Tramadol Hydrochloride Extended-Release Capsules [see Use in Specific Populations (8.2)].

Infertility

Inform patients that use of opioids for an extended period of time may cause reduced fertility. It is not known whether these effects on fertility are reversible [see Adverse Reactions (6.2), Use in Specific Populations (8.3)].

Manufactured by: Galephar P.R., Inc.Juncos, Puerto Rico 00777

{ "type": "p", "children": [], "text": "Manufactured by:\tGalephar P.R., Inc.Juncos, Puerto Rico 00777" }

Distributed by: Trigen Laboratories, LLCAlpharetta, GA 30005, USA

{ "type": "p", "children": [], "text": "Distributed by: Trigen Laboratories, LLCAlpharetta, GA 30005, USA" }

Rev. 3/2024

{ "type": "p", "children": [], "text": "Rev. 3/2024" }

<div class="scrollingtable"><table width="100%"> <col align="left" valign="top" width="30%"/> <col align="left" valign="top" width="55%"/> <col align="right" valign="top" width="15%"/> <tfoot> <tr class="First Last"> <td align="left" colspan="2" valign="top"><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></td><td align="right" valign="top">Issued: 3/2024</td> </tr> </tfoot> <tbody class="Headless"> <tr class="Botrule First"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">Medication Guide<br/>Tramadol Hydrochloride Extended-Release Capsules, CIV</span></td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">Tramadol Hydrochloride Extended-Release Capsules is:</span> <ul> <li>A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine when other pain medicines do not treat your pain well enough or you cannot tolerate them.</li> <li>A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</li> <li>Not to be taken on an "as needed" basis.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">Important information about Tramadol Hydrochloride Extended-Release Capsules:</span> <ul> <li> <span class="Bold">Get emergency help right away or call 911 right away if you take too much Tramadol Hydrochloride Extended-Release Capsules (overdose)</span>. When you first start taking Tramadol Hydrochloride Extended-Release Capsules, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.</li> <li>Taking Tramadol Hydrochloride Extended-Release Capsules with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</li> <li>Never give anyone else your Tramadol Hydrochloride Extended-Release Capsules. They could die from taking it. Selling or giving away Tramadol Hydrochloride Extended-Release Capsules is against the law.</li> <li>Store Tramadol Hydrochloride Extended-Release Capsules securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">Important Information Guiding Use in Pediatric Patients:</span> <ul> <li>Do not give Tramadol Hydrochloride Extended-Release Capsules to a child younger than 12 years of age.</li> <li>Do not give Tramadol Hydrochloride Extended-Release Capsules to a child younger than 18 years of age after surgery to remove the tonsils and/or adenoids.</li> <li>Avoid giving Tramadol Hydrochloride Extended-Release Capsules to children between 12 to 18 years of age who have risk factors for breathing problems such as obstructive sleep apnea, obesity, or underlying lung problems.</li> </ul> <span class="Bold">Do not take Tramadol Hydrochloride Extended-Release Capsules if you have:</span> <ul> <li>severe asthma, trouble breathing, or other lung problems. </li> <li>a bowel blockage or have narrowing of the stomach or intestines.</li> </ul> </td> </tr> <tr> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">Before taking Tramadol Hydrochloride Extended-Release Capsules, tell your healthcare provider if you have a history of:</span></td> </tr> <tr> <td align="left" class="Lrule"> <ul> <li>head injury, seizures</li> <li>problems urinating </li> </ul> </td><td align="left" class="Rrule" colspan="2"> <ul> <li>liver, kidney, thyroid problems </li> <li>pancreas or gallbladder problems</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="3"> <ul> <li>abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems.</li> </ul> <span class="Bold">Tell your healthcare provider if you are:</span> <ul> <li> <span class="Bold">noticing your pain getting worse.</span> If your pain gets worse after you take Tramadol Hydrochloride Extended-Release Capsules, do not take more of Tramadol Hydrochloride Extended-Release Capsules without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking Tramadol Hydrochloride Extended-Release Capsules.</li> <li> <span class="Bold">pregnant or planning to become pregnant.</span> Use of Tramadol Hydrochloride Extended-Release Capsules for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.</li> <li> <span class="Bold">breastfeeding.</span> Not recommended during treatment with Tramadol Hydrochloride Extended-Release Capsules; it may harm your baby.</li> <li>living in a household where there are small children or someone who has abused street or prescription drugs.</li> <li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking Tramadol Hydrochloride Extended-Release Capsules with certain other medicines can cause serious side effects that could lead to death.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">When taking Tramadol Hydrochloride Extended-Release Capsules:</span> <ul> <li>Do not change your dose. Take Tramadol Hydrochloride Extended-Release Capsules exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.</li> <li>Take your prescribed dose once a day at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.</li> <li>Swallow Tramadol Hydrochloride Extended-Release Capsules whole. Do not split, break, chew, crush, dissolve, snort, or inject Tramadol Hydrochloride Extended-Release Capsules because this may cause you to overdose and die.</li> <li> <span class="Bold">Call your healthcare provider if the dose you are taking does not control your pain.</span> </li> <li> <span class="Bold">Do not stop taking Tramadol Hydrochloride Extended-Release Capsules without talking to your healthcare provider.</span> </li> <li>Dispose of expired, unwanted, or unused Tramadol Hydrochloride Extended-Release Capsules by taking your drug to an authorized DEA-registered collector or drug take-back program. If one is not available, you can dispose of Tramadol Hydrochloride Extended-Release Capsules by mixing the product with dirt, cat litter, or coffee grounds; placing the mixture in a sealed plastic bag and throwing the bag in your trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</li> </ul> </td> </tr> <tr class="Botrule"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">While taking Tramadol Hydrochloride Extended-Release Capsules DO NOT:</span> <ul> <li>Drive or operate heavy machinery, until you know how Tramadol Hydrochloride Extended-Release Capsules affects you. Tramadol Hydrochloride Extended-Release Capsules can make you sleepy, dizzy, or lightheaded. </li> <li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with Tramadol Hydrochloride Extended-Release Capsules may cause you to overdose and die.</li> </ul> </td> </tr> <tr class="Last"> <td align="left" class="Lrule Rrule" colspan="3"><span class="Bold">The possible side effects of Tramadol Hydrochloride Extended-Release Capsules:</span> <ul> <li>constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain, seizure. Call your healthcare provider if you have any of these symptoms and they are severe. </li> </ul> <span class="Bold">Get emergency medical help or call 911 right away if you have:</span> <ul> <li>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</li> </ul>These are not all the possible side effects of Tramadol Hydrochloride Extended-Release Capsules. Call your healthcare provider for medical advice about side effects. You may report side effects to Trigen Laboratories, LLC at 1-877-482-3788 or FDA at 1-800-FDA-1088. <span class="Bold">For more information go to dailymed.nlm.nih.gov</span> <br/>Manufactured for: Trigen Laboratories, LLC, Alpharetta, GA 30005, USA, call 1-877-482-3788.</td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"100%\">\n<col align=\"left\" valign=\"top\" width=\"30%\"/>\n<col align=\"left\" valign=\"top\" width=\"55%\"/>\n<col align=\"right\" valign=\"top\" width=\"15%\"/>\n<tfoot>\n<tr class=\"First Last\">\n<td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></td><td align=\"right\" valign=\"top\">Issued: 3/2024</td>\n</tr>\n</tfoot>\n<tbody class=\"Headless\">\n<tr class=\"Botrule First\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">Medication Guide<br/>Tramadol Hydrochloride Extended-Release Capsules, CIV</span></td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">Tramadol Hydrochloride Extended-Release Capsules is:</span>\n<ul>\n<li>A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine when other pain medicines do not treat your pain well enough or you cannot tolerate them.</li>\n<li>A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</li>\n<li>Not to be taken on an \"as needed\" basis.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">Important information about Tramadol Hydrochloride Extended-Release Capsules:</span>\n<ul>\n<li>\n<span class=\"Bold\">Get emergency help right away or call 911 right away if you take too much Tramadol Hydrochloride Extended-Release Capsules (overdose)</span>. When you first start taking Tramadol Hydrochloride Extended-Release Capsules, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.</li>\n<li>Taking Tramadol Hydrochloride Extended-Release Capsules with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</li>\n<li>Never give anyone else your Tramadol Hydrochloride Extended-Release Capsules. They could die from taking it. Selling or giving away Tramadol Hydrochloride Extended-Release Capsules is against the law.</li>\n<li>Store Tramadol Hydrochloride Extended-Release Capsules securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">Important Information Guiding Use in Pediatric Patients:</span>\n<ul>\n<li>Do not give Tramadol Hydrochloride Extended-Release Capsules to a child younger than 12 years of age.</li>\n<li>Do not give Tramadol Hydrochloride Extended-Release Capsules to a child younger than 18 years of age after surgery to remove the tonsils and/or adenoids.</li>\n<li>Avoid giving Tramadol Hydrochloride Extended-Release Capsules to children between 12 to 18 years of age who have risk factors for breathing problems such as obstructive sleep apnea, obesity, or underlying lung problems.</li>\n</ul>\n<span class=\"Bold\">Do not take Tramadol Hydrochloride Extended-Release Capsules if you have:</span>\n<ul>\n<li>severe asthma, trouble breathing, or other lung problems. </li>\n<li>a bowel blockage or have narrowing of the stomach or intestines.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">Before taking Tramadol Hydrochloride Extended-Release Capsules, tell your healthcare provider if you have a history of:</span></td>\n</tr>\n<tr>\n<td align=\"left\" class=\"Lrule\">\n<ul>\n<li>head injury, seizures</li>\n<li>problems urinating </li>\n</ul>\n</td><td align=\"left\" class=\"Rrule\" colspan=\"2\">\n<ul>\n<li>liver, kidney, thyroid problems </li>\n<li>pancreas or gallbladder problems</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\">\n<ul>\n<li>abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems.</li>\n</ul>\n<span class=\"Bold\">Tell your healthcare provider if you are:</span>\n<ul>\n<li>\n<span class=\"Bold\">noticing your pain getting worse.</span> If your pain gets worse after you take Tramadol Hydrochloride Extended-Release Capsules, do not take more of Tramadol Hydrochloride Extended-Release Capsules without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking Tramadol Hydrochloride Extended-Release Capsules.</li>\n<li>\n<span class=\"Bold\">pregnant or planning to become pregnant.</span> Use of Tramadol Hydrochloride Extended-Release Capsules for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.</li>\n<li>\n<span class=\"Bold\">breastfeeding.</span> Not recommended during treatment with Tramadol Hydrochloride Extended-Release Capsules; it may harm your baby.</li>\n<li>living in a household where there are small children or someone who has abused street or prescription drugs.</li>\n<li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking Tramadol Hydrochloride Extended-Release Capsules with certain other medicines can cause serious side effects that could lead to death.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">When taking Tramadol Hydrochloride Extended-Release Capsules:</span>\n<ul>\n<li>Do not change your dose. Take Tramadol Hydrochloride Extended-Release Capsules exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.</li>\n<li>Take your prescribed dose once a day at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.</li>\n<li>Swallow Tramadol Hydrochloride Extended-Release Capsules whole. Do not split, break, chew, crush, dissolve, snort, or inject Tramadol Hydrochloride Extended-Release Capsules because this may cause you to overdose and die.</li>\n<li>\n<span class=\"Bold\">Call your healthcare provider if the dose you are taking does not control your pain.</span>\n</li>\n<li>\n<span class=\"Bold\">Do not stop taking Tramadol Hydrochloride Extended-Release Capsules without talking to your healthcare provider.</span>\n</li>\n<li>Dispose of expired, unwanted, or unused Tramadol Hydrochloride Extended-Release Capsules by taking your drug to an authorized DEA-registered collector or drug take-back program. If one is not available, you can dispose of Tramadol Hydrochloride Extended-Release Capsules by mixing the product with dirt, cat litter, or coffee grounds; placing the mixture in a sealed plastic bag and throwing the bag in your trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Botrule\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">While taking Tramadol Hydrochloride Extended-Release Capsules DO NOT:</span>\n<ul>\n<li>Drive or operate heavy machinery, until you know how Tramadol Hydrochloride Extended-Release Capsules affects you. Tramadol Hydrochloride Extended-Release Capsules can make you sleepy, dizzy, or lightheaded. </li>\n<li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with Tramadol Hydrochloride Extended-Release Capsules may cause you to overdose and die.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Last\">\n<td align=\"left\" class=\"Lrule Rrule\" colspan=\"3\"><span class=\"Bold\">The possible side effects of Tramadol Hydrochloride Extended-Release Capsules:</span>\n<ul>\n<li>constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain, seizure. Call your healthcare provider if you have any of these symptoms and they are severe. </li>\n</ul>\n<span class=\"Bold\">Get emergency medical help or call 911 right away if you have:</span>\n<ul>\n<li>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</li>\n</ul>These are not all the possible side effects of Tramadol Hydrochloride Extended-Release Capsules. Call your healthcare provider for medical advice about side effects. You may report side effects to Trigen Laboratories, LLC at 1-877-482-3788 or FDA at 1-800-FDA-1088. <span class=\"Bold\">For more information go to dailymed.nlm.nih.gov</span>\n<br/>Manufactured for: Trigen Laboratories, LLC, Alpharetta, GA 30005, USA, call 1-877-482-3788.</td>\n</tr>\n</tbody>\n</table></div>" }

NDC 13811-689-30

{ "type": "p", "children": [], "text": "NDC 13811-689-30" }

Tramadol Hydrochloride CIVExtended-Release Capsules

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride CIVExtended-Release Capsules" }

100 mg per capsule

{ "type": "p", "children": [], "text": "100 mg per capsule" }

Once DailyRx ONLY

{ "type": "p", "children": [], "text": "Once DailyRx ONLY" }

TRIGENLABORATORIES

{ "type": "p", "children": [], "text": "TRIGENLABORATORIES" }

30 Capsules

{ "type": "p", "children": [], "text": "30 Capsules" }

NDC 13811-690-30

{ "type": "p", "children": [], "text": "NDC 13811-690-30" }

Tramadol Hydrochloride CIVExtended-Release Capsules

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride CIVExtended-Release Capsules" }

200 mg per capsule

{ "type": "p", "children": [], "text": "200 mg per capsule" }

Once DailyRx ONLY

{ "type": "p", "children": [], "text": "Once DailyRx ONLY" }

TRIGENLABORATORIES

{ "type": "p", "children": [], "text": "TRIGENLABORATORIES" }

30 Capsules

{ "type": "p", "children": [], "text": "30 Capsules" }

NDC 13811-691-30

{ "type": "p", "children": [], "text": "NDC 13811-691-30" }

Tramadol Hydrochloride CIVExtended-Release Capsules

{ "type": "p", "children": [], "text": "Tramadol Hydrochloride CIVExtended-Release Capsules" }

300 mg per capsule

{ "type": "p", "children": [], "text": "300 mg per capsule" }

Once DailyRx ONLY

{ "type": "p", "children": [], "text": "Once DailyRx ONLY" }

TRIGENLABORATORIES

{ "type": "p", "children": [], "text": "TRIGENLABORATORIES" }

30 Capsules

{ "type": "p", "children": [], "text": "30 Capsules" }

Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate." }

Limitations of Use

{ "type": "p", "children": [], "text": "\nLimitations of Use\n" }

Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.1)], reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

{ "type": "p", "children": [], "text": "\nBecause of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.1)], reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:\n" }

{ "type": "ul", "children": [ "\nHave not been tolerated or are not expected to be tolerated.\n", "\nHave not provided adequate analgesia or are not expected to provide adequate analgesia.\n" ], "text": "" }

Tramadol hydrochloride tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.

{ "type": "p", "children": [], "text": "\nTramadol hydrochloride tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.\n" }

Do not use tramadol hydrochloride tablets concomitantly with other tramadol-containing products.

Do not administer tramadol hydrochloride tablets at a dose exceeding 400 mg per day.

Tramadol hydrochloride tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks.

Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see Warnings and Precautions (5)]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of tramadol hydrochloride tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.

Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available.

There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)].

Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with tramadol hydrochloride tablets. Consider this risk when selecting an initial dose and when making dose adjustments [see Warnings and Precautions (5)].

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with tramadol hydrochloride tablets [see Warnings and Precautions (5.2), Patient Counseling Information (17)].

Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).

Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. However, the presence of risk factors for overdose should not prevent the proper management of pain in any given patient [see Warnings and Precautions (5.1, 5.2, 5.3)].

Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental exposure or overdose.

Initiating Treatment with Tramadol Hydrochloride Tablets

Initiate treatment at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of tramadol hydrochloride tablets.

For patients not requiring rapid onset of analgesic effect, the tolerability of tramadol hydrochloride tablets can be improved by initiating therapy with the following titration regimen: Start tramadol hydrochloride tablets at 25 mg/day and titrated in 25 mg increments as separate doses every 3 days to reach 100 mg/day (25 mg four times a day). Thereafter the total daily dose may be increased by 50 mg as tolerated every 3 days to reach 200 mg/day (50 mg four times a day). After titration, tramadol hydrochloride tablets 50 mg to 100 mg can be administered as needed for pain relief every 4 to 6 hours not to exceed 400 mg/day.

For the subset of patients for whom rapid onset of analgesic effect is required and for whom the benefits outweigh the risk of discontinuation due to adverse events associated with higher initial doses, tramadol hydrochloride tablets 50 mg to 100 mg can be administered as needed for pain relief every four to six hours, not to exceed 400 mg per day.

Conversion from Tramadol Hydrochloride to Extended-Release Tramadol

The relative bioavailability of tramadol hydrochloride compared to extended-release tramadol is unknown, so conversion to extended-release formulations may lead to increased risk of excessive sedation and respiratory depression.

Dosage Modification in Patients with Hepatic Impairment

The recommended dose for adult patients with severe hepatic impairment is 50 mg every 12 hours.

Dosage Modification in Patients with Renal Impairment

In all patients with creatinine clearance less than 30 mL/min, it is recommended that the dosing interval of tramadol hydrochloride tablets be increased to 12 hours, with a maximum daily dose of 200 mg. Since only 7% of an administered dose is removed by hemodialysis, dialysis patients can receive their regular dose on the day of dialysis.

Dosage Modification in Geriatric Patients

Do not exceed a total dose of 300 mg/day in patients over 75 years old.

Individually titrate tramadol hydrochloride tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving tramadol hydrochloride tablets to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1, 5.18)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the tramadol hydrochloride tablets dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Do not abruptly discontinue tramadol hydrochloride tablets in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.

When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.

There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on tramadol hydrochloride tablets who are physically opioid-dependent, initiate the taper by a small enough increment, (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.

It may be necessary to provide the patient with a lower dosage strength to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.

When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see Warnings and Precautions (5.18), Drug Abuse and Dependence (9.3)].

Tramadol hydrochloride tablets USP, 50 mg (equivalent to 43.9 mg of tramadol) are white, film-coated, oval-shaped tablets, scored on both sides. Debossed with “T” on the left side and “V” on the right side of the score line on one side of tablet. Debossed with “7” on the left side and “T” on the right side of the score line on the other side of tablet.

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets USP, 50 mg (equivalent to 43.9 mg of tramadol) are white, film-coated, oval-shaped tablets, scored on both sides. Debossed with “T” on the left side and “V” on the right side of the score line on one side of tablet. Debossed with “7” on the left side and “T” on the right side of the score line on the other side of tablet." }

Tramadol hydrochloride tablets are contraindicated for:

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets are contraindicated for:" }

{ "type": "ul", "children": [ "all children younger than 12 years of age [see Warnings and Precautions (5.6)].", "postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Warnings and Precautions (5.6)]." ], "text": "" }

Tramadol hydrochloride tablets are also contraindicated in patients with:

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets are also contraindicated in patients with:" }

{ "type": "ul", "children": [ "Significant respiratory depression [see Warnings and Precautions (5.2)].", "Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.12)].", "Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.16)].", "Hypersensitivity to tramadol, any other component of this product or opioids [see Warnings and Precautions (5.17)].", "Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days [see Drug Interactions (7)]." ], "text": "" }

Tramadol hydrochloride tablets contain tramadol, a Schedule IV controlled substance. As an opioid, tramadol hydrochloride tablets expose users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed tramadol hydrochloride tablets. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing tramadol hydrochloride tablets, and reassess all patients receiving tramadol hydrochloride tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as tramadol hydrochloride tablets, but use in such patients necessitates intensive counseling about the risks and proper use of tramadol hydrochloride tablets along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing tramadol hydrochloride tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status [see Overdosage (10)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of tramadol hydrochloride tablets, the risk is greatest during the initiation of therapy or following a dosage increase.

To reduce the risk of respiratory depression, proper dosing and titration of tramadol hydrochloride tablets are essential [see Dosage and Administration (2)]. Overestimating the tramadol hydrochloride tablets dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.

Accidental ingestion of even one dose of tramadol hydrochloride tablets, especially by children, can result in respiratory depression and death due to an overdose of tramadol.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Patient Counseling Information (17)].

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.5)].

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with tramadol. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered [see Patient Counseling Information (17)].

Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. However, the presence of risk factors for overdose should not prevent the proper management of pain in any given patient. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental exposure or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone [see Warnings and Precautions (5.1, 5.3), Overdosage (10), Patient Counseling Information (17)].

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of tramadol hydrochloride tablets with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions (7)].

If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation).

If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Advise both patients and caregivers about the risks of respiratory depression and sedation when tramadol hydrochloride tablets are used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions (7); and Patient Counseling Information (17)].

Use of tramadol hydrochloride tablets for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations (8.1) and Patient Counseling Information (17)].

To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following:

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com. FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint.

Life-threatening respiratory depression and death have occurred in children who received tramadol. Tramadol and codeine are subject to variability in metabolism based upon CYP2D6 genotype (described below), which can lead to increased exposure to an active metabolite. Based upon postmarketing reports with tramadol or with codeine, children younger than 12 years of age may be more susceptible to the respiratory depressant effects of tramadol. Furthermore, children with obstructive sleep apnea who are treated with opioids for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to their respiratory depressant effect. Because of the risk of life-threatening respiratory depression and death:

Nursing Mothers

Tramadol is subject to the same polymorphic metabolism as codeine, with ultra-rapid metabolizers of CYP2D6 substrates being potentially exposed to life-threatening levels of the active metabolite O-desmethyltramadol (M1). At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. A baby nursing from an ultra-rapid metabolizer mother taking tramadol hydrochloride tablets could potentially be exposed to high levels of M1, and experience life-threatening respiratory depression. For this reason, breastfeeding is not recommended during treatment with tramadol hydrochloride tablets [see Use in Specific Populations (8.2)].

CYP2D6 Genetic Variability: Ultra-rapid Metabolizer

Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (e.g., gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 1 to 10% for Whites (European, North American), 3 to 4% for Blacks (African Americans), 1 to 2% for East Asians (Chinese, Japanese, Korean), and may be greater than 10% in certain racial/ethnic groups (i.e., Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican). These individuals convert tramadol into its active metabolite, O-desmethyltramadol (M1), more rapidly and completely than other people. This rapid conversion results in higher than expected serum M1 levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) [see Overdosage (10)]. Therefore, individuals who are ultra-rapid metabolizers should not use tramadol hydrochloride tablets.

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors on levels of tramadol and M1 from tramadol hydrochloride tablets are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol hydrochloride tablets requires careful consideration of the effects on the parent drug, tramadol which is a weak serotonin and norepinephrine reuptake inhibitor and µ-opioid agonist, and the active metabolite, M1, which is more potent than tramadol in µ-opioid receptor binding [see Drug Interactions (7)].

Risks of Concomitant Use or Discontinuation of Cytochrome P450 2D6 Inhibitors

The concomitant use of tramadol hydrochloride tablets with all cytochrome P450 2D6 inhibitors (e.g., amiodarone, quinidine) may result in an increase in tramadol plasma levels and a decrease in the levels of the active metabolite, M1. A decrease in M1 exposure in patients who have developed physical dependence to tramadol, may result in signs and symptoms of opioid withdrawal and reduced efficacy. The effect of increased tramadol levels may be an increased risk for serious adverse events including seizures and serotonin syndrome.

Discontinuation of a concomitantly used cytochrome P450 2D6 inhibitor may result in a decrease in tramadol plasma levels and an increase in active metabolite M1 levels, which could increase or prolong adverse reactions related to opioid toxicity and may cause potentially fatal respiratory depression.

Evaluate patients receiving tramadol hydrochloride tablets and any CYP2D6 inhibitor at frequent intervals for the risk of serious adverse events including seizures and serotonin syndrome, signs and symptoms that may reflect opioid toxicity, and opioid withdrawal when tramadol hydrochloride tablets are used in conjunction with inhibitors of CYP2D6 [see Drug Interactions (7)].

Cytochrome P450 3A4 Interaction

The concomitant use of tramadol hydrochloride tablets with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations, which could increase or prolong adverse reactions, increase the risk for serious adverse events including seizures and serotonin syndrome, and may cause potentially fatal respiratory depression.

The concomitant use of tramadol hydrochloride tablets with all cytochrome P450 3A4 inducers or discontinuation of a cytochrome P450 3A4 inhibitor may result in lower tramadol levels. This may be associated with a decrease in efficacy, and in some patients, may result in signs and symptoms of opioid withdrawal.

Evaluate patients receiving tramadol hydrochloride tablets and any CYP3A4 inhibitor or inducer at frequent intervals for the risk for serious adverse events including seizures and serotonin syndrome, signs and symptoms that may reflect opioid toxicity and opioid withdrawal when tramadol hydrochloride tablets are used in conjunction with inhibitors and inducers of CYP3A4 [see Drug Interactions (7)].

Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see Dependence (9.3)]. Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.

Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see Dosage and Administration (2.5); Warnings and Precautions (5.18)].

Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, particularly during concomitant use with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including MAO inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions (7)]. This may occur within the recommended dosage range.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms generally occurs within several hours to a few days of concomitant use, but may occur later than that. Discontinue tramadol hydrochloride tablets if serotonin syndrome is suspected.

Seizures have been reported in patients receiving tramadol hydrochloride tablets within the recommended dosage range. Spontaneous postmarketing reports indicate that seizure risk is increased with doses of tramadol hydrochloride tablets above the recommended range.

Concomitant use of tramadol hydrochloride tablets increases the seizure risk in patients taking [see Drug Interactions (7)]:

Risk of seizure may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections). In tramadol hydrochloride tablets overdose, naloxone administration may increase the risk of seizure.

The use of tramadol hydrochloride tablets in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients with Chronic Pulmonary Disease

Tramadol hydrochloride tablet-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of tramadol hydrochloride tablets [see Warnings and Precautions (5.2)].

Elderly, Cachectic, or Debilitated Patients

Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see Warnings and Precautions (5.2)].

Regularly evaluate such patients closely, particularly when initiating and titrating tramadol and when tramadol hydrochloride tablets are given concomitantly with other drugs that depress respiration [see Warnings and Precautions (5.3); Drug Interactions (7)]. Alternatively, consider the use of non-opioid analgesics in these patients.

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Tramadol hydrochloride tablets may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [see Drug Interactions (7)]. Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of tramadol hydrochloride tablets. In patients with circulatory shock, tramadol hydrochloride tablets may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of tramadol hydrochloride tablets in patients with circulatory shock.

In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), tramadol hydrochloride tablets may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with tramadol hydrochloride tablets.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of tramadol hydrochloride tablets in patients with impaired consciousness or coma.

Tramadol hydrochloride tablets are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus [see Contraindications (4)].

The tramadol in tramadol hydrochloride tablets may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis for worsening symptoms.

Serious and rarely fatal anaphylactic reactions have been reported in patients receiving therapy with tramadol hydrochloride tablets. When these events do occur it is often following the first dose. Other reported allergic reactions include pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis and Stevens-Johnson syndrome. Patients with a history of hypersensitivity reactions to tramadol and other opioids may be at increased risk and therefore should not receive tramadol hydrochloride tablets [see Contraindications (4)]. If anaphylaxis or other hypersensitivity occurs, stop administration of tramadol hydrochloride tablets immediately, discontinue tramadol hydrochloride tablets permanently, and do not rechallenge with any formulation of tramadol. Advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction [see Contraindications (4); Patient Counseling Information (17)].

Do not abruptly discontinue tramadol hydrochloride tablets in a patient physically dependent on opioids. When discontinuing tramadol hydrochloride tablets in a physically dependent patient, gradually taper the dosage. Rapid tapering of tramadol in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see Dosage and Administration (2.5), Drug Abuse and Dependence (9.3)].

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including tramadol hydrochloride tablets. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms [see Drug Interactions (7)].

Tramadol hydrochloride tablets may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of tramadol hydrochloride tablets and know how they will react to the medication [see Patient Counseling Information (17)].

Hyponatremia (serum sodium < 135 mmol/L) has been reported with the use of tramadol, and many cases are severe (sodium level < 120 mmol/L). Most cases of hyponatremia occurred in females over the age of 65 and within the first week of therapy. In some reports, hyponatremia resulted from the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Regularly evaluate patients for signs and symptoms of hyponatremia (e.g., confusion, disorientation), during treatment with tramadol hydrochloride tablets, especially during initiation of therapy. If signs and symptoms of hyponatremia are present, initiate appropriate treatment (e.g., fluid restriction) and discontinue tramadol hydrochloride tablets [see Dosage and Administration: Safe Reduction or Discontinuation of Tramadol Hydrochloride Tablets (2.5)].

Cases of tramadol-associated hypoglycemia have been reported, some resulting in hospitalization. In most cases, patients had predisposing risk factors (e.g. diabetes). If hypoglycemia is suspected, monitor blood glucose levels and consider drug discontinuation as appropriate [see Dosage and Administration: Safe Reduction or Discontinuation of Tramadol Hydrochloride Tablets (2.5)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tramadol hydrochloride tablets were administered to 550 patients during the double-blind or open-label extension periods in U.S. studies of chronic nonmalignant pain. Of these patients, 375 were 65 years old or older. Table 1 reports the cumulative incidence rate of adverse reactions by 7, 30 and 90 days for the most frequent reactions (5% or more by 7 days). The most frequently reported events were in the central nervous system and gastrointestinal system. Although the reactions listed in the table are felt to be probably related to tramadol hydrochloride tablets administration, the reported rates also include some events that may have been due to underlying disease or concomitant medication. The overall incidence rates of adverse experiences in these trials were similar for tramadol hydrochloride tablets and the active control groups, TYLENOL® with Codeine #3 (acetaminophen 300 mg with codeine phosphate 30 mg), and aspirin 325 mg with codeine phosphate 30 mg, however, the rates of withdrawals due to adverse events appeared to be higher in the tramadol hydrochloride tablets groups.

<div class="scrollingtable"><table border="1" cellpadding="5" cellspacing="0"> <col width="119.7pt"/> <col/> <col/> <col/> <tbody class="Headless"> <tr class="First"> <td colspan="4"><span class="Bold">Table 1:  Cumulative Incidence of Adverse Reactions for Tramadol Hydrochloride Tablets in Chronic Trials of Nonmalignant Pain (N=427)</span></td> </tr> <tr> <td class="Toprule"></td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Up to 7 Days</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Up to 30 Days</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Up to 90 Days</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Dizziness/Vertigo</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">26%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">31%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">33%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Nausea</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">24%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">34%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">40%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Constipation</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">24%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">38%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">46%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Headache</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">18%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">26%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">32%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Somnolence</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">16%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">23%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">25%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Vomiting</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">9%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">13%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">17%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Pruritus</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">8%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">10%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">11%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">“CNS Stimulation”<span class="Sup">1</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">7%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">11%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">14%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Asthenia</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">6%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">11%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">12%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Sweating</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">6%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">7%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">9%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Dyspepsia</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">5%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">9%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">13%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Dry Mouth</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">5%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">9%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">10%</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Diarrhea</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">5%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">6%</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">10%</p> </td> </tr> <tr class="Last"> <td colspan="4"> <span class="Sup">1 </span>“CNS Stimulation” is a composite of nervousness, anxiety, agitation, tremor, spasticity, euphoria, emotional lability and hallucinations</td> </tr> </tbody> </table></div>

Incidence 1% to Less than 5% Possibly Causally Related

The following lists adverse reactions that occurred with an incidence of 1% to less than 5% in clinical trials, and for which the possibility of a causal relationship with tramadol hydrochloride tablets exists.

Body as a Whole: Malaise.

Cardiovascular: Vasodilation.

Central Nervous System:  Anxiety, Confusion, Coordination disturbance, Euphoria, Miosis, Nervousness, Sleep disorder.

Gastrointestinal: Abdominal pain, Anorexia, Flatulence.

Musculoskeletal: Hypertonia.

Skin: Rash.

Special Senses: Visual disturbance.

Urogenital: Menopausal symptoms, Urinary frequency, Urinary retention.

Incidence Less than 1%, Possibly Causally Related

The following lists adverse reactions that occurred with an incidence of less than 1% in clinical trials of tramadol and/or reported in postmarketing experience with tramadol-containing products.

Body as a Whole: Accidental injury, Allergic reaction, Anaphylaxis, Death, Suicidal tendency, Weight loss, Serotonin syndrome (mental status change, hyperreflexia, fever, shivering, tremor, agitation, diaphoresis, seizures and coma).

Cardiovascular: Orthostatic hypotension, Syncope, Tachycardia.

Central Nervous System: Abnormal gait, Amnesia, Cognitive dysfunction, Depression, Difficulty in concentration, Hallucinations, Paresthesia, Seizure, Tremor.

Respiratory: Dyspnea.

Skin: Stevens-Johnson syndrome/Toxic epidermal necrolysis, Urticaria, Vesicles.

Special Senses: Dysgeusia.

Urogenital: Dysuria, Menstrual disorder.

Other Adverse Experiences, Causal Relationship Unknown

A variety of other adverse events were reported infrequently in patients taking tramadol hydrochloride tablets during clinical trials and/or reported in postmarketing experience. A causal relationship between tramadol hydrochloride tablets and these events has not been determined. However, the most significant events are listed below as alerting information to the physician.

Cardiovascular: Abnormal ECG, Hypertension, Hypotension, Myocardial ischemia, Palpitations, Pulmonary edema, Pulmonary embolism.

Central Nervous System: Migraine.

Gastrointestinal: Gastrointestinal bleeding, Hepatitis, Stomatitis, Liver failure.

Laboratory Abnormalities: Creatinine increase, Elevated liver enzymes, Hemoglobin decrease, Proteinuria.

Sensory: Cataracts, Deafness, Tinnitus.

The following adverse reactions have been identified during post-approval use of tramadol hydrochloride tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.

Androgen deficiency: Cases of androgen deficiency have occurred with use of opioids for an extended period of time [see Clinical Pharmacology (12.2)].

Hyperalgesia and Allodynia: Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see Warnings and Precautions (5.8)].

QT prolongation/torsade de pointes: Cases of QT prolongation and/or torsade de pointes have been reported with tramadol use. Many of these cases were reported in patients taking another drug labeled for QT prolongation, in patients with a risk factor for QT prolongation (e.g., hypokalemia), or in the overdose setting.

Eye disorders – mydriasis

Metabolism and nutrition disorders – Hyponatremia: Cases of severe hyponatremia and/or SIADH have been reported in patients taking tramadol, most often in females over the age of 65, and within the first week of therapy [see Warnings and Precautions (5.20)].

Hypoglycemia: Cases of hypoglycemia have been reported in patients taking tramadol. Most reports were in patients with predisposing risk factors, including diabetes or renal insufficiency, or in elderly patients [see Warnings and Precautions (5.21)].

Nervous system disorders – movement disorder, speech disorder

Psychiatric disorders – delirium

<div class="scrollingtable"><table border="1" cellpadding="0" cellspacing="0"> <col width="473.4pt"/> <col/> <tbody class="Headless"> <tr class="First"> <td colspan="2"><span class="Bold">Table 2:  Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets</span></td> </tr> <tr> <td class="Toprule" colspan="2"> <p class="First"> <span class="Bold">Inhibitors of CYP2D6</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent µ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome. After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase. This could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, such as potentially fatal respiratory depression <span class="Italics">[see Clinical Pharmacology (<a href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</a>)]</span>.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures and serotonin syndrome. If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride tablets dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Quinidine, fluoxetine, paroxetine and bupropion</p> </td> </tr> <tr> <td colspan="2"> <p class="First"> <span class="Bold">Inhibitors of CYP3A4</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">The concomitant use of tramadol hydrochloride tablets and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved.</p> <p>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <span class="Italics">[see Clinical Pharmacology (<span class="Italics"><a href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</a></span>)]</span>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to tramadol.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">If concomitant use is necessary, consider dosage reduction of tramadol hydrochloride tablets until stable drug effects are achieved. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of seizures, serotonin syndrome, and signs of respiratory depression and sedation.</p> <p> If a CYP3A4 inhibitor is discontinued, consider increasing the tramadol hydrochloride tablets dosage until stable drug effects are achieved and evaluate patients at frequent intervals for signs and symptoms of opioid withdrawal.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">CYP3A4 Inducers</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">The concomitant use of tramadol hydrochloride tablets and CYP3A4 inducers can decrease the plasma concentration of tramadol <span class="Italics">[see Clinical Pharmacology (<span class="Italics"><a href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</a></span>)]</span>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol.</p> <p>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <span class="Italics">[see Clinical Pharmacology (<span class="Italics"><a href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</a></span>)]</span>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures, serotonin syndrome, and/or potentially fatal respiratory depression.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">If concomitant use is necessary, consider increasing the tramadol hydrochloride tablets dosage until stable drug effects are achieved. Evaluate patients for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider tramadol hydrochloride tablets dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation.</p> <p> Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of tramadol hydrochloride tablets and carbamazepine is not recommended.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Rifampin, carbamazepine, phenytoin</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation) <span class="Italics">[see Warnings and Precautions (<a href="#www.splportal.comLINK_38231343-9df3-4a64-8f5e-0c3f3f811874">5.7</a>)]</span>. If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <span class="Italics">[see Dosage and Administration (<a href="#www.splportal.comLINK_1b235d49-d955-4673-b0e0-98823ff1d50e">2.2</a>), Warnings and Precautions (<a href="#www.splportal.comLINK_16e13ce0-062f-429b-85e2-3f4fca65d33e">5.1</a>, <a href="#www.splportal.comLINK_8a037e6f-9eff-44e5-b817-a36982010968">5.2</a>, <a href="#www.splportal.comLINK_543c7959-1995-4988-9046-cf9b350fc0ae">5.3</a>)]</span>.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, and alcohol.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Serotonergic Drugs</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride tablets immediately if serotonin syndrome is suspected.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Monoamine Oxidase Inhibitors (MAOIs)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">MAOI interactions with opioids may manifest as serotonin syndrome <span class="Italics">[see Warnings and Precautions (<a href="#www.splportal.comLINK_40d339bd-de15-4ccf-8ec1-e4ac8d301a6d">5.9</a>)] </span>or opioid toxicity (e.g., respiratory depression, coma) <span class="Italics">[see Warnings and Precautions (<a href="#www.splportal.comLINK_acd4b56e-d3a4-40e5-93f3-d651d8b8f4d6">5.2</a>)]</span>.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Do not use tramadol hydrochloride tablets in patients taking MAOIs or within 14 days of stopping such treatment.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">phenelzine, tranylcypromine, linezolid</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">May reduce the analgesic effect of tramadol hydrochloride tablets and/or precipitate withdrawal symptoms.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Avoid concomitant use.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Examples:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">butorphanol, nalbuphine, pentazocine, buprenorphine</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Muscle Relaxants</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Because respiratory depression may be greater than otherwise expected, decrease the dosage of tramadol hydrochloride tablets and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <span class="Italics">[see Dosage and Administration (<a href="#www.splportal.comLINK_43853947-7fdd-426e-93b2-4ae0f10c6cd7">2.2</a>), Warnings and Precautions (<a href="#www.splportal.comLINK_8a037e6f-9eff-44e5-b817-a36982010968">5.2</a>, <a href="#www.splportal.comLINK_543c7959-1995-4988-9046-cf9b350fc0ae">5.3</a>)]</span>.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Diuretics</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Anticholinergic Drugs</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Evaluate patients for signs of urinary retention or reduced gastric motility when tramadol hydrochloride tablets are used concomitantly with anticholinergic drugs.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Digoxin</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Postmarketing surveillance of tramadol has revealed rare reports of digoxin toxicity.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Evaluate patients for signs of digoxin toxicity and adjust dosage of digoxin as needed.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">Warfarin</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Clinical Impact:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Postmarketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Italics">Intervention:</span> </p> </td><td class="Botrule Lrule Rrule Toprule"> <p class="First">Frequently reevaluate the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.</p> </td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\">\n<col width=\"473.4pt\"/>\n<col/>\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td colspan=\"2\"><span class=\"Bold\">Table 2:  Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets</span></td>\n</tr>\n<tr>\n<td class=\"Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Inhibitors of CYP2D6</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent µ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome. After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase. This could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, such as potentially fatal respiratory depression <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455\">12.3</a>)]</span>.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">If concomitant use of a CYP2D6 inhibitor is necessary, evaluate patients at frequent intervals for adverse reactions including opioid withdrawal, seizures and serotonin syndrome. If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride tablets dosage until stable drug effects are achieved. Evaluate patients at frequent intervals for adverse events including respiratory depression and sedation.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Quinidine, fluoxetine, paroxetine and bupropion</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Inhibitors of CYP3A4</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">The concomitant use of tramadol hydrochloride tablets and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved.</p>\n<p>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <span class=\"Italics\">[see Clinical Pharmacology (<span class=\"Italics\"><a href=\"#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455\">12.3</a></span>)]</span>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to tramadol.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">If concomitant use is necessary, consider dosage reduction of tramadol hydrochloride tablets until stable drug effects are achieved. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of seizures, serotonin syndrome, and signs of respiratory depression and sedation.</p>\n<p> If a CYP3A4 inhibitor is discontinued, consider increasing the tramadol hydrochloride tablets dosage until stable drug effects are achieved and evaluate patients at frequent intervals for signs and symptoms of opioid withdrawal.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">CYP3A4 Inducers</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">The concomitant use of tramadol hydrochloride tablets and CYP3A4 inducers can decrease the plasma concentration of tramadol <span class=\"Italics\">[see Clinical Pharmacology (<span class=\"Italics\"><a href=\"#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455\">12.3</a></span>)]</span>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol.</p>\n<p>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <span class=\"Italics\">[see Clinical Pharmacology (<span class=\"Italics\"><a href=\"#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455\">12.3</a></span>)]</span>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures, serotonin syndrome, and/or potentially fatal respiratory depression.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">If concomitant use is necessary, consider increasing the tramadol hydrochloride tablets dosage until stable drug effects are achieved. Evaluate patients for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider tramadol hydrochloride tablets dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation.</p>\n<p> Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of tramadol hydrochloride tablets and carbamazepine is not recommended.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Rifampin, carbamazepine, phenytoin</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Benzodiazepines and Other Central Nervous System (CNS) Depressants</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation) <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#www.splportal.comLINK_38231343-9df3-4a64-8f5e-0c3f3f811874\">5.7</a>)]</span>. If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <span class=\"Italics\">[see Dosage and Administration (<a href=\"#www.splportal.comLINK_1b235d49-d955-4673-b0e0-98823ff1d50e\">2.2</a>), Warnings and Precautions (<a href=\"#www.splportal.comLINK_16e13ce0-062f-429b-85e2-3f4fca65d33e\">5.1</a>, <a href=\"#www.splportal.comLINK_8a037e6f-9eff-44e5-b817-a36982010968\">5.2</a>, <a href=\"#www.splportal.comLINK_543c7959-1995-4988-9046-cf9b350fc0ae\">5.3</a>)]</span>.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, and alcohol.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Serotonergic Drugs</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride tablets immediately if serotonin syndrome is suspected.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Monoamine Oxidase Inhibitors (MAOIs)</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">MAOI interactions with opioids may manifest as serotonin syndrome <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#www.splportal.comLINK_40d339bd-de15-4ccf-8ec1-e4ac8d301a6d\">5.9</a>)] </span>or opioid toxicity (e.g., respiratory depression, coma) <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#www.splportal.comLINK_acd4b56e-d3a4-40e5-93f3-d651d8b8f4d6\">5.2</a>)]</span>.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Do not use tramadol hydrochloride tablets in patients taking MAOIs or within 14 days of stopping such treatment.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">phenelzine, tranylcypromine, linezolid</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">May reduce the analgesic effect of tramadol hydrochloride tablets and/or precipitate withdrawal symptoms.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Avoid concomitant use.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Examples:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">butorphanol, nalbuphine, pentazocine, buprenorphine</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Muscle Relaxants</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Because respiratory depression may be greater than otherwise expected, decrease the dosage of tramadol hydrochloride tablets and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <span class=\"Italics\">[see Dosage and Administration (<a href=\"#www.splportal.comLINK_43853947-7fdd-426e-93b2-4ae0f10c6cd7\">2.2</a>), Warnings and Precautions (<a href=\"#www.splportal.comLINK_8a037e6f-9eff-44e5-b817-a36982010968\">5.2</a>, <a href=\"#www.splportal.comLINK_543c7959-1995-4988-9046-cf9b350fc0ae\">5.3</a>)]</span>.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Diuretics</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Anticholinergic Drugs</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Evaluate patients for signs of urinary retention or reduced gastric motility when tramadol hydrochloride tablets are used concomitantly with anticholinergic drugs.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Digoxin</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Postmarketing surveillance of tramadol has revealed rare reports of digoxin toxicity.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Evaluate patients for signs of digoxin toxicity and adjust dosage of digoxin as needed.</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\" colspan=\"2\">\n<p class=\"First\">\n<span class=\"Bold\">Warfarin</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Clinical Impact:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Postmarketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.</p>\n</td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Italics\">Intervention:</span>\n</p>\n</td><td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">Frequently reevaluate the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.</p>\n</td>\n</tr>\n</tbody>\n</table></div>" }

Risk Summary

Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.4)]. Available data with tramadol hydrochloride tablets in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.

In animal reproduction studies, tramadol administration during organogenesis decreased fetal weights and reduced ossification in mice, rats, and rabbits at 1.4, 0.6, and 3.6 times the maximum recommended human daily dosage (MRHD). Tramadol decreased pup body weight and increased pup mortality at 1.2 and 1.9 times the MRHD [see Data]. Based on animal data, advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in respiratory depression and physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

Neonatal opioid withdrawal syndrome can present as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms and signs of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings and Precautions (5.4)].

Neonatal seizures, neonatal withdrawal syndrome, fetal death and still birth have been reported during postmarketing.

Labor or Delivery

Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Tramadol hydrochloride tablets are not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including tramadol hydrochloride tablets, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.

Tramadol has been shown to cross the placenta. The mean ratio of serum tramadol in the umbilical veins compared to maternal veins was 0.83 for 40 women given tramadol during labor.

The effect of tramadol hydrochloride tablets, if any, on the later growth, development, and functional maturation of the child is unknown.

Data

Animal Data

Tramadol has been shown to be embryotoxic and fetotoxic in mice, (120 mg/kg), rats (25 mg/kg) and rabbits (75 mg/kg) at maternally toxic dosages, but was not teratogenic at these dose levels. These doses on a mg/m2 basis are 1.4, 0.6, and 3.6 times the maximum recommended human daily dosage (MRHD) for mouse, rat and rabbit, respectively.

No drug-related teratogenic effects were observed in progeny of mice (up to 140 mg/kg), rats (up to 80 mg/kg) or rabbits (up to 300 mg/kg) treated with tramadol by various routes. Embryo and fetal toxicity consisted primarily of decreased fetal weights, decreased skeletal ossification and increased supernumerary ribs at maternally toxic dose levels. Transient delays in developmental or behavioral parameters were also seen in pups from rat dams allowed to deliver. Embryo and fetal lethality were reported only in one rabbit study at 300 mg/kg, a dose that would cause extreme maternal toxicity in the rabbit. The dosages listed for mouse, rat and rabbit are 1.7, 1.9 and 14.6 times the MRHD, respectively.

Tramadol was evaluated in pre- and post-natal studies in rats. Progeny of dams receiving oral (gavage) dose levels of 50 mg/kg (1.2 times the MRHD) or greater had decreased weights, and pup survival was decreased early in lactation at 80 mg/kg (1.9 times the MRHD).

Risk Summary

Tramadol hydrochloride tablets are not recommended for obstetrical preoperative medication or for post-delivery analgesia in nursing mothers because its safety in infants and newborns has not been studied.

Tramadol and its metabolite, O-desmethyltramadol (M1), are present in human milk. There is no information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The M1 metabolite is more potent than tramadol in mu opioid receptor binding [see Clinical Pharmacology (12)]. Published studies have reported tramadol and M1 in colostrum with administration of tramadol to nursing mothers in the early post-partum period. Women who are ultra-rapid metabolizers of tramadol may have higher than expected serum levels of M1, potentially leading to higher levels of M1 in breast milk that can be dangerous in their breastfed infants. In women with normal tramadol metabolism, the amount of tramadol secreted into human milk is low and dose-dependent. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with tramadol hydrochloride tablets [see Warnings and Precautions (5.6)].

Clinical Considerations

If infants are exposed to tramadol hydrochloride through breast milk, they should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.

Data

Following a single IV 100 mg dose of tramadol, the cumulative excretion in breast milk within 16 hours post dose was 100 mcg of tramadol (0.1% of the maternal dose) and 27 mcg of M1.

Infertility

Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Adverse Reactions (6.2)].

The safety and effectiveness of tramadol hydrochloride tablets in pediatric patients have not been established.

Life-threatening respiratory depression and death have occurred in children who received tramadol [see Warnings and Precautions (5.6)]. In some of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and one of the children had evidence of being an ultra-rapid metabolizer of tramadol (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of tramadol. Because of the risk of life-threatening respiratory depression and death:

Avoid the use of tramadol hydrochloride tablets in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of tramadol unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression.

A total of 455 elderly (65 years of age or older) subjects were exposed to tramadol hydrochloride tablets in controlled clinical trials. Of those, 145 subjects were 75 years of age and older.

In studies including geriatric patients, treatment-limiting adverse events were higher in subjects over 75 years of age compared to those under 65 years of age. Specifically, 30% of those over 75 years of age had gastrointestinal treatment-limiting adverse events compared to 17% of those under 65 years of age. Constipation resulted in discontinuation of treatment in 10% of those over 75.

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of tramadol hydrochloride tablets slowly in geriatric patients starting at the low end of the dosing range and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.12)].

Tramadol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.

Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, dosing reduction is recommended [see Dosage and Administration (2.3)]. Metabolism of tramadol and M1 is reduced in patients with severe hepatic impairment based on a study in patients with advanced cirrhosis of the liver. In patients with severe hepatic impairment, dosing reduction is recommended [see Dosage and Administration (2.3)].

With the prolonged half-life in these conditions, achievement of steady-state is delayed, so that it may take several days for elevated plasma concentrations to develop.

Tramadol hydrochloride tablets contain tramadol, a Schedule IV controlled substance.

Tramadol hydrochloride tablets contain tramadol, a substance with potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see Warnings and Precautions (5.1)].

Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of tramadol hydrochloride tablets increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of tramadol hydrochloride tablets with alcohol and other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.

All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of tramadol hydrochloride tablets abuse include those with a history of prolonged use of any opioid, including products containing tramadol, those with a history of drug or alcohol abuse, or those who use tramadol hydrochloride tablets in combination with other abused drugs.

“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control.

Tramadol hydrochloride tablets, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of Tramadol Hydrochloride Tablets

Abuse of tramadol hydrochloride tablets poses a risk of overdose and death. The risk is increased with concurrent use of tramadol hydrochloride tablets with alcohol and/or other CNS depressants.

Tramadol hydrochloride tablets are approved for oral use only. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue tramadol hydrochloride tablets in a patient physically dependent on opioids. Rapid tapering of tramadol hydrochloride tablets in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing tramadol hydrochloride tablets, gradually taper the dosage using a patient-specific plan that considers the following: the dose of tramadol hydrochloride tablets the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage and Administration (2.5), Warnings and Precautions (5.18)].

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1)].

Clinical Presentation

{ "type": "p", "children": [], "text": "\nClinical Presentation\n" }

Acute overdosage with tramadol hydrochloride tablets can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, QT prolongation, hypotension, partial or complete airway obstruction, atypical snoring, seizures, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

{ "type": "p", "children": [], "text": "Acute overdosage with tramadol hydrochloride tablets can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, QT prolongation, hypotension, partial or complete airway obstruction, atypical snoring, seizures, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations." }

Deaths due to overdose have been reported with abuse and misuse of tramadol [see Warnings and Precautions (5.1); Drug Abuse and Dependence (9.2)]. Review of case reports has indicated that the risk of fatal overdose is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids.

{ "type": "p", "children": [], "text": "Deaths due to overdose have been reported with abuse and misuse of tramadol [see Warnings and Precautions (5.1); Drug Abuse and Dependence (9.2)]. Review of case reports has indicated that the risk of fatal overdose is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids." }

Treatment of Overdose

{ "type": "p", "children": [], "text": "\nTreatment of Overdose\n" }

In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or serious arrhythmias will require advanced life-supporting measures. Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center (where available) to determine the latest recommendations for the management of an overdose.

{ "type": "p", "children": [], "text": "In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or serious arrhythmias will require advanced life-supporting measures. Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center (where available) to determine the latest recommendations for the management of an overdose." }

Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid antagonist.

{ "type": "p", "children": [], "text": "Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid antagonist. " }

While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals, convulsions following the administration of toxic doses of tramadol hydrochloride tablets could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.

{ "type": "p", "children": [], "text": "While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals, convulsions following the administration of toxic doses of tramadol hydrochloride tablets could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period." }

Because the duration of opioid reversal is expected to be less than the duration of action of tramadol in tramadol hydrochloride tablets, carefully monitor the patient until spontaneous respiration is reliably re­established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information.

{ "type": "p", "children": [], "text": "Because the duration of opioid reversal is expected to be less than the duration of action of tramadol in tramadol hydrochloride tablets, carefully monitor the patient until spontaneous respiration is reliably re­established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information." }

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.

{ "type": "p", "children": [], "text": "In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist." }

Tramadol hydrochloride tablets, USP, for oral use, are an opioid agonist. The chemical name for tramadol hydrochloride, USP is (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride. Its structural formula is:

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets, USP, for oral use, are an opioid agonist. The chemical name for tramadol hydrochloride, USP is (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride. Its structural formula is:" }

C16H25NO2•HCl        M.W. 299.84

{ "type": "p", "children": [], "text": "C16H25NO2•HCl        M.W. 299.84" }

Tramadol hydrochloride, USP is a white, bitter, crystalline and odorless powder. It is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7. Tramadol hydrochloride tablets, USP contain 50 mg of tramadol hydrochloride, USP (equivalent to 43.9 mg of tramadol) and are white in color. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 4000, pregelatinized corn starch, sodium starch glycolate, and titanium dioxide.

{ "type": "p", "children": [], "text": "Tramadol hydrochloride, USP is a white, bitter, crystalline and odorless powder. It is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7. Tramadol hydrochloride tablets, USP contain 50 mg of tramadol hydrochloride, USP (equivalent to 43.9 mg of tramadol) and are white in color. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 4000, pregelatinized corn starch, sodium starch glycolate, and titanium dioxide." }

Tramadol hydrochloride tablets contain tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re-uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to µ-opioid receptors and weak inhibition of re-uptake of norepinephrine and serotonin.

Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in µ-opioid binding. Tramadol-induced analgesia is only partially antagonized by the opioid antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human analgesia is dependent upon the plasma concentrations of each compound [see Clinical Pharmacology (12.2)].

Analgesia in humans begins approximately within one hour after administration and reaches a peak in approximately two to three hours.

Effects on the Central Nervous System

Tramadol produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.

Tramadol administration may produce a constellation of symptoms including nausea and vomiting, dizziness, and somnolence.

Tramadol causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.

Effects on the Gastrointestinal Tract and Other Smooth Muscle

Tramadol causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Effects on the Cardiovascular System

Tramadol produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of peripheral vasodilation may include pruritus, flushing, red eyes, sweating and/or orthostatic hypotension.

The effect of oral tramadol on the QTcF interval was evaluated in a double-blind, randomized, four-way crossover, placebo- and positive- (moxifloxacin) controlled study in 68 adult male and female healthy subjects. At a 600 mg/day dose (1.5-fold the maximum immediate-release daily dose), the study demonstrated no significant effect on the QTcF interval.

Effects on the Endocrine System

Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon [see Warnings and Precautions (5.13); Adverse Reactions (6)].

Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [see Adverse Reactions (6)].

Effects on the Immune System

Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.

Concentration–Efficacy Relationships

The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists. The minimum effective analgesic concentration of tramadol for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome and/or the development of analgesic tolerance [see Dosage and Administration (2)].

Concentration–Adverse Reaction Relationships

There is a relationship between increasing tramadol plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions [see Dosage and Administration (2)].

The analgesic activity of tramadol hydrochloride is due to both parent drug and the M1 metabolite [see Clinical Pharmacology (12.1, 12.2)]. Tramadol is administered as a racemate and both the [-] and [+] forms of both tramadol and M1 are detected in the circulation. Linear pharmacokinetics have been observed following multiple doses of 50 and 100 mg to steady-state.

Absorption

The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults. In general, both enantiomers of tramadol and M1 follow a parallel time course in the body following single and multiple doses although small differences (~ 10%) exist in the absolute amount of each enantiomer present.

Steady-state plasma concentrations of both tramadol and M1 are achieved within two days with four times per day dosing. There is no evidence of self-induction (see Figure 1 and Table 3 below).

Figure 1:  Mean Tramadol and M1 Plasma Concentration Profiles after a Single 100 mg Oral Dose and after Twenty-Nine 100 mg Oral Doses of Tramadol HCl given four times per day.

<div class="scrollingtable"><table border="1" cellpadding="5" cellspacing="0" width="100%"> <col width="24.22%"/> <col/> <col/> <col/> <col/> <col/> <tbody class="Headless"> <tr class="First"> <td class="Botrule" colspan="6"><span class="Bold">Table 3:  Mean (%CV) Pharmacokinetic Parameters for Racemic Tramadol and M1 Metabolite</span></td> </tr> <tr> <td> <p class="First"> <span class="Bold">Population/ </span> </p> <p> <span class="Bold">Dosage Regimen<span class="Sup">a</span></span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Parent Drug/ Metabolite</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Peak Conc. (ng/mL)</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Time to Peak (hrs)</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Clearance/F<span class="Sup">b</span> (mL/min/Kg)</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">t<span class="Sub">1/2 </span>(hrs)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" rowspan="2"> <p class="First">Healthy Adults, </p> <p>100 mg qid, MD p.o.</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">592 (30)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">2.3 (61)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">5.90 (25)<span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">6.7 (15)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">M1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">110 (29)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">2.4 (46)</p> </td><td class="Botrule Lrule Rrule Toprule"></td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">7.0 (14)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" rowspan="2"> <p class="First">Healthy Adults, </p> <p>100 mg SD p.o.</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">308 (25)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">1.6 (63)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">8.50 (31)<span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">5.6 (20)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">M1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">55.0 (36)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">3.0 (51)</p> </td><td class="Botrule Lrule Rrule Toprule"></td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">6.7 (16)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First">Geriatric, (&gt;75 yrs) </p> <p>50 mg SD p.o.</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol</p> <p>M1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">208 (31)<span class="Sup">d</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">2.1 (19)<span class="Sup">d</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">6.89 (25)<span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">7.0 (23)<span class="Sup">d</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" rowspan="2"> <p class="First">Hepatic Impaired, </p> <p>50 mg SD p.o. </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">217 (11)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">1.9 (16)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">4.23 (56)<span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">13.3 (11)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">M1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">19.4 (12)</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">9.8 (20)</p> </td><td class="Botrule Lrule Rrule Toprule"></td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">18.5 (15)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" rowspan="2"> <p class="First">Renal Impaired, </p> <p>CL<span class="Sub">cr</span> 10 to 30 mL/min </p> <p>100 mg SD i.v. </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">4.23 (54)<span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">10.6 (31)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">M1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td class="Botrule Lrule Rrule Toprule"></td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">11.5 (40)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" rowspan="2"> <p class="First">Renal Impaired, </p> <p>CL<span class="Sub">cr</span> &lt;5mL/min </p> <p>100 mg SD i.v.</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">Tramadol</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">3.73 (17)<span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">11.0 (29)</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">M1</p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Sup">c</span> </p> </td><td class="Botrule Lrule Rrule Toprule"></td><td align="center" class="Botrule Lrule Rrule Toprule"> <p class="First">16.9 (18)</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule Toprule" colspan="6"><span class="Sup">a.</span> SD = Single dose, MD = Multiple dose, p.o.= Oral administration, i.v.= Intravenous administration, q.i.d. = Four times daily<br/> <span class="Sup">b.</span> F represents the oral bioavailability of tramadol<br/> <span class="Sup">c.</span> Not applicable<br/> <span class="Sup">d.</span> Not measured   </td> </tr> </tbody> </table></div>

Food Effects

Oral administration of tramadol hydrochloride tablets with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride tablets can be administered without regard to food.

Distribution

The volume of distribution of tramadol was 2.6 and 2.9 liters/kg in male and female subjects, respectively, following a 100 mg intravenous dose. The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 mcg/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range.

Elimination

Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. The mean (%CV) apparent total clearance of tramadol after a single 100 mg oral dose is 8.50 (31) mL/min/kg. The mean terminal plasma elimination half- lives of racemic tramadol and racemic M1 are 6.3 ± 1.4 and 7.4 ± 1.4 hours, respectively. The plasma elimination half-life of racemic tramadol increased from approximately six hours to seven hours upon multiple dosing.

Metabolism

Tramadol is extensively metabolized after oral administration by a number of pathways, including CYP2D6 and CYP3A4, as well as by conjugation of parent and metabolites. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The remainder is excreted either as unidentified or as unextractable metabolites. The major metabolic pathways appear to be N- and O-demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. Formation of M1 is dependent on CYP2D6 and as such is subject to inhibition, which may affect the therapeutic response [Warnings and Precautions (5.6); Drug Interactions (7)].

Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P-450. These individuals are “poor metabolizers” of debrisoquine, dextromethorphan, tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase 1 studies in healthy subjects, concentrations of tramadol were approximately 20% higher in “poor metabolizers” versus “extensive metabolizers”, while M1 concentrations were 40% lower. Concomitant therapy with inhibitors of CYP2D6 such as fluoxetine, paroxetine and quinidine could result in significant drug interactions. In vitro drug interaction studies in human liver microsomes indicate that inhibitors of CYP2D6 such as fluoxetine and its metabolite norfluoxetine, amitriptyline and quinidine inhibit the metabolism of tramadol to various degrees, suggesting that concomitant administration of these compounds could result in increases in tramadol concentrations and decreased concentrations of M1. The full pharmacological impact of these alterations in terms of either efficacy or safety is unknown. Concomitant use of serotonin re-uptake inhibitors and MAO inhibitors may enhance the risk of adverse events, including seizure and serotonin syndrome [see Warnings and Precautions (5.9) and Drug Interactions (7)].

Excretion

Tramadol metabolites are eliminated primarily by the kidneys. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The remainder is excreted either as unidentified or as unextractable metabolites.

Special Populations

Hepatic Impairment

Metabolism of tramadol and M1 is reduced in patients with severe hepatic impairment based on a study in patients with advanced cirrhosis of the liver, resulting in both a larger area under the concentration time curve for tramadol and longer tramadol and M1 elimination half-lives (13 hrs. for tramadol and 19 hrs. for M1). In patients with severe hepatic impairment, adjustment of the dosing regimen is recommended [see Dosage and Administration (2)].

Renal Impairment

Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, adjustment of the dosing regimen is recommended [see Dosage and Administration (2)]. The total amount of tramadol and M1 removed during a 4-hour dialysis period is less than 7% of the administered dose.

Age: Geriatric

Healthy elderly subjects aged 65 to 75 years have plasma tramadol concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. In subjects over 75 years, maximum serum concentrations are elevated (208 vs. 162 ng/mL) and the elimination half-life is prolonged (7 vs. 6 hours) compared to subjects 65 to 75 years of age. Adjustment of the daily dose is recommended for patients older than 75 years [see Dosage and Administration (2.3)].

Sex

The absolute bioavailability of tramadol was 73% in males and 79% in females. The plasma clearance was 6.4 mL/min/kg in males and 5.7 mL/min/kg in females following a 100 mg IV dose of tramadol. Following a single oral dose, and after adjusting for body weight, females had a 12% higher peak tramadol concentration and a 35% higher area under the concentration-time curve compared to males. The clinical significance of this difference is unknown.

Poor / Extensive Metabolizers, CYP2D6

The formation of the active metabolite, M1, is mediated by CYP2D6, a polymorphic enzyme. Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P450 metabolizing enzyme system. These individuals are “poor metabolizers” of debrisoquine, dextromethorphan and tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase 1 studies with IR tablets in healthy subjects, concentrations of tramadol were approximately 20% higher in “poor metabolizers” versus “extensive metabolizers,” while M1 concentrations were 40% lower.

Carcinogenesis

A slight, but statistically significant, increase in two common murine tumors, pulmonary and hepatic, was observed in an NMRI mouse carcinogenicity study, particularly in aged mice. Mice were dosed orally up to 30 mg/kg in the drinking water (0.36 times the MRHD) for approximately two years, although the study was not done with the Maximum Tolerated Dose. This finding is not believed to suggest risk in humans. No evidence of carcinogenicity was noted in a rat 2-year carcinogenicity study testing oral doses of up to 30 mg/kg in the drinking water, 0.73 times the MRHD.

Mutagenesis

Tramadol was mutagenic in the presence of metabolic activation in the mouse lymphoma assay. Tramadol was not mutagenic in the in vitro bacterial reverse mutation assay using Salmonella and E. coli (Ames), the mouse lymphoma assay in the absence of metabolic activation, the in vitro chromosomal aberration assay, or the in vivo micronucleus assay in bone marrow.

Impairment of Fertility

No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg in male rats and 75 mg/kg in female rats. These dosages are 1.2 and 1.8 times the maximum recommended human daily dose based on body surface area, respectively.

Tramadol hydrochloride tablets have been given in single oral doses of 50, 75 and 100 mg to patients with pain following surgical procedures and pain following oral surgery (extraction of impacted molars).

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets have been given in single oral doses of 50, 75 and 100 mg to patients with pain following surgical procedures and pain following oral surgery (extraction of impacted molars)." }

In single-dose models of pain following oral surgery, pain relief was demonstrated in some patients at doses of 50 mg and 75 mg. A dose of 100 mg tramadol hydrochloride tablets tended to provide analgesia superior to codeine sulfate 60 mg, but it was not as effective as the combination of aspirin 650 mg with codeine phosphate 60 mg.

{ "type": "p", "children": [], "text": "In single-dose models of pain following oral surgery, pain relief was demonstrated in some patients at doses of 50 mg and 75 mg. A dose of 100 mg tramadol hydrochloride tablets tended to provide analgesia superior to codeine sulfate 60 mg, but it was not as effective as the combination of aspirin 650 mg with codeine phosphate 60 mg." }

Tramadol hydrochloride tablets have been studied in three long-term controlled trials involving a total of 820 patients, with 530 patients receiving tramadol hydrochloride tablets. Patients with a variety of chronic painful conditions were studied in double-blind trials of one to three months duration.  Average daily doses of approximately 250 mg of tramadol hydrochloride tablets in divided doses were generally comparable to five doses of acetaminophen 300 mg with codeine phosphate 30 mg (TYLENOL® with Codeine #3) daily, five doses of aspirin 325 mg with codeine phosphate 30 mg daily, or two to three doses of acetaminophen 500 mg with oxycodone hydrochloride 5 mg (TYLOX®) daily.

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets have been studied in three long-term controlled trials involving a total of 820 patients, with 530 patients receiving tramadol hydrochloride tablets. Patients with a variety of chronic painful conditions were studied in double-blind trials of one to three months duration.  Average daily doses of approximately 250 mg of tramadol hydrochloride tablets in divided doses were generally comparable to five doses of acetaminophen 300 mg with codeine phosphate 30 mg (TYLENOL® with Codeine #3) daily, five doses of aspirin 325 mg with codeine phosphate 30 mg daily, or two to three doses of acetaminophen 500 mg with oxycodone hydrochloride 5 mg (TYLOX®) daily." }

Titration Trials

{ "type": "p", "children": [], "text": "\nTitration Trials\n" }

In a randomized, blinded clinical study with 129 to 132 patients per group, a 10-day titration to a daily tramadol hydrochloride tablets dose of 200 mg (50 mg four times per day), attained in 50 mg increments every 3 days, was found to result in fewer discontinuations due to dizziness or vertigo than titration over only 4 days or no titration. In a second study with 54 to 59 patients per group, patients who had nausea or vomiting when titrated over 4 days were randomized to re-initiate tramadol hydrochloride tablets therapy using slower titration rates.

{ "type": "p", "children": [], "text": "In a randomized, blinded clinical study with 129 to 132 patients per group, a 10-day titration to a daily tramadol hydrochloride tablets dose of 200 mg (50 mg four times per day), attained in 50 mg increments every 3 days, was found to result in fewer discontinuations due to dizziness or vertigo than titration over only 4 days or no titration. In a second study with 54 to 59 patients per group, patients who had nausea or vomiting when titrated over 4 days were randomized to re-initiate tramadol hydrochloride tablets therapy using slower titration rates." }

A 16-day titration schedule, starting with 25 mg every morning and using additional doses in 25 mg increments every third day to 100 mg/day (25 mg four times per day), followed by 50 mg increments in the total daily dose every third day to 200 mg/day (50 mg four times per day), resulted in fewer discontinuations due to nausea or vomiting and fewer discontinuations due to any cause than did a 10-day titration schedule.

{ "type": "p", "children": [], "text": "A 16-day titration schedule, starting with 25 mg every morning and using additional doses in 25 mg increments every third day to 100 mg/day (25 mg four times per day), followed by 50 mg increments in the total daily dose every third day to 200 mg/day (50 mg four times per day), resulted in fewer discontinuations due to nausea or vomiting and fewer discontinuations due to any cause than did a 10-day titration schedule. " }

Figure 2:

{ "type": "p", "children": [], "text": "\nFigure 2:\n" }

Tramadol hydrochloride tablets USP, 50 mg, are available as white, film-coated, oval-shaped tablets, scored on both sides. Debossed with “T” on the left side and “V” on the right side of the score line on one side of tablet. Debossed with “7” on the left side and “T” on the right side of the score line on the other side of tablet. They are available in bottles of 100 (NDC 0093-3301-01) and 500 (NDC 0093-3301-05).

{ "type": "p", "children": [], "text": "Tramadol hydrochloride tablets USP, 50 mg, are available as white, film-coated, oval-shaped tablets, scored on both sides. Debossed with “T” on the left side and “V” on the right side of the score line on one side of tablet. Debossed with “7” on the left side and “T” on the right side of the score line on the other side of tablet. They are available in bottles of 100 (NDC 0093-3301-01) and 500 (NDC 0093-3301-05). " }

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

{ "type": "p", "children": [], "text": "Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]." }

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

{ "type": "p", "children": [], "text": "Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required)." }

Keep this and all medications out of the reach of children.

{ "type": "p", "children": [], "text": "Keep this and all medications out of the reach of children." }

Store tramadol hydrochloride tablets securely and dispose of properly [see Patient Counseling Information (17)].

{ "type": "p", "children": [], "text": "Store tramadol hydrochloride tablets securely and dispose of properly [see Patient Counseling Information (17)]." }

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

{ "type": "p", "children": [], "text": "Advise the patient to read the FDA-approved patient labeling (Medication Guide)." }

Storage and Disposal

{ "type": "p", "children": [], "text": "\nStorage and Disposal\n" }

Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store tramadol hydrochloride tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving tramadol hydrochloride tablets unsecured can pose a deadly risk to others in the home [see Warnings and Precautions (5.1, 5.18), Drug Abuse and Dependence (9.2)].

{ "type": "p", "children": [], "text": "Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store tramadol hydrochloride tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving tramadol hydrochloride tablets unsecured can pose a deadly risk to others in the home [see Warnings and Precautions (5.1, 5.18), Drug Abuse and Dependence (9.2)]." }

Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines. If no take back programs or Drug Enforcement Administration (DEA)-registered collectors are available, instruct patients to dispose of tramadol hydrochloride tablets by following these four steps:

{ "type": "p", "children": [], "text": "Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines. If no take back programs or Drug Enforcement Administration (DEA)-registered collectors are available, instruct patients to dispose of tramadol hydrochloride tablets by following these four steps:" }

{ "type": "ul", "children": [ "Mix tramadol hydrochloride tablets (do not crush) with an unpalatable substance such as dirt, cat litter, or used coffee grounds;", "Place the mixture in a container such as a sealed plastic bag;", "Throw the container in the household trash;", "Delete all personal information on the prescription label of the empty bottle." ], "text": "" }

Inform patients that they can visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

{ "type": "p", "children": [], "text": "Inform patients that they can visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines." }

Addiction, Abuse, and Misuse

{ "type": "p", "children": [], "text": "\nAddiction, Abuse, and Misuse\n" }

Inform patients that the use of tramadol hydrochloride tablets, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see Warnings and Precautions (5.1)]. Instruct patients not to share tramadol hydrochloride tablets with others and to take steps to protect tramadol hydrochloride tablets from theft or misuse.

{ "type": "p", "children": [], "text": "Inform patients that the use of tramadol hydrochloride tablets, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see Warnings and Precautions (5.1)]. Instruct patients not to share tramadol hydrochloride tablets with others and to take steps to protect tramadol hydrochloride tablets from theft or misuse." }

Life-Threatening Respiratory Depression

{ "type": "p", "children": [], "text": "\nLife-Threatening Respiratory Depression\n" }

Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting tramadol hydrochloride tablets or when the dosage is increased, and that it can occur even at recommended dosages. Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Warnings and Precautions (5.2)].

{ "type": "p", "children": [], "text": "Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting tramadol hydrochloride tablets or when the dosage is increased, and that it can occur even at recommended dosages. Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Warnings and Precautions (5.2)]." }

Accidental Ingestion

{ "type": "p", "children": [], "text": "\nAccidental Ingestion\n" }

Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [see Warnings and Precautions (5.2)].

{ "type": "p", "children": [], "text": "Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [see Warnings and Precautions (5.2)]. " }

Interactions with Benzodiazepines and Other CNS Depressants

{ "type": "p", "children": [], "text": "\nInteractions with Benzodiazepines and Other CNS Depressants\n" }

Inform patients and caregivers that potentially fatal additive effects may occur if tramadol hydrochloride tablets are used with benzodiazepines, CNS depressants, including alcohol, or some illicit drugs and not to use these concomitantly unless supervised by a healthcare provider [see Warnings and Precautions (5.3); Drug Interactions (7)].

{ "type": "p", "children": [], "text": "Inform patients and caregivers that potentially fatal additive effects may occur if tramadol hydrochloride tablets are used with benzodiazepines, CNS depressants, including alcohol, or some illicit drugs and not to use these concomitantly unless supervised by a healthcare provider [see Warnings and Precautions (5.3); Drug Interactions (7)]." }

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose

{ "type": "p", "children": [], "text": "\nPatient Access to Naloxone for the Emergency Treatment of Opioid Overdose\n" }

Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with tramadol hydrochloride tablets. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

{ "type": "p", "children": [], "text": "Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with tramadol hydrochloride tablets. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see Dosage and Administration (2.2), Warnings and Precautions (5.2)]." }

Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.

{ "type": "p", "children": [], "text": "Educate patients and caregivers on how to recognize the signs and symptoms of an overdose." }

Explain to patients and caregivers that naloxone’s effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered [see Overdosage (10)].

{ "type": "p", "children": [], "text": "Explain to patients and caregivers that naloxone’s effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered [see Overdosage (10)]." }

If naloxone is prescribed, also advise patients and caregivers:

{ "type": "p", "children": [], "text": "If naloxone is prescribed, also advise patients and caregivers:" }

{ "type": "ul", "children": [ "How to treat with naloxone in the event of an opioid overdose", "To tell family and friends about their naloxone and to keep it in a place where family and friends can access it in an emergency", "To read the Patient Information (or other educational material) that will come with their naloxone. Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do." ], "text": "" }

Ultra-Rapid Metabolism of Tramadol and Other Risk Factors for Life-threatening Respiratory Depression in Children

{ "type": "p", "children": [], "text": "\nUltra-Rapid Metabolism of Tramadol and Other Risk Factors for Life-threatening Respiratory Depression in Children\n" }

Advise caregivers that tramadol hydrochloride tablets are contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Advise caregivers of children ages 12 to 18 years of age receiving tramadol hydrochloride tablets to monitor for signs of respiratory depression [see Warnings and Precautions (5.6)].

{ "type": "p", "children": [], "text": "Advise caregivers that tramadol hydrochloride tablets are contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Advise caregivers of children ages 12 to 18 years of age receiving tramadol hydrochloride tablets to monitor for signs of respiratory depression [see Warnings and Precautions (5.6)]." }

Hyperalgesia and Allodynia

{ "type": "p", "children": [], "text": "\nHyperalgesia and Allodynia\n" }

Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see Warnings and Precautions (5.8); Adverse Reactions (6.2)].

{ "type": "p", "children": [], "text": "Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see Warnings and Precautions (5.8); Adverse Reactions (6.2)]." }

Maximum single-dose and 24-hour dose

{ "type": "p", "children": [], "text": "\nMaximum single-dose and 24-hour dose\n" }

Advise patients not to exceed the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in respiratory depression, seizures and death [see Dosage and Administration (2); Warnings and Precautions (5.2)].

{ "type": "p", "children": [], "text": "Advise patients not to exceed the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in respiratory depression, seizures and death [see Dosage and Administration (2); Warnings and Precautions (5.2)]." }

Serotonin Syndrome

{ "type": "p", "children": [], "text": "\nSerotonin Syndrome\n" }

Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome, and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications [see Warnings and Precautions (5.9)].

{ "type": "p", "children": [], "text": "Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome, and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications [see Warnings and Precautions (5.9)]." }

Seizures

{ "type": "p", "children": [], "text": "\nSeizures\n" }

Inform patients that tramadol hydrochloride tablets may cause seizures with concomitant use of serotonergic agents (including SSRIs, SNRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol [see Warnings and Precautions (5.10)].

{ "type": "p", "children": [], "text": "Inform patients that tramadol hydrochloride tablets may cause seizures with concomitant use of serotonergic agents (including SSRIs, SNRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol [see Warnings and Precautions (5.10)]." }

MAOI Interaction

{ "type": "p", "children": [], "text": "\nMAOI Interaction\n" }

Inform patients not to take tramadol hydrochloride tablets while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking tramadol hydrochloride tablets [see Drug Interactions (7)].

{ "type": "p", "children": [], "text": "Inform patients not to take tramadol hydrochloride tablets while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking tramadol hydrochloride tablets [see Drug Interactions (7)]." }

Important Administration Instructions

{ "type": "p", "children": [], "text": "\nImportant Administration Instructions\n" }

{ "type": "ul", "children": [ "Instruct patients how to properly take tramadol hydrochloride tablets [see Dosage and Administration (2)].", "Advise patients not to adjust the dose of tramadol hydrochloride tablets without consulting with a physician or other healthcare professional." ], "text": "" }

Important Discontinuation Instructions

{ "type": "p", "children": [], "text": "\nImportant Discontinuation Instructions\n" }

{ "type": "ul", "children": [ "In order to avoid developing withdrawal symptoms, instruct patients not to discontinue tramadol hydrochloride tablets without first discussing a tapering plan with the prescriber [see Dosage and Administration (2.5)]." ], "text": "" }

Driving or Operating Heavy Machinery

{ "type": "p", "children": [], "text": "\nDriving or Operating Heavy Machinery\n" }

{ "type": "ul", "children": [ "Inform patients that tramadol hydrochloride tablets may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication [see Warnings and Precautions (5.19)]." ], "text": "" }

Constipation

{ "type": "p", "children": [], "text": "\nConstipation\n" }

{ "type": "ul", "children": [ "Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see Adverse Reactions (6)]." ], "text": "" }

Adrenal Insufficiency

{ "type": "p", "children": [], "text": "\nAdrenal Insufficiency\n" }

Inform patients that opioids could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [see Warnings and Precautions (5.13)].

{ "type": "p", "children": [], "text": "Inform patients that opioids could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [see Warnings and Precautions (5.13)]." }

Hypotension

{ "type": "p", "children": [], "text": "\nHypotension\n" }

Inform patients that tramadol hydrochloride tablets may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see Warnings and Precautions (5.14)].

{ "type": "p", "children": [], "text": "Inform patients that tramadol hydrochloride tablets may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see Warnings and Precautions (5.14)]." }

Anaphylaxis

{ "type": "p", "children": [], "text": "\nAnaphylaxis\n" }

Inform patients that anaphylaxis has been reported with ingredients contained in tramadol hydrochloride tablets. Advise patients how to recognize such a reaction and when to seek medical attention [see Contraindications (4); Warnings and Precautions (5.17); Adverse Reactions (6)].

{ "type": "p", "children": [], "text": "Inform patients that anaphylaxis has been reported with ingredients contained in tramadol hydrochloride tablets. Advise patients how to recognize such a reaction and when to seek medical attention [see Contraindications (4); Warnings and Precautions (5.17); Adverse Reactions (6)]." }

Pregnancy

{ "type": "p", "children": [], "text": "\nPregnancy\n" }

Neonatal Opioid Withdrawal Syndrome

{ "type": "p", "children": [], "text": "\nNeonatal Opioid Withdrawal Syndrome\n" }

Inform female patients of reproductive potential that use of tramadol hydrochloride tablets for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. The patient should inform their healthcare provider if they have used opioids at any time during their pregnancy [see Warnings and Precautions (5.4); Use in Specific Populations (8.1)].

{ "type": "p", "children": [], "text": "Inform female patients of reproductive potential that use of tramadol hydrochloride tablets for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. The patient should inform their healthcare provider if they have used opioids at any time during their pregnancy [see Warnings and Precautions (5.4); Use in Specific Populations (8.1)]." }

Embryo-Fetal Toxicity

{ "type": "p", "children": [], "text": "\nEmbryo-Fetal Toxicity\n" }

Inform female patients of reproductive potential that tramadol hydrochloride tablets may cause fetal harm and to inform the healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)].

{ "type": "p", "children": [], "text": "Inform female patients of reproductive potential that tramadol hydrochloride tablets may cause fetal harm and to inform the healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)]." }

Lactation

{ "type": "p", "children": [], "text": "\nLactation\n" }

Advise women that breastfeeding is not recommended during treatment with tramadol hydrochloride tablets [see Warnings and Precautions (5.6); Use in Specific Populations (8.2)].

{ "type": "p", "children": [], "text": "Advise women that breastfeeding is not recommended during treatment with tramadol hydrochloride tablets [see Warnings and Precautions (5.6); Use in Specific Populations (8.2)]." }

Infertility

{ "type": "p", "children": [], "text": "\nInfertility\n" }

Inform patients that use of opioids for an extended period of time may cause reduced fertility. It is not known whether these effects on fertility are reversible [see Use in Specific Populations (8.3)].

{ "type": "p", "children": [], "text": "Inform patients that use of opioids for an extended period of time may cause reduced fertility. It is not known whether these effects on fertility are reversible [see Use in Specific Populations (8.3)]." }

Brands listed are the trademarks of their respective owners.

{ "type": "p", "children": [], "text": "Brands listed are the trademarks of their respective owners." }

Dispense with Medication Guide available at: www.tevausa.com/medguides

{ "type": "p", "children": [], "text": "Dispense with Medication Guide available at: www.tevausa.com/medguides" }

Manufactured In Czech Republic By: Teva Czech Industries, s.r.o. Opava-Komarov, Czech Republic

{ "type": "p", "children": [], "text": "Manufactured In Czech Republic By:\nTeva Czech Industries, s.r.o.\nOpava-Komarov, Czech Republic" }

Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054

{ "type": "p", "children": [], "text": "Manufactured For:\nTeva Pharmaceuticals\nParsippany, NJ 07054" }

Rev. AP 2/2024

{ "type": "p", "children": [], "text": "Rev. AP 2/2024" }

<div class="scrollingtable"><table border="1" cellpadding="0" cellspacing="0" width="1000px"> <col width="1pt"/> <tbody class="Headless"> <tr class="First"> <td> Dispense with Medication Guide available at: www.tevausa.com/medguides</td> </tr> <tr> <td align="center"> <p class="First"> <span class="Bold">MEDICATION GUIDE</span> </p> <p> <span class="Bold">Tramadol Hydrochloride (<span class="Bold"><span class="Bold">tram′ a dol hye″ droe klor′ ide</span></span>) </span> </p> <p> <span class="Bold">Tablets, C-IV</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Tramadol hydrochloride tablets are:</span> </p> <ul class="Disc"> <li>A strong prescription pain medicine that contains an opioid (narcotic) that is used for the management of pain in adults, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.</li> <li>An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</li> </ul> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Important information about tramadol hydrochloride tablets:</span> </p> <ul class="Disc"> <li> <span class="Bold">Get emergency help or call 911 right away if you take too many tramadol hydrochloride tablets (overdose).</span> When you first start taking tramadol hydrochloride tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.</li> <li>Taking tramadol hydrochloride tablets with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</li> <li>Never give anyone else your tramadol hydrochloride tablets. They could die from taking them. Selling or giving away tramadol hydrochloride tablets is against the law.</li> <li>Store tramadol hydrochloride tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</li> </ul> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">Important Information Guiding Use in Pediatric Patients: </span> </p> <ul class="Disc"> <li>Do not give tramadol hydrochloride tablets to a child younger than 12 years of age. </li> <li>Do not give tramadol hydrochloride tablets to a child younger than 18 years of age after surgery to remove the tonsils and/or adenoids. </li> <li>Avoid giving tramadol hydrochloride tablets to children between 12 to 18 years of age who have risk factors for breathing problems such as obstructive sleep apnea, obesity, or underlying lung problems.</li> </ul> <p> <span class="Bold">Do not take tramadol hydrochloride tablets if you have:</span> </p> <ul class="Disc"> <li>Severe asthma, trouble breathing, or other lung problems.</li> <li>A bowel blockage or have narrowing of the stomach or intestines.</li> <li>An allergy to tramadol.</li> <li>Taken a Monoamine Oxidase Inhibitor, MAOI, (medicine used for depression) within the last 14 days.</li> </ul> <p> <span class="Bold">Before taking tramadol hydrochloride tablets, tell your healthcare provider if you have a history of:</span> </p> <ul class="Disk"> <li>head injury, seizures</li> <li>liver, kidney, thyroid problems</li> <li>problems urinating</li> <li>pancreas or gallbladder problems</li> <li>abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems.</li> </ul> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"><span class="Bold">Tell your healthcare provider if you are:</span> <ul class="Disc"> <li>noticing your pain getting worse. If your pain gets worse after you take tramadol hydrochloride tablets, do not take more of tramadol hydrochloride tablets without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking tramadol hydrochloride tablets.</li> <li> <span class="Bold">pregnant or planning to become pregnant.</span> Use of tramadol hydrochloride tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.</li> <li> <span class="Bold">breastfeeding.</span> Not recommended; it may harm your baby. </li> <li>living in a household where there are small children or someone who has abused street or prescription drugs.</li> <li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking tramadol hydrochloride tablets with certain other medicines can cause serious side effects that could lead to death.</li> </ul> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">When taking tramadol hydrochloride tablets:</span> </p> <ul class="Disc"> <li>Do not change your dose. Take tramadol hydrochloride tablets exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.</li> <li>For acute (short-term) pain, you may only need to take tramadol hydrochloride tablets for a few days. You may have some tramadol hydrochloride tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused tramadol hydrochloride tablets.</li> <li>Take your prescribed dose as indicated by your healthcare provider. The maximum dosage is 1 or 2 tablets every 4 to 6 hours, as needed for pain relief. Do not take more than your prescribed dose and do not take more than 8 tablets per day. If you miss a dose, take your next dose at your usual time.</li> <li>Call your healthcare provider if the dose you are taking does not control your pain.</li> <li>If you have been taking tramadol hydrochloride tablets regularly, do not stop taking tramadol hydrochloride tablets without talking to your healthcare provider.</li> <li>Dispose of expired, unwanted, or unused tramadol hydrochloride tablets by taking your drug to an authorized Drug Enforcement Administration (DEA)-registered collector or drug take-back program. If one is not available, you can dispose of tramadol hydrochloride tablets by mixing the product with dirt, cat litter, or coffee grounds; placing the mixture in a sealed plastic bag, and throwing the bag in your trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</li> </ul> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">While taking tramadol hydrochloride tablets DO NOT:</span> </p> <ul class="Disc"> <li>Drive or operate heavy machinery, until you know how tramadol hydrochloride tablets affect you. Tramadol hydrochloride tablets can make you sleepy, dizzy, or lightheaded.</li> <li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with tramadol hydrochloride tablets may cause you to overdose and die.</li> </ul> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule Toprule"> <p class="First"> <span class="Bold">The possible side effects of tramadol hydrochloride tablets:</span> </p> <ul class="Disc"> <li>constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</li> </ul> <p> <span class="Bold">Get emergency medical help or call 911 right away if you have:</span> </p> <ul class="Disk"> <li>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</li> <li>These are not all the possible side effects of tramadol hydrochloride tablets. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.</li> </ul> <p>Manufactured In Czech Republic By: <span class="Bold">Teva Czech Industries, s.r.o., </span>Opava-Komarov, Czech Republic<br/> Manufactured For: <span class="Bold">Teva Pharmaceuticals, </span>Parsippany, NJ 07054</p> </td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"1000px\">\n<col width=\"1pt\"/>\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td> Dispense with Medication Guide available at: www.tevausa.com/medguides</td>\n</tr>\n<tr>\n<td align=\"center\">\n<p class=\"First\">\n<span class=\"Bold\">MEDICATION GUIDE</span>\n</p>\n<p>\n<span class=\"Bold\">Tramadol Hydrochloride (<span class=\"Bold\"><span class=\"Bold\">tram′ a dol hye″ droe klor′ ide</span></span>) </span>\n</p>\n<p>\n<span class=\"Bold\">Tablets, C-IV</span>\n</p>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Bold\">Tramadol hydrochloride tablets are:</span>\n</p>\n<ul class=\"Disc\">\n<li>A strong prescription pain medicine that contains an opioid (narcotic) that is used for the management of pain in adults, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.</li>\n<li>An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Bold\">Important information about tramadol hydrochloride tablets:</span>\n</p>\n<ul class=\"Disc\">\n<li>\n<span class=\"Bold\">Get emergency help or call 911 right away if you take too many tramadol hydrochloride tablets (overdose).</span> When you first start taking tramadol hydrochloride tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.</li>\n<li>Taking tramadol hydrochloride tablets with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</li>\n<li>Never give anyone else your tramadol hydrochloride tablets. They could die from taking them. Selling or giving away tramadol hydrochloride tablets is against the law.</li>\n<li>Store tramadol hydrochloride tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Bold\">Important Information Guiding Use in Pediatric Patients: </span>\n</p>\n<ul class=\"Disc\">\n<li>Do not give tramadol hydrochloride tablets to a child younger than 12 years of age. </li>\n<li>Do not give tramadol hydrochloride tablets to a child younger than 18 years of age after surgery to remove the tonsils and/or adenoids. </li>\n<li>Avoid giving tramadol hydrochloride tablets to children between 12 to 18 years of age who have risk factors for breathing problems such as obstructive sleep apnea, obesity, or underlying lung problems.</li>\n</ul>\n<p>\n<span class=\"Bold\">Do not take tramadol hydrochloride tablets if you have:</span>\n</p>\n<ul class=\"Disc\">\n<li>Severe asthma, trouble breathing, or other lung problems.</li>\n<li>A bowel blockage or have narrowing of the stomach or intestines.</li>\n<li>An allergy to tramadol.</li>\n<li>Taken a Monoamine Oxidase Inhibitor, MAOI, (medicine used for depression) within the last 14 days.</li>\n</ul>\n<p>\n<span class=\"Bold\">Before taking tramadol hydrochloride tablets, tell your healthcare provider if you have a history of:</span>\n</p>\n<ul class=\"Disk\">\n<li>head injury, seizures</li>\n<li>liver, kidney, thyroid problems</li>\n<li>problems urinating</li>\n<li>pancreas or gallbladder problems</li>\n<li>abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\"><span class=\"Bold\">Tell your healthcare provider if you are:</span>\n<ul class=\"Disc\">\n<li>noticing your pain getting worse. If your pain gets worse after you take tramadol hydrochloride tablets, do not take more of tramadol hydrochloride tablets without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking tramadol hydrochloride tablets.</li>\n<li>\n<span class=\"Bold\">pregnant or planning to become pregnant.</span> Use of tramadol hydrochloride tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.</li>\n<li>\n<span class=\"Bold\">breastfeeding.</span> Not recommended; it may harm your baby. </li>\n<li>living in a household where there are small children or someone who has abused street or prescription drugs.</li>\n<li>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking tramadol hydrochloride tablets with certain other medicines can cause serious side effects that could lead to death.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Bold\">When taking tramadol hydrochloride tablets:</span>\n</p>\n<ul class=\"Disc\">\n<li>Do not change your dose. Take tramadol hydrochloride tablets exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.</li>\n<li>For acute (short-term) pain, you may only need to take tramadol hydrochloride tablets for a few days. You may have some tramadol hydrochloride tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused tramadol hydrochloride tablets.</li>\n<li>Take your prescribed dose as indicated by your healthcare provider. The maximum dosage is 1 or 2 tablets every 4 to 6 hours, as needed for pain relief. Do not take more than your prescribed dose and do not take more than 8 tablets per day. If you miss a dose, take your next dose at your usual time.</li>\n<li>Call your healthcare provider if the dose you are taking does not control your pain.</li>\n<li>If you have been taking tramadol hydrochloride tablets regularly, do not stop taking tramadol hydrochloride tablets without talking to your healthcare provider.</li>\n<li>Dispose of expired, unwanted, or unused tramadol hydrochloride tablets by taking your drug to an authorized Drug Enforcement Administration (DEA)-registered collector or drug take-back program. If one is not available, you can dispose of tramadol hydrochloride tablets by mixing the product with dirt, cat litter, or coffee grounds; placing the mixture in a sealed plastic bag, and throwing the bag in your trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Bold\">While taking tramadol hydrochloride tablets DO NOT:</span>\n</p>\n<ul class=\"Disc\">\n<li>Drive or operate heavy machinery, until you know how tramadol hydrochloride tablets affect you. Tramadol hydrochloride tablets can make you sleepy, dizzy, or lightheaded.</li>\n<li>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with tramadol hydrochloride tablets may cause you to overdose and die.</li>\n</ul>\n</td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule Lrule Rrule Toprule\">\n<p class=\"First\">\n<span class=\"Bold\">The possible side effects of tramadol hydrochloride tablets:</span>\n</p>\n<ul class=\"Disc\">\n<li>constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</li>\n</ul>\n<p>\n<span class=\"Bold\">Get emergency medical help or call 911 right away if you have:</span>\n</p>\n<ul class=\"Disk\">\n<li>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</li>\n<li>These are not all the possible side effects of tramadol hydrochloride tablets. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.</li>\n</ul>\n<p>Manufactured In Czech Republic By: <span class=\"Bold\">Teva Czech Industries, s.r.o., </span>Opava-Komarov, Czech Republic<br/>\n Manufactured For: <span class=\"Bold\">Teva Pharmaceuticals, </span>Parsippany, NJ 07054</p>\n</td>\n</tr>\n</tbody>\n</table></div>" }

This Medication Guide has been approved by the U.S. Food and Drug Administration.                                                                                        Rev. I 2/2024

{ "type": "p", "children": [], "text": "This Medication Guide has been approved by the U.S. Food and Drug Administration.                                                                                        Rev. I 2/2024" }

New NDC

{ "type": "p", "children": [], "text": "New NDC" }

New Product Appearance

{ "type": "p", "children": [], "text": "New Product Appearance" }

NDC 0093-3301-01

{ "type": "p", "children": [], "text": "NDC 0093-3301-01" }

traMADol Hydrochloride Tablets, USP CIV

{ "type": "p", "children": [], "text": "traMADol Hydrochloride Tablets, USP CIV" }

50 mg

{ "type": "p", "children": [], "text": "50 mg" }

PHARMACIST: Dispense the accompanying Medication Guide to each patient.

{ "type": "p", "children": [], "text": "PHARMACIST: Dispense the accompanying Medication Guide to each patient." }

Rx only

{ "type": "p", "children": [], "text": "Rx only" }

100 Tablets

{ "type": "p", "children": [], "text": "100 Tablets" }